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The most challenging task in treatment of various diseases or injuries in the 
central nervous system (CNS) is to overcome the barrier preventing the drugs moving 
into the brain parenchyma. The blood brain barrier (BBB) lies between the blood flow 
and the brain parenchyma. The BBB prohibits most foreign molecules entering from 
the blood to brain, including CNS drugs. The limited penetration of drugs through the 
BBB into the brain parenchyma is the rule, not the exception  
 
In the treatment of brain infection or inflammatory diseases, antibiotics such as 
ciprofloxacin, penicillin or doxycycline are commonly used, especially for those 
diseases caused by bacteria. However, high mortality and morbidity among those 
infected diseases are still inevitable because of the difficulty in delivering antibiotics 
across the BBB. Therefore, exploring strategies for delivering drugs across the BBB is 
of great importance in the therapy of CNS diseases. 
 
Up to now, three main strategies have been developed to penetrate the BBB: 
neurosurgically-based strategy to physically introduce a drug in the brain by 
temporally opening the BBB; pharmacologically-based strategy to increase 
permeability of drugs to the BBB through the modification of molecular features of 
drugs; and physiologically-based strategy to enhance permeability of drugs through 
the BBB by physiological carrier. The physiologically-based strategy is a safe way to 
deliver a drug with high drug transport efficiency. The present study is intended to 
  XIX
develop a novel biologically active drug carrier in the physiologically-based strategy. 
Here, antibiotic molecules will be coupled to a vector by chemical or physical force. 
The efficacy of the novel drug delivery system to cross the BBB through receptor 
mediated transcytosis (RMT) or absorptive mediated transcytosis (AMT) will be 
tested. 
 
In the first part of this thesis, a new core shell nanoparticles system for the 
ciprofloxacin delivery was devised. Firstly, the hydrophilic poly (ethylene glycol) 
(PEG) chain was connected to hydrophobic b-cholesterol molecules by EDC/NHS 
chemistry in organic solvent. The amphiphilic polymeric micelles of PEG-b- 
cholesterol can self-assemble a core shell structure in aqueous solution. Then, 
transactivator of transcription (TAT) peptide ---a cell penetrating peptide which can 
recognize some receptors of cell membrane---was conjugated to the surface of 
PEG-b-cholesterol to form the final nanoparticle micelle drug carrier designed--- 
TAT-PEG-b-Chol. Lastly, FITC, Quantum dots (QDs) and ciprofloxacin molecules 
were efficiently loaded into the core shell of the nanoparticles by a membrane dialysis 
method respectively. The morphology of blank and drug-loaded micelles was 
characterized using dynamic light scattering and transmission electron microscopy 
(TEM). These particles were spherical in nature, having an average size lower than 
200 nm. Meanwhile, sustained in vitro drug release of ciprofloxacin from micelles 
was achieved in PBS solution.  
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The in vitro uptake of nanoparticles was test by cultured human brain endothelial 
cells and astrocytes. Many more particles with TAT peptide were taken by these cells 
than those without TAT. Most importantly, the in vivo bio-distribution investigation 
demonstrated that only TAT-PEG-b-Chol could penetrate the BBB and carry drug 
molecules to the brain parenchyma. Further study had indicated that the nanoparticles 
of TAT-PEG-b-Chol were mainly taken up by neurons after they reached the brain 
parenchyma. They only distributed in the cytoplasm of neuron but not nuclei. The 
primary pharmacokinetics study of TAT-PEG-b-Chol showed that they could reach the 
brain parenchyma shortly within 15 minutes after they entered the blood stream. In a 
word, the nanoparticle of TAT-PEG-b-Chol may be a promising drug carrier to deliver 
antibiotics across the BBB in the future clinical therapy of brain infectious diseases. 
 
   Successfully delivery of hydrophilic Penicillin G potassium was the main goal of 
the second part of this thesis. Here, this antibiotic was directly conjugated to TAT 
peptide via EDC/NHS chemistry since the drug cannot be well encapsulated into the 
core shell of TAT-PEG-b-Chol micelles. The drug-carrier system was characterized by 
NMR and MALDI-TOF/MS. The in vitro absorption test and antibiotics screening 
experiments proved that conjugation of TAT to Penicillin G potassium not only 
increase the penetration of this antibiotic to cell membrane but also enhance their 
antibacterial efficacy to infectious microorganisms to achieve better therapeutical 
results. Results of its cytotoxicity test indicated that TAT-Penicillin G was safe to be a 
drug carrier in the treatment of certain brain infectious diseases. Direct conjugation of 
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TAT penetrating peptide may become a feasible way to deliver hydrophilic Penicillin 
G through the BBB. 
 
   In the last part, a pathological rat brain model was successfully mimicked by focal 
cerebral injection of lipopolysaccharide (LPS). In this modle, the responses of NG2 
cells in response to the injury were studied. In the LPS injection surrounding areas, 
NG2 cells were activated and undergone dramatic morphological changes. NG2 
expression was significantly upregulated. Using anti-CD11b antibody to block 
microglial complement receptor type 3 (CR3) in the injury site resulted in a down- 
regulation of NG2 cell reaction contrast to those accepted LPS administration only. It 
suggests that NG2 cells may respond to the pathological stimulation as a component 
downstream to microglia in pathological brain. In future, the novel drug delivery 
system and the roles of various types of neurons and non-neuronal cells on drug 
delivery, release, and effects will be further studied in this model. 
    
In conclusion, nanoparticle of TAT-PEG-b-Chol is a good nano-carrier to deliver 
drug molecules cross the BBB. In pathological brain, sustained drug release could be 
expected in targeted site. With the aid of TAT cell penetrating peptide, Penicillin 
G-TAT system also was able to penetrate the BBB. They may be a promising drug 











































The most challenging task in treatment of various diseases or injuries in the 
central nervous system (CNS) is to overcome the barrier preventing the drugs moving 
from blood circulation into the brain parenchyma. The limited penetration of drugs 
through the blood brain barrier (BBB) is the rule, not the exception (Pardridge, 2007). 
Essentially, almost 100% of large-molecule pharmaceutics, including peptides, 
recombinant proteins, monoclonal antibodies and RNA interference (RNAi)-based 
drugs, do not cross the BBB. More than 98% of small molecules cannot cross the 
BBB either (Greig, 1989). Ghose have analyzed drugs in the comprehensive 
medicinal chemistry (CMC) database and reported that among more than 7000 drugs, 
only 5% of these drugs may have treatment effects on the CNS diseases, but those 
drug were limited to treatment of just three conditions: depression, schizophrenia and 
insomnia (Ghose et al., 1999). Similarly, Lipinski has also pointed out that although 
12% of all drugs are active in the CNS, only 8% of them are active in the brain for the 
treatment of diseases or disorders (Lipinski, 2000).  
The BBB lies between the blood flow and the brain parenchyma and formed with 
three layers. The first layer of the BBB is mainly consists of a monolayer of polarized 
endothelial cells connected by complex tight junctions (Brightman, 1977). The 
basement membrane forms the second layer. Other cells, such as astrocytes, neurons 
or pericytes which dynamically regulate BBB’s function are the third layer (Janzer 
and Raff, 1987). The specific property of BBB (tight junction) was formed by 
endothelial cells inside the blood vessels. It was just the tight junction which enables 
BBB to prohibit most foreign molecules from entering the brain including CNS drugs. 
INTRODUCTION
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In physiological condition, the BBB provide stability and prevention for the CNS. But 
under pathological condition, the BBB may block the drugs entering the brain and 
therefore void drug effects. For example, many infectious diseases such as 
encephalitis may lead to CNS infection or inflammation, causing hearing loss, 
learning disability, or even endanger the patient life. However, in the therapy of CNS 
infectious and inflammatory diseases, the drug effects may have been hampered by 
the existence of the BBB simply because we may fail to deliver the drug components 
into the brain parenchyma. Thus, exploring strategies for delivering drug across the 
BBB is of great importance in the CNS diseases therapy.  
Up to now, three main strategies have been developed for drug molecules 
penetrating the BBB. The neurosurgically-based strategy intends to temporarily open 
tight junctions between endothelial cells and thus allowing drug molecules to enter the 
BBB directly. The pharmacologically-based strategy is designed to work through 
modification of drug molecules, such as improving their lipophilicity and reducing 
their molecule weights in order to create new properties to facilitate drug transport 
crossing the BBB. However, certain problems are encountered for these two strategies, 
while the neurosurgically-based strategy may face the problem of infection and the 
pharmacologically-based strategy can probably change the therapeutic effects of drug 
components. Recently, a third strategy emerged. It is a physiologically-based strategy. 
This strategy uses chemical bond to couple or physical force to encapsulate the drug 
molecules to a vector or carrier. The vector or carrier may help drug molecules cross 
the BBB through receptor mediated transcytosis or absorptive mediated transcytosis. 
INTRODUCTION
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In this strategy, different kinds of vector/carrier systems, such as monoclonal antibody 
and cationic protein, have been investigated (Bickel et al., 1993; Pardridge et al., 1995; 
Tamai et al., 1997). Among them, the nanoparticle carrier system (Kreuter, 2001) may 
be an outstanding system in the drug transport as many physical properties of the 
nanoparticles can benefit drug transport efficiency across the BBB.  
In this study, a new core-shell nanoparticle micelle system was firstly devised to 
deliver an antibiotic to cross the BBB. This nanoparticle micelle system is made from 
amphiphilic copolymers by self-assembly in aqueous solution. Then, a cell 
penetrating peptide from human immunodeficiency virus (HIV) protein, 
trans-activating transcriptor (TAT) peptide was conjugated to the surface of the 
amphiphilic copolymer. TAT can recognize some receptors of cell plasma membrane 
to induce the transcytosis to bring the drug-nanopartilces system across the BBB 
(Brooks et al., 2005; Lewin et al., 2000; Torchilin et al., 2001). FITC, Quantum Dots 
and hydrophobic antibiotics molecules were successfully encapsulated into this core 
shell structured nanoparticle. They had achieved good penetration through the BBB in 
vivo and in vitro. In addition, hydrophilic antibiotics molecules were directly coupled 
to TAT peptide to form drug-vector system. The delivery of coupled antibiotics was 
primarily investigated. In summary, physiologically-based strategy was used to 
encapsulate or couple drug molecules to a delivery vector. The successful delivery of 
those antibiotics molecules across the BBB suggesting that the TAT-conjugated drug 




1. Central nervous system inflammatory diseases 
Inflammation is the reaction of a tissue and its microcirculation to a pathogenic 
insult. It is characterized by the generation of inflammatory mediators and movement 
of fluid and leukocyte from the blood into tissues (Raphael et al., 2004). CNS 
inflammatory diseases are those inflammation reactions involved diseases that are 
happened in brain or spinal cord. They can be triggered by immunological challenges 
(bacterial or viral infections), neuronal injury, and other epigenetic factors including 
chronic inflammatory syndromes and environmental toxins (Aloisi, 1999; Block and 
Hong, 2005; Hirsch et al., 2005; Kreutzberg, 1996; Minghetti, 2005; Minghetti et al., 
2005; Mrak and Griffin, 2005; Streit, 2000). 
1.1. Brain infectious diseases 
Brain infectious disease is a severe CNS disease. Generally, the infection that 
predominantly affects the meninges surrounding the brain and the spinal cord is called 
meningitis. The infection of the brain tissue is called encephalitis. If both brain and 
meninges are affected, the term meningo-encephalitis is then used (Raphael et al., 
2004). Virus and bacteria are two main sources to infect the brain and induce the 
infectious diseases. 
1.1.1 Viral infections 
Encephalitis is an inflammation of the brain, usually caused by a direct viral 
infection or a hypersensitivity reaction to foreign proteins (such as prion). It is well 
known that Japanese encephalitis virus (JEV) can cause the viral infection of 
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encephalitis (Shoji et al., 1993). Therefore, JEV has been experimentally used to 
create a preclinical model of post-encephalitic parkinsonism in rats (Ogata et al., 
1997). In addition, other viruses such as HSV or HIV can also cause inflammation in 
the CNS.  
1.1.2 Bacterial infections 
Meningitis is mostly caused by bacterial infection. Neisseria meningitidis and 
Haemophil influenzae are the most important causes of this gram-negative bacterial 
meningitis. However, part of gram-negative bacteria or its secretion products can also 
induce brain inflammation. Lipopolysaccharide (LPS), the major component of the 
outer membrane of the gram-negative bacterial cell wall, is just a potent stimulus of 
brain inflammatory diseases (Rietschel and Brade, 1992). The LPS can stimulate the 
secretion of many products by microglial cells including cytokines (TNF-, IL-1, 
and IL-6), chemokines, and prostaglandins (Ajmone-Cat et al., 2003; Chao et al., 
1992; Nagai et al., 2001). Streptococcus pneumoniae is another most common and 
most serious cause of bacterial meningitis, with a mortality rate of 30% and 
neurologic sequelae in 30% to 50% of survivors (Durand et al., 1993; Pfister et al., 
1993). In addition, brain abscesses, CNS tuberculosis and Lyme disease also are 
serious brain inflammatory diseases caused by bacterial infections (Curto et al., 2004; 
Leonard and Des Prez, 1990; Mathisen and Johnson, 1997; Rock et al., 2004; 
Townsend and Scheld, 1998). 
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1.2 Treatment of CNS infectious diseases 
1.2.1 Anti-inflammatory drugs 
Use of anti-inflammatory agents is one of potential therapies for CNS 
informatory diseases. A number of animal studies have indicated that there were 
upregulated expressions of certain inflammatory cytokines such as TNF-, IL-1, 
IL-2, IL-4 and IL-6 by activated microglial cells in inflammation area (Hunot et al., 
1999; Mogi et al., 1994; Mogi et al., 1996). Therefore, a strategy has been developed 
to inhibit the glial reaction or target inflammatory cytokines. For example, IL-1 
levels have been reported to increase rapidly after nigral administration of LPS in 
mice, so the neuroprotection can be achieved with nigral administration of an 
anti-IL-1 neutralizing antibody (Arai et al., 2004; Arai et al., 2006). 
There are many anti-inflammatory drugs that have been used in current therapies, 
including monoamine oxidase B (MAO) inhibitor drug pargyline (Kohutnicka et al., 
1998) and selegiline (Deprenyl) (Klegeris and McGeer, 2000). In addition, the 
immuno-suppressants cyclosporine A and FK-506 and the nonselective COX-2 
inhibitor sodium salicylate have all shown neuroprotective activity in CNS 
inflammatory diseases (Liu and Hong, 2003; Wersinger and Sidhu, 2002). 
In recent years, it has been reported that selective inducible Nitric Oxide 
Synthase (iNOS) inhibitors S-methylisothiourea and LN (G)-nitroarginine had 
neuroprotective effects on dopamine neurons in rats treated with LPS (Arimoto and 
Bing, 2003; Hemmer et al., 2001; Iravani et al., 2002; Le et al., 2001). It is therefore 
suggested that free radical scavengers or iNOS inhibitors may have potential 
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therapeutic effects in CNS inflammatory diseases. 
1.2.2 Anti-Pathogen drugs  
The choice of treatment for brain infection generally depends on its cause (Liu et 
al., 2008b). For the encephalitis caused by virus, the best treatment way is to find 
compound inhibits the replication of the virus. For instance, inosiplex and interferon- 
were reported to be effective for the CNS disease of subacute sclerosing 
panencephalitis (SSPE), which is a progressive and fatal CNS disorder that results 
from a persistent SSPE virus infection (Hosoya, 2007). 
However, for the therapy of CNS inflammatory diseases caused by bacteria or 
fungi, antibiotics (Dashti et al., 2008; Grayo et al., 2008; Kanellakopoulou et al., 2008; 
Kramer and Bleck, 2008; McPherson et al., 2008) and steroids (Dvorak et al., 2004; 
Fitch and van de Beek, 2008; Jubelt, 2006; van de Beek and de Gans, 2006; van de 
Beek, 2007; Weisfelt et al., 2007) may be good choices. Antibiotics are drugs derived 
wholly or partially from certain microorganisms and are used to treat bacterial or 
fungal infections. Antibiotics can either kill microorganisms or stop them from 
reproducing, allowing the body's natural defense system to eliminate them. They have 
been administrated for several decades, and are capable of sterilizing the cerebral 
spinal fluid (CSF) in a relatively rapid and reliable way. 
Antibiotics that are effective in the laboratory may not necessarily work in an 
infected brain or spinal cord. However, the effectiveness of the treatment depends on 
how well the drug will be absorbed into the bloodstream, how much of the drug can 
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reaches the sites of infection in the body, and how quickly the body can eliminate the 
drug. During the clinical application, the biggest obstacle in the antibiotic therapy of 
CNS infectious diseases lies in the successfully delivery of effective antibiotics from 
the bloodstream to the brain parenchyma or spinal cord (Pardridge, 1997; Rubin and 
Staddon, 1999), due to the existence of the blood brain barrier (BBB) or the blood 
cerebral spinal fluid barrier (BCSFB).  
 
1.2.3 Antibiotics selected in this study 
Ciprofloxacin is a broad-spectrum synthetic antibiotic, belonging to an 
antibiotics group called fluoroquinolones. Its mode of action depends upon blocking 
bacterial DNA replication by binding itself to an enzyme called DNA gyrase, a type II 
topoisomerase, and topoisomerase , which is an enzyme necessary to separate 
replicated DNA (Drlica and Zhao, 1997), thereby inhibiting the unwinding of 
bacterial chromosomal DNA during and after the replication (Ball, 1986). 
Ciprofloxacin is used in the chemotherapy of various infectious diseases, including 
CNS infectious diseases, because of their broad and strong antibacterial activity, 
especially against Gram-negative bacteria (de Lange et al., 2000; Ivanov and Budanov, 
2006; Moellering, 1996). Unlike Ciprofloxacin, Penicillin is a group of antibiotics 
derived from Penicillium fungi. They are Beta-lactam antibiotics used in the treatment 
of bacterial infections caused by susceptible, usually Gram-positive, organisms. 
Penicillin works by inhibiting the formation of peptidoglycan cross-links in the 
bacterial cell wall. The -lactam moiety (functional group) of penicillin binds to the 
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enzyme (DD-transpeptidase) that links the peptidoglycan molecules in bacteria, which 
weakens the cell wall of the bacterium. In addition, the build-up of peptidoglycan 
precursors triggers the activation of bacterial cell wall hydrolases and autolysins, 
which further digest the bacteria's existing peptidoglycan. Penicillin G has been 
widely used in the treatment of CNS infectious diseases, especially brain bacterial 
meningitis, in recent decades (Reed, 1986; Tunkel et al., 1990; Vital Durand et al., 
2002).  
Ciprofloxacin and Penicillin are two typical broad-spectrum antibiotics 
commonly used. Ciprofloxacin is mainly against Gram-negative bacteria and 
Penicillin is usually against Gram-positive bacteria. In addition, Ciprofloxacin is 
hydrophobic but Penicillin is hydrophilic. Without any vectors, these two type 
antibiotics both have poor penetration rates through the BBB. As the BBB represents 
an obstacle for the delivery of these antibiotics from the blood to the brain, therefore, 
these two FDA approved antibiotics have been chosen in this study for the 
investigation of drug delivery through the BBB with designed nanoparticles micelles. 
2. The cell biology of the blood brain barrier (BBB) 
The existence of the BBB has been recognized for more than 100 years. In 1885, 
a German microbiologist, Ehrlich, first demonstrated the BBB. He showed the 
evidence for the existence of this barrier between the blood and brain parenchyma. He 
injected vital dyes intravenously and found that, in contrast to other tissues, the brain 
parenchyma was not stained (Ehrlich, 1885). His successor Goldman injected the dyes 
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into the CSF and observed the staining of the brain parenchyma but not of the 
peripheral organs (Goldman, 1913). Since these discoveries, extensive studies have 
been done on the physiology and pharmacology of the BBB (Abbott, 2005; Begley 
and Brightman, 2003; Hawkins and Davis, 2005). 
The brain is perhaps one of the least accessible organs for the delivery of 
functional pharmacological compounds. There are two physiological barriers that 
separate the brain from its blood supply and control the entry and exit of endogenous 
and exogenous compounds. One is the BBB and the other is the BCSFB. The BBB is 
mainly consists of a monolayer of polarized endothelial cells connected by complex 
tight junctions (Brightman, 1977). The function of BBB is dynamically regulated by 
various cells, including astrocytes, neurons and pericytes (Janzer and Raff, 1987). The 
endothelial cells are separated from these other cells by a basal lamina, whose 
components such as type IV collagen, laminin, fibronectin and heparan sulfate may be 
involved in drug transport (Vorbrodt, 1989).  
The BCSFB is located at the choroid plexuses. They are mainly formed by 
epithelial cells held together at their apices by tight junctions. There is a stroma 
containing the blood vessels beneath the epithelial cells. Thus, the fenestrated blood 
vessels of the choroid plexus allow large molecules to pass, but the tight junctions at 
the epithelial cell surfaces restrict their passage into the CSF (Spector and Johanson, 
1989). Because the surface area of the human BBB is estimated to be 5000 times 
greater than that of the BCSFB, the BBB is considered to be the main region 
controlling the uptake of drugs into the brain parenchyma and the target for drug 
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delivery to the brain (Pardridge, 1995). 
2.1 Structure of the BBB 
2.1.1 Endothelial cells 
The BBB is mainly formed by brain capillary endothelial cells (BCEC) (Rubin 
and Staddon, 1999), as Figure 1.1 shown. The tight junctions (TJ) between the 
endothelial cells are an important structural element of the BBB. They prevent 
paracellular transport of foreign compounds from the blood to the brain (Brightman 
and Reese, 1969; Reese and Karnovsky, 1967; Rubin and Staddon, 1999). The tight 
junction consists of tight junctional strands between adjacent brain capillary 
endothelial cells at multiple appositional sites by freeze fracture electron microscopy 




Figure 1.1: The structure of the BBB. The BBB is mainly formed by endothelial 
cells, astrocytes, pericytes and interneuron.(Abbott, 2002) 
 
BCEC generally are situated at the interface between the blood and the brain. 
They perform many essential biological functions such as barrier, transport of 
micronutrients and macronutrients, receptor-mediated signaling, leukocyte trafficking, 
and osmoregulation (Persidsky et al., 2006). However, their most important function 
is the barrier function that prevents the free entry of compounds from the blood to the 
brain (Doolittle et al., 2005). BCEC have greater number and volume of mitochondria 
as compared with endothelium of other organs. The increased content of mitochondria 
enhances the energy potential and is thought to be required for active transport of 
nutrients to the brain. It is estimated that cerebral capillaries have five to six times 
more mitochondria per capillary section than rat skeletal muscle capillaries 
(Oldendorf et al., 1977). 
2.1.2 Other cell types 
Other cell types, such as pericytes, astrocytes, and interneurons, also play an 
important role in the structure and function of the BBB (Gaillard et al., 2000; Janzer 
and Raff, 1987; Lai and Kuo, 2005). Among them, astrocytes form a network fully 
surrounding the capillaries with their foot processes. The tight junction is just induced 
and maintained by the endfeet of these astrocyte cells surrounding the BCEC (Rubin 
and Staddon, 1999). Pericytes share the continuous capillary basement membrane 
with the BCEC (Lai and Kuo, 2005). Their phagocytotic activity forms an additional 
BBB property. Furthermore, pericytes also regulate endothelial homeostasis, thereby 
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negatively regulating brain endothelial fibrinolysis (Kim et al., 2006)). Axons from 
neurons also connect closely against the endothelial cells and contain vasoactive 
neurotransmitters and peptides (Gaillard et al., 2000; Janzer and Raff, 1987). 
2.1.2.1 Astrocytes 
Astrocytes are glial cells that envelop >99% of the BBB endothelium (Hawkins 
and Davis, 2005). In addition to the support function of astrocytes to endothelial cells, 
these two cell types can influence each other’s structure. Their interactions not only 
induce and modulate the development of the BBB and unique BCEC phenotype, but 
also greatly enhance endothelial cell TJ and reduce gap junctional area (Tao-Cheng 
and Brightman, 1988). Besides that, this interaction can increase the number of 
astrocytes membrane particle assemblies and astrocyte density (Abbott, 2002; 
Tao-Cheng et al., 1987; Tao-Cheng and Brightman, 1988). Astrocytes are greatly 
essential for proper neuronal function, suggesting that astrocyte–BCEC interactions 
are essential for a functional neurovascular unit (Abbott et al., 2006). Therefore, it is 
plausible that astrocytes may modulate the BBB phenotype without being directly 
involved in changing the physical BBB properties. 
2.1.2.2 Pericytes 
It has been reported that the association of pericytes to blood vessels may 
regulate endothelial cell proliferation, survival, migration, differentiation, and 
vascular branching (Lai and Kuo, 2005). Pericytes are flat, undifferentiated, 
contractile connective tissue cells that develop around capillary walls (Figure 1.1). 
Microvascular pericytes lack the -actin isoform, suggesting that these cells may not 
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be involved in capillary contraction (Lai and Kuo, 2005). Part of pericytes of the BBB 
may belong to macrophage lineage and they possess the capacity to phagocytose 
exogenous proteins and present antigen (Williams et al., 2001). It was found that the 
lack of pericytes resulted in endothelial hyperplasia and abnormal vascular 
morphogenesis in the brain. There is evidence that pericytes are able to mimic 
astrocyte ability to induce BBB “tightness”(Persidsky et al., 2006). These evidences 
support the hypothesis that pericytes play an important role in maintaining the 
structural integrity of the BBB. 
2.1.2.3 Neurons 
High level of neuronal activity requires tight junction regulation of the 
microcirculation. Also, a close relationship between regional brain activity and blood 
flow was demonstrated by neuroimaging (Paemeleire, 2002). In addition, there are 
evidences that neurons induce expression of enzymes unique for BCEC, such as 
reversible expression of sm alpha-actin protein and sm alpha-actin mRNA induced by 
neuron in cloned cerebral endothelial cells (Tontsch and Bauer, 1991). Therefore, 
these significant evidences suggest that neurons also can regulate functions of the 
BBB. 
2.2 The permeability properties of the BBB 
The BBB significantly impedes free entry of all molecules from blood to brain, 
except those compounds are lipophilic and/or with small molecular weight. Generally, 
the drug molecules with a molecular weight higher than 500 Da and lower 
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lipophilicity cannot penetrate the BBB (de Boer and Gaillard, 2007). These 
impermeable macromolecules may include peptide, protein or other drug molecules. 
However, there are a number of small and large hydrophilic molecules that can enter 
the brain by active transport (Rowland et al., 1992). This active transport is a 
mediated process of moving particles across BBB cell membrane against a 
concentration gradient using chemical energy. For the transport of some essential 
nutrients, such as glucose and certain amino acids (or related molecules, including 
L-DOPA), specific active membrane transporting proteins are present in relatively 
high concentrations in brain endothelial cells. There also seems to be receptor 
mediated transport which is capable of transferring macromolecules into the brain. 
The best known of these is the transferrin receptor (Pardridge, 1997) . Therefore, the 
impermeability or permeability of the BBB is selective. 
 
 
Figure 1.2: Essential features of the blood brain barrier. The BCEC are 
coupled by adherent junction and tight junctions, the latter limiting the paracellular 
flux. (Rubin and Staddon, 1999) 
    The permeability properties of the BBB greatly affect the therapy of the CNS 
inflammatory diseases. The BBB is by far the biggest obstacle to CNS drug delivery 
since the BBB excludes proteins, complex carbohydrates, and other "foreign" 
molecules such as toxins and drugs to enter the brain parenchyma. It results in many 
INTRODUCTION
 17
potential therapeutic agents such as antibiotics cannot reach the CNS (Ghose et al., 
1999; Lipinski, 2000; Pardridge, 2007). For selected antibiotics in this study, they also 
have the difficulty to pass through the BBB. Although Ciprofloxacin tend to distribute 
rapidly into peripheral tissues and fluids, and reach concentrations often higher than 
found in serum or plasma (Sorgel et al., 1989), However, distribution of the unbound 
drugs into the cerebrospinal fluid (CSF) and brain extracellular fluid was shown to be 
poor (Ooie et al., 1996a; Ooie et al., 1996b; Ooie et al., 1996c). For Penicillin G, after 
they enter the blood stream (100%), only 2.6-4.9% (rabbit) or 7.8% (human) of 
Penicillin G entered the CSF because of existence of BBB and BCSFB (Lutsar et al., 
1998; Richards et al., 1981). Therefore, it is of great importance to explode effective 
strategies to overcome the obstacle and deliver the antibiotic drugs to brain. 
 
3. Drug delivery into the brain 
Since the BBB represents an insurmountable obstacle for a large number of 
drugs, including antibiotics, antineoplastic agents, and a variety of CNS-active drugs, 
especially neuropeptides (Kreuter, 2001), for the therapy of brain infectious diseases, 
the biggest challenge is how to introduce a drug to penetrate this barrier. According 
the Comprehensive Medicinal Chemistry database, among more than 7000 drugs, 
only 5% of these drugs may have treatment effects on the CNS diseases, but they are 
limited to treatment of just three conditions: depression, schizophrenia and insomnia 
(Ghose et al., 1999). Another study reports that 12% of all drugs are active in the CNS, 
but of which only 8% are active in the brain for diseases or disorders (Lipinski, 2000). 
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Therefore, it is necessary to develop effective strategies to successfully deliver drug 
molecules through the BBB. 
 
3.1 Possible ways of delivering a compound from blood to brain 
The existing possible ways to deliver a compound from the blood to the brain are 
shown in Figure 1.3.  
 
Figure 1.3: Potential routes for transport through the BBB: cell migration (a), 
passive diffusion (b), active transport (c, d, e and f) and tight junction modulation (g) 
(Begley, 2004) 
 
3.1.1 Cell migration 
It is reported that the leukocyte cells of immune system can migrate through tight 
junction of the BBB under the inflammatory conditions (Begley, 2004; Coisne et al., 
2007; Edens and Parkos, 2000; Shumei Man, 2007). The entry of leukocyte cells into 
brain tissues is governed by the presence of chemokines and adhesion molecules at 
post-capillary venules (Butcher and Picker, 1996; Schenkel et al., 2004; Shumei Man, 
2007; Springer, 1994; Weninger and von Andrian, 2003). Based on the concept of cell 
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migration, the endothelial cells of the BBB actively participate in the inflammatory 
leukocyte migration into the brain by sequential molecular interactions with 
circulating leukocytes. Therefore, if a compound (including possible drugs) can be 
successfully taken into the body of leukocyte cells, it can enter the brain through this 
pathway using drug loaded leukocytes as drug carriers. 
3.1.2 Passive diffusion 
Passive diffusion is a direct and energy free transport way of substance from the 
blood to brain from high concentration side to low concentration side. It only depends 
on lipophilicity and molecular weight of the compound being delivered (Pardridge, 
1995). In general, Lipinski’s rule-of-five and the Abraham’s equation can be used to 
predict the passive transport of a drug molecule across the BBB (Abraham and 
Weathersby, 1994; Lipinski et al., 2001). For hydrophilic compounds, their transport 
via the paracellular route is limited. However, lipophilic drugs smaller than 400–600 
Da may freely enter the brain via this transcellular route. 
3.1.3 Tight junction modulation 
The connection of tight junction is adjusted by stretch and shrinkage of 
endothelial cells and some inflammatory mediators (Abbott and Revest, 1991). The 
result of tight junction modulation would change the permeability of the BBB. Recent 
evidence suggests that many mediators may increase the trans-endothelial 
permeability by raising intracellular free calcium or causing a contractile event that 
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pulls apart the tight junctions (Coisne et al., 2007; Huber et al., 2001; Staddon and 
Rubin, 1996). It suggests that the tight junction modulation can “relaxes” the 
junctions and wholly or partially opens the paracellular aqueous diffusional pathway 
and let the compounds in (Begley and Brightman, 2003). 
 
3.1.4 Active transport 
    Active transport system is the most important transport pathway in the drug 
delivery from the blood to the brain. It can be divided into absorptive-, carrier-, or 
receptor mediated transcytosis. 
    3.1.4.1 Carrier mediated transcytosis (CMT) 
Carrier-mediated transcytosis is generally used for the delivery of nutrients, such 
as glucose, amino acids, and purine bases to the brain (Abbott and Romero, 1996; 
Ikumi Tamai, 2000). Up to now, at least eight different nutrient transport systems 
have been identified, with each transporting a group of nutrients of the same structure. 
CMT is substrate selective and the transport rate is dependent on the degree of 
occupation of the carrier (Smith, 1993). Therefore, only drugs that closely mimic the 
endogenous carrier substrates will be taken up and transported into the brain. 
3.1.4.2 Receptor mediated transcytosis (RMT) 
In contrast to CMT, some larger molecules, such as peptides, proteins, and genes 
specifically enter the brain via receptor-mediated transcytosis. Classical examples of 
receptors involved in receptor-mediated transcytosis are the insulin receptor (Duffy 
and Pardridge, 1987); the transferrin receptor (Moos and Morgan, 2000; Pardridge et 
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al., 1987); and the transporters for low-density lipoprotein (Dehouck et al., 1997), 
leptin (Bjorbaek et al., 1998), and insulin-like growth factors (Duffy et al., 1988). 
3.1.4.3 Absorptive mediated transcytosis (AMT) 
Absorptive-mediated transcytosis is initiated by the binding of poly-cationic 
substances (such as most cell-penetrating peptides) to negative charges on the surface 
of cell plasma membrane (Vorbrodt, 1989). The substance for delivery was charged. 
This is the biggest difference contrast to those substance transported by RMT. This 
process of AMT does not involve any specific plasma membrane receptors. 
Endocytosis occurs upon the binding of the cationic compound to the plasma 
membrane. Some nanoparticle drug delivery systems with a cell-penetrating peptide 
may use this way to penetrate the BBB and bring drug molecules to the brain (Santra 
et al., 2005; Torchilin et al., 2001). 
3.2 Strategies for drug delivery into the brain
Clinically, several strategies for drug delivery into the brain have been 
developed according possible routes of transport through the BBB
3.2.1 Neurosurgically-based strategy 
The BBB disruption is a neurosurgically-based strategy (Bobo et al., 1994; Kroll 
et al., 1996). A number of means such as intra-carotid arterial infusion of 
hyperosmotic solutions, administration of noxious agents including vasoactive 
compounds, or local ultrasonic irradiation of the brain can transiently disrupt the BBB 
(Emerich et al., 1998; Neuwelt and Rapoport, 1984). The temporary opened tight 
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junction of the BBB will allow the drug molecules to enter the brain parenchyma. 
Although these invasive methods are traditional and have achieved some success, the 
risks of infection and neuropathological changes due to disruption of the BBB 
emphasize the need to develop new noninvasive delivery strategies. 
3.2.2 Pharmacologically-based strategy 
The pharmacologically-based strategy is a noninvasive approach. Recent studies 
have found that factors such as lipophilicity and molecular weight may modulate the 
passive transport of a drug across the BBB. Therefore, this strategy will focus on drug 
molecule modification by reducing polar groups or adding methyl groups to create 
new drug properties (such as lipophilicity) to allow drug crossing the BBB easily 
(Greig, 1989). 
 3.2.2.1 Drug lipophilicity modification 
Lipophilicity modification can convert water-soluble drugs into lipid-soluble 
drugs or attach lipid carriers to water-soluble drugs to facilitate the drugs to cross the 
BBB. However, it is not easy for the reformulation of a water-soluble drug with 
lipidization modifications. Therefore, currently no drug has been successfully 
converted from non-brain-penetrating into a brain penetrating molecule that could 
cross the BBB in pharmaceutical market. 
Lipid carriers that have been used include dihydropyridine, adamantane and fatty 
acylcarriers, such as N-docohexaenoyl (Bodor, 1994; Shashoua and Hesse, 1996; 
Tsuzuki et al., 1994). However, the increased lipid solubility obtained by attaching a 
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lipid carrier to a drug may not simply increase its passage across the BBB; it may also 
increase its penetration into other cells and tissues in the body. 
   3.2.2.2 Other modifications 
As the BBB generally allowed molecules <400 Da crossing the BBB and reach 
brain, drug molecule can be modified by reducing the relative number of group 
without affecting the functional group to get a lower molecule weight. It will promote 
the penetration of the drug through the BBB. In addition to the molecular weight 
modification, drugs can also be modified to take advantage of native BBB nutrient 
transport systems. For example, the BBB large neutral amino-acid carrier has been 
used to deliver L-DOPA in Parkinson’s disease (Wade and Katzman, 1975). 
However, in most cases, the modification of the drug molecules may change the 
therapeutic properties of the drug, resulting in the dysfunction of drug. Therefore, a 
better drug delivery strategy is required to transport a drug with preservation of the 
functional molecular structure into the brain. 
3.2.3 Physiologically-based strategy 
This strategy takes advantages of the physiological transport of endogenous 
substances from blood to brain. It uses physical force to encapsulate or chemical 
bonds to couple the drug molecules to a vector and deliver them across the BBB 
through RMT or AMT (Pardridge, 1999; Tamai et al., 1997). These vectors can be 
monoclonal antibody, liposome, cationic protein and nanoparticle system. Vectors can 
be recognized by the receptors located in the endothelial cell membrane and absorbed 
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into the cell by transcytosis. Besides, vectors may form the endosomes at cell plasma 
membrane to induce transcytosis. This strategy is also noninvasive to the BBB and 
has good safety profiles and high efficacy drug transport. 
 3.2.3.1 Endogenous BBB transporters 
This approach is based on knowledge of endogenous BBB transporters. It aims to 
reformulate drugs to be substrates for various endogenous transporters at the BBB so 
that these molecules can cross the BBB via endogenous transport systems. The 
principle of this strategy can be also applied to large peptides and proteins that may 
use either RMT or CMT to carry the peptide or protein across the cerebral 
endothelium (Bickel et al., 1994). 
An example of the drug transport by endogenous BBB transporters is the use of 
monoclonal antibodies (OX26) to the transferring receptor that abundantly expressed 
in the luminal membrane of the BBB. The OX26 antibody may be used as a vector for 
CNS delivery and can be linked to a drug or biologically active peptide or protein 
which normally can not cross the BBB. The binding of the OX26 antibody to the 
transferrin receptor appears to induce endocytosis and the entire construct will then 
penetrate the BBB (Bickel et al., 1994).   
Drugs that enter the brain via endogenous transporters includes valproic acid, 
L-DOPA, mepyramine, oxazolamine COR3224 et al (Begley, 2004). They use 
different transports (such as Medium-chain fatty acid carrier, large neutral amino acid 
carrier or Nucleoside carrier) to cross the BBB by RMT or CMT. 
   3.2.3.2 Cell-penetrating peptide vectors 
INTRODUCTION
 25
Several cell-penetrating peptides which can quickly enter cells have been 
developed recently (Wadia and Dowdy, 2002; Zhao and Weissleder, 2004). At present, 
it is still not completely clear what the mechanism by which these peptides can cross 
the cell membrane is. Some researchers believed that the peptides by virtue of their 
structure penetrated directly through the cell membrane (Derossi et al., 1996; Vives et 
al., 1997). They may thus be able to penetrate the cell membrane without causing any 
damage. They may use a similar manner to a signal peptide entering the endoplasmic 
reticulum and carrying with it a nascent protein during the normal process of protein 
synthesis and post-translational modification. 
   One of these cell-penetrating peptides, transactivating-transduction (TAT), has 
been a research hotpot in recent years. It acts in the process of replication of the HIV 
virus by penetrating the nuclear membrane and acting as an activator of transcription 
(Torchilin et al., 2001; Wadia and Dowdy, 2002). The TAT peptide has been shown 
to carry heterologous proteins into several cell types (Fawell et al., 1994) and across 
the BBB (Schwarze et al., 1999). Other two cell-penetrating peptides, penetratin and 
SynB1 were also investigated. When they were linked to doxorubicin in a rat in situ 
brain perfusion model, the increased CNS levels of doxorubicin by 3 to 8 times 
compared with doxorubicin alone was found (Rousselle et al., 2000). 
Therefore, this physiologically-based strategy may require drug molecules to be 
linked to the cell-penetrating peptide vector by chemical or physical force (Liu et al., 
2008a). With the aid of the vector, the drug can penetrate the BBB and be delivered to 
the brain parenchyma. 
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    3.2.3.3 Liposomes and nanoparticles 
Liposomes and nanoparticles have large and complex constructs which can be 
made from a variety of chemical constituents. Relatively large amounts of drug or 
agent can be incorporated into these structures. Liposomes and nanoparticles may 
provide the possibility for significant drug delivery to the CNS. The surface of the 
liposome or nanoparticle can be modified and be attached with some biological 




Figure 1.4: An immunoliposome (A) and a PBCA nanoparticle (B).  A: A 
plasmid DNA containing a gene is packaged into the center of an 85 nm diameter 
liposome. The surface of the liposome is coated with ~2000 strands of PEG, which 
reduces uptake by the RER.   B:A drug can be incorporated into the 250 nm 
diameter nanoparticle during polymerization or absorbed onto the surface of the 
preformed particle. The particle is then coated with polysorbate 80 (Tween 80), which 
further binds Apo-E in the bloodstream.(Begley, 2004) 
 
PEGylated immunoliposomes or nanoparticles have been employed to deliver 
many kinds of CNS drugs. Also, they are applied to target and transfect 
h-galactosidase (LacZ reporter gene) or luciferase into the brain (Pardridge, 2002; Shi 
et al., 2001). The gene is encapsulated into the center of the liposome and its surface 
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is then coated with polyethylene glycol (PEG) to prolong the circulation time by 
reducing uptake by the reticulo-endothelial system (RES). Using this approach, both 
hgalactosidase and luciferase have been targeted to the brain and the relevant enzyme 
is expressed (Shi et al., 2001). 
Poly(butyl)cyanoacrylate (PBCA) nanoparticle is another nanoparticle that has 
also been used to deliver drugs to the CNS with a good degree of success (Alyautdin 
et al., 1997; Alyautdin et al., 1998; Steiniger et al., 2004). Drugs such as Loperamide 
(Alyautdin et al., 1997), Tubocurarine (Alyautdin et al., 1998), Doxorubicin (Steiniger 
et al., 2004) have been successfully delivered to the CNS using PBCA nanoparticles 
TAT cell-penetrating peptide may be conjugated to the surface of both liposomes 
(Torchilin et al., 2001) and nanoparticles (Lewin et al., 2000). It appears to greatly 
penetration ability through the BBB, although nanoparticles and liposomes are 
relatively complex and large structures. This may be applied in the drug delivery 
targeted the brain. 
 
4. Nanoparticles in the brain drug delivery 
Nanoparticles are solid colloidal matrix-like polymeric particles made of natural 
or artificial polymers (Soppimath et al., 2001) or lipids (Wissing et al., 2004). Their 
particle sizes range from about 10 nm to 1000 nm (Kreuter, 1994). Generally 
administered by the intravenous route similar like liposomes, they have been 
developed as therapeutic or imaging agents for targeted brain delivery. Their main 
advantages over liposomes are the simple preparation procedures, a high physical 
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stability, and the possible sustained drug release and these advantages may be suitable 
for treatment of chronic diseases (Olivier, 2005). 
One potential application of nanoparticles is the drug delivery to the brain. It 
accompanied with the local sustained release of the new large therapeutic molecules, 
such as peptides, proteins, genes or anticancer drugs, to treat CNS diseases. However, 
due to their size ranging between 10 and 1000 nm (generally 50–300 nm), they are 
unable to diffuse through the BBB to reach the brain parenchyma. The RMT or AMT 
might be the route for the particle to cross the BBB and deliver the drug to the 
targeted site. 
4.1 Ideal properties of nanoparticles for brain drug delivery
Based on general formulation considerations and specific BBB features, the ideal 
properties of nanoparticles for brain drug delivery must meet the requirements as 
follows: 1) Nontoxic, biodegradable, and biocompatible; 2) Particle diameter <200 
nm; 3) Physical stability in blood (no aggregation); 4) Avoidance of the monuclear 
phagocyte system (MPS, no opsonization), prolonged blood circulation time; 5) 
BBB-targeted and brain delivery (receptor-mediated transcytosis across brain 
capillary endothelial cells); 6) Scalable and cost-effective manufacturing process; 7) 
Amenable to small molecules, peptides, proteins, or nucleic acids; 8) Minimal 
nanoparticle excipient-induced drug alteration (chemical degradation/alteration, 




4.2 Some successfully developed nanoparticles in brain drug delivery 
Since the first papers in 1995, nanoparticles made of poly(butyl) cyanoacrylate 
(PBCA) that coated with the nonionic surfactant polysorbate 80 have been intensely 
investigated. This nanoparticle permits the delivery of drugs to the brain (Kreuter et 
al., 1995). Also, in the mid 1990s, long-circulating PEGylated PLA or PLGA 
nanoparticles have opened great opportunities for targeted drug delivery to brain 
(Gref et al., 1995). The nanoparticle made of polylactide homopolymers (PLA) or 
poly(lac-tide-co-glycolide) heteropolymers (PLGA) may be a promising drug delivery 
carrier to deliver drugs across the BBB. 
 
4.2.1 PBCA nanoparticles 
Nanoparticles made by poly(alkylcyanoacrylate) polymers were described in 
1977 at the first time (Couvreur et al., 1977). They are generally prepared from (iso) 
butyl-cyanoacrylate or (iso)hexyl-cyanoacrylate monomers (Figure 1.5) by emulsion 
anionic polymerization in an acidic aqueous solution of a colloidal stabilizer such as 
dextran 70, polysorbates, and poloxamers. These particles typically have diameters of 
250nm. Inclusion of a drug can be made during the polymerization process or by 
adsorption into preformed nanoparticles. The particles are then coated with 
polysorbate 80 (Ramge et al., 2000), a compound that might induce the transcytosis in 





Figure 1.5: Structure of poly(alkylcyanoacrylate).
 
The use of PBCA nanoparticles to deliver a drug to the CNS has achieved a good 
degree of success (Alyautdin et al., 1997; Alyautdin et al., 1998; Gulyaev et al., 1999; 
Kreuter, 2001; Steiniger et al., 2004). It was reported that intravenous administration 
of polysorbate 80-coated PBCA nanoparticles encapsulated with doxorubicin 
(Gulyaev et al., 1999; Steiniger et al., 2004), loperamide (Alyautdin et al., 1997), 
tubocurarine (Alyautdin et al., 1998) or hexapeptide dalargin (Kreuter et al., 1995) 
could facilitate the delivery of the compounds to the brain, where they could have 
their pharmacological effects. As for the mechanism, it was hypothesized that 
polysorbate-coated nanoparticles were transported across the BBB via endocytosis by 
the brain capillary endothelial cells (Kreuter, 2001). This endocytosis may be 
triggered by a serum protein, apolipoprotein E. It was reported that the absorption on 
polysorbate 80-coated nanoparticles occurred 5 minutes after incubation in 
citrate-stabilized plasma at 37°C. Despite a number of arguments listed by Kreuter 
(Kreuter, 2001), Oliver hypothesized a possible mechanism involved in a 
nanoparticle-induced nonspecific BBB permeabilization (Olivier et al., 1999), which 
has been supported by some important observations (Olivier, 2005), It suggested that 
the polysorbate 80 can cause BBB disturbance and dramatically increase BBB 
permeability. However, the exact mechanism of the transport through this 
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nanoparticle system is still not clear. 
   Although the study of the PBCA nanoparticle carrier has achieved great success in 
delivering some drugs to the CNS, certain limitations may preclude, or at least limit, 
their potential in clinical applications. First, the interaction between capsulated drugs 
and the nanoparticles may lack stability (Olivier et al., 1999), or, the drug-capsulated 
nanoparticles may disperse in blood stream by a combined effect of serum protein 
competition and polymer degradation (Olivier et al., 1996). Second, the rapid 
degradation rate of nanoparticles in vivo greatly limits their application. Because of 
the lacking of stable properties, the PBCA nanoparticles intravenously administrated 
will be rapidly cleared from the blood stream by the mononuclear phagocyte system 
(MPS) and mainly accumulate in liver and spleen (Douglas et al., 1987; Grislain et al., 
1983; Waser et al., 1987). The degradation of nanoparticles may also affect the loss of 
compounds entrapped (Lobenberg et al., 1998; Simeonova et al., 1988; Verdun et al., 
1990). At last, the toxicity of nanoparticles can not be neglected. It has been known 
for a long time that polysorbate 80 can cause BBB disturbance (Azmin et al., 1985) 
and dramatically increase BBB permeability. This is a potential threat to the safe 
application of drugs in the CNS. The polysorbate 80-coated PBCA nanoparticles can 
induce a dramatic decrease in mice locomotor activity in vivo. In summary, novel 
designed nanoparticles, which are nontoxic and have prolonged blood circulation time 
and lower mononuclear phagocyte system uptake, should be developed to serve as a 
drug carrier system for brain drug delivery. 
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4.2.2 PEGylated PLA/PLGA nanoparticles 
PEGylated nanoparticles are a newly developed drug delivery system for 
intravenous drug administration. The PEG coating on the particle surface can provide 
protection against interference from the blood components, resulting in a prolonged 
time in blood circulation by reducing the particle capture by the reticulo-endothelial 
system (RES) cells (Mosqueira et al., 2001). The degradable core of nanoparticle was 
formed by a variety of polymers, such as polylactide (PLA) or poly(lac-tide-co- 
glycolide) (PLGA). Various drugs could be encapsulated into the core and released 
continuously (Gref et al., 1995). PEGylated nanosparticles could be good candidates 
to encapsulate drugs and transport them through the BBB and reach the brain 
parenchyma. 
    4.2.2.1 Nanoparticle preparation
Nanoparticles made of mPEG-PLA/PLGA copolymers are mainly prepared by 
the technique of emulsion/solvent evaporation or the precipitation/solvent diffusion 
(Soppimath et al., 2001). Briefly, for the technique using emulsion/solvent 
evaporation, copolymers are dissolved in an organic solvent immiscible to water and 
emulsified in an aqueous phase generally containing an emulsifying agent. Then the 
solvent is evaporated off under normal or low pressure to form nanoparticles. In the 
method employing solvent diffusion, polymers are dissolved in an organic solvent 
miscible to water and dispersed in an aqueous phase generally containing a colloid 
stabilizer. The almost instantaneous diffusion of the organic solvent into the aqueous 
phase results in the precipitation of the copolymers as nanoparticles. Finally, the 
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solvent is evaporated off as above or extracted by dialysis against water (Lee et al., 
2004). Generally, only compounds that can dissolve in the organic solvent can be 
incorporated by the second method. 
Because of their difference in water solubility, the hydrophobic PLA/PLGA and 
hydrophilic PEG of the mPEG-PLA/PLGA copolymer tend to phase-separate in 
aqueous solvent. Therefore, in the process of the organic solvent evaporation or 
diffusion, the PEG chains migrate to the aqueous phase, whereas the hydrophobic 




Figure 1.6: Structure of methoxypoly (ethylene glycol)-polylactide [or poly 
(lactic acid)] (mPEG-PLA)(A), methoxypoly (ethylene glycol)–poly (lactide-co 
-glycolide) [or poly-(lactic-co-glycolic acid)] (mPEG-PLGA) (B) and the core shell 
structure of nanoparticles (C). 
 
 4.2.2.2 PEGylated nanoparticles conformations 
mPEG-PLA/PLGA nanoparticles are constituted of a PLA/PLGA hydrophobic 
core inside and surrounded by a hydrophilic PEG corona outside. PEG conformation 
at the surface of PLA-PEG nanoparticle is important for the function of the PEG layer 
(Chognot et al., 2003; Gref R et al., 1998; Riley T et al., 1999; Riley T et al., 2001; 
Stolnik et al., 2001). The thickness of PEG layer depends on the PEG molecular 
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weight and surface density. Depending on their surface density, PEG chains may have 
brush-like (high density) or mushroom-like (low density) conformations (Gref R et al., 
1998; Stolnik et al., 2001). PEG surfaces in brush-like and intermediate 
configurations may be able to reduce phagocytosis and complement activation, 
whereas PEG surfaces in mushroom-like configuration could be potent complement 
activators and favored phagocytosis (Gbadamosi et al., 2002; Gref R et al., 2000; 
Moghimi and Szebeni, 2003; Vittaz et al., 1996). Due to the variation in the PLA or 
PEG molecular weights, the conformation of PEG chains at the PEG-PLA 
nanoparticle surface is a complex issue to be addressed. At nanoparticle surface, the 
area available per PEG chain at the outer boundary of the shell is dependent on PEG 
to PLA molecular weight ratio that governs the PLA packing density and the surface 
curvature (linked to the nanoparticle size) of the assembly (Chognot et al., 2003; 
Heald et al., 2003; Riley T et al., 1999).  
 4.2.2.3 Application of PEGylated nanoparticles in brain drug delivery 
Various kinds of conventional drugs can be encapsulated into the PEGylated 
PLA/PLGA nanoparticles. Examples are savoxepine (Allemann et al., 1993), 
doxorubicin (Yoo and Park, 2001) and irinotecan (Onishi et al., 2003). Because PLA 
and PLGA are hydrophobic molecules, lipophilic or hydrophobic drugs are easier to 
encapsulate in PLA/mPEGPLA nanoparticles than hydrosoluble ones.  
Besides conventional drugs, peptides, polypeptides, and protein drugs also can 
be formulated as PEGylated nanoparticles. Except for the formulation issues inherent 
to peptide chemical instability or chemical reaction between peptides and polymer 
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degradation products (Lucke et al., 2002), the formulation of peptide-encapsulated 
nanoparticles is similar to conventional drugs (Elamanchili et al., 2004; Hiroaki et al., 
1994; Kawashima et al., 1998). But for the protein drug, it is of great importance for 
their stability, integrity and activity during the process of encapsulation. It requires 
that each nanoparticle encapsulation of protein is unique and requires specific 
adaptation and evaluation. This goal can be achieved by various means such as 
altering preparation processes (Zambaux et al., 1999) and changing polymer (Gasper 
et al., 1998; Tobio et al., 1998), which may provide sustained release of active protein 
over several weeks in vitro (Gasper et al., 1998; Tobio et al., 1998). 
PEGylated nanoparticles have also been used to targeted transfection of 
h-galactosidase (LacZ reporter gene) and luciferase into the brain (Pardridge, 2002; 
Shi et al., 2001). This kind of plasmid DNA encapsulated nanoparticles are generally 
prepared using the solvent evaporation technique (Perez et al., 2001; Prabha et al., 
2002) to incorporate drugs into the center of the nanoparticles. 
Great successes have achieved in the field of brain targeting with colloidal drug 
carriers with PEGylated immunoliposomes that access the brain from blood via RMT 
and deliver small drug molecules or plasmid into the brain parenchyma, without 
damaging the BBB (Huwyler et al., 1996; Shi and Pardridge, 2000; Shi et al., 2001; 
Zhang et al., 2003). This requires the presence of receptor-specific biological 
targeting ligands at the tip of 1-2% of the PEG2000 strands, such as TAT peptide. Up 
to now, several functionalized copolymers have been recently synthesized: the 
biotinylated (Salem et al., 2001), the amine-reactive (Tessmar et al., 2002) and the 
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thiol-reactive copolymers (Olivier et al., 2002; Tessmar et al., 2003) that permit 
protein chemical conjugation in nondenaturing conditions. Biotinylated PEG-PLA 
nanoparticles may link biotinylated antibodies through an avidin spacer (Gref et al., 
2003), or avidinantibody conjugates (Kang et al., 1995). Amine-reactive PEG-PLA 
can directly react with amino groups of the lysine residues of antibodies in mild 
conditions. With the biological ligands, the PEGylated nanoparticles could be 
promising brain drug carrier for the delivery across the BBB. 
4.2.3 The advantages and the disadvantages 
Most of PEGylated nanoparticles are biodegradable and have a good CNS 
biocompatibility. They can provide sustained drug release in vitro and in vivo. The 
core shell structure formed by PEG and hydrophobic molecules can encapsulate 
various drug molecules. Therefore, this PEGylated nanoparticle can be carrier for 
drug delivery to the brain. After penetrating the BBB with the aid of different 
biological ligands, these targeted specific nanoparticles can be delivered to the 
specific area of the brain. 
In addition, PEGylated nanoparticles may be possibly used for encapsulation of 
various contrast agents. This encapsulation of contrast-enhancing agents have been 
developed to resolve and contrast tissues for diagnostic imaging (Unger et al., 1989).  
Another advantage of PEGylated nanoparticles is the possibility of attaching 
antibodies or a fragment of them to the surface of the particles. In order to achieve site 
specific drug delivery, it is not necessary to destabilize these antibodies and fragments 
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because of the stability of PEGylated nanoparticles (Gref et al., 1995). 
Although the mPEG-PLA/ PLGA nanoparticle provides great opportunities for 
drug delivery through the BBB, it still faces the problem of toxicity. The PLA parts of 
nanoparticles are toxic with 40% death at a 220 mg/kg dose and 100% at a 440 mg/kg 
dose along with marked clinical signs such as dyspnea, reduced locomotor activity or 
alteration of hematological and biochemical parameters and lung hemorrhage (Plard 
and Didier, 1999). As compounds with both hydrophobic and hydrophilic groups can 
form the core shell structure by self assembly, in this project, a new core sell 
PEGylated nanoparticle can be designed using nontoxic b-Cholesterol to substitute 
toxic PLA/PLGA. 
 
4.3 Possible mechanism of nanoparticle-mediated transport of drugs 
across the BBB 
The mechanism by which the nanoparticles facilitate drug entry into the brain is 
not fully elucidated. In principle, six different possibilities exist that could enhance 
transport of drugs across the BBB by means of nanoparticles (Kreuter and Alyautdin, 
2000): 
    1) Preferential adsorption of nanoparticles to the walls of the brain blood vessel 
without transport of particles across the endothelium; 2) Fluidization of the 
endothelium by the surface activity of the surfactant polysorbate-80; 3) Opening of 
the tight junctions of the brain endothelium; 4) Endocytosis by the brain endothelial 
cells; 5) Transcytosis through the brain endothelial cells; 6) Blockage of the 
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P-glycoprotein by polysorbate 80. 
 
5. Drug delivery system designed in this study 
As described before, PEGylated polymer micelles formed by a hydrophilic shell 
and a hydrophobic core are promising carriers for incorporation of hydrophobic drugs 
to improve the bioavailability of the drugs and prolong their blood circulation. In this 
project, in order to take advantage and overcome disadvantage of PEGylated 
nanoparticles, a novel nanoparticle carrier system with PEG and b-cholesterol has 
designed in the current study. A cell penetrating peptide, TAT, was further conjugated 
to the surface of the nanoparticle to facilitate the cell transcytosis. The drug molecules 
will be encapsulated into the core of the PEGylated polymer micelles. 
 
5.1 PEG (poly (ethylene glycol)) and b-cholesterol
In early 1980s, Illum and Davis found that after coating of the nanoparticles with 
PEG-containing surfactants, the blood circulation time for the compound could be 
prolonged and their uptake by the RES organs was reduced significantly (Illum and 
Davis, 1983). A highly flexible and hydrated PEG chain attached to the nanoparticle 
surface is assumed to have an effective protein-resistant property due to its steric 
repulsion effect. Polysorbate 80 coated PBCA nanoparticles were first investigated in 
vivo to enhance the brain transport of the hexapeptide dalargin (Schroder and Sabel, 
1996). The results showed that after intravenous injection, polysorbate 80 coating 
enabled the highest induction of analgesia in mice. Likewise, other drugs that 
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normally do not penetrate the BBB, such as tubocurarine, loperamide and doxorubicin 
showed higher concentrations in the brain when associated with polysorbate 
80-coated nanoparticles (Blasi et al., 2007). The protein ApoE or B absorption on the 
nanoparticles, followed by low density lipoproeitn (LDL) receptor mediated 
endocytosis and transcytosis, is believed to facilitate the uptake of the nanoparticles 
by the brain (Figure 1.7). 
 
Figure 1.7: A proposed mechanism of brain uptake of polysorbate 80-coated 
nanoparticles. 1. Apo adsorption on nanoparticle surface. 2. Nanoparticle binding to 
the LDL receptors of the BBB. 3. Drug release after endocytosis and transcytosis. 
(Blasi et al., 2007) 
 
In addition to PEG-surfactant coating, micelles self-assembled from amphiphilic 
PEGylated polymers provide better choice due to chemical binding of PEG. The PEG 
chains were first bound to poly (lactic acid) nanoparticles by Gref (Gref et al., 1994) 
and (Bazile et al., 1995). Later on PEG was chemically linked to poly(hexadecyl 
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cyanoacrylate nanoparticles (PHDCA) (Peracchia et al., 1997; Peracchia et al., 
1999).The preparation of the PEG-PHDCA copolymer was achieved by the synthesis 
of a cyanoacrylate monomer substituted with PEG and its co-polymerization with 
hexadecylcyanoacrylate in a 1:4 ratio. Both types of nanoparticles, the PEGylated 
poly (lactic acid) and poly (hexadecylcyanoacrylate) (PHDCA) nanoparticles, 
significantly prolonged the blood circulation time and reduced the liver uptake. Calvo 
et al. investigated the distribution of PEG-PHDCA nanoparticles in EAE rats (Calvo 
et al., 2001). Analysis by confocal microscopy evidenced that fluorescent 
PEG-PHDCA nanoparticles were present in the endothelial cells of the brain and 
spinal cord surface and in the ependymal cells of the choroid plexus. It was 
hypothesized that PEG-PHDCA nanoparticles reached the brain by two mechanisms: 
passive diffusion due to the increase of the BBB permeability and transport by 
nanoparticles-containing macrophages, which infiltrated these inflammatory tissues. 
The PEGylated PHDCA nanoparticles accumulated in the brain was at a 4-8 fold 
higher concentration than non-PEGylated PHDCA nanoparticles after intravenous 
injection into rats (Brigger et al., 2002). 
Therefore, the covalent attachment of PEG chains is a promising step forward. 
Other PEG-containing copolymers showing potential ability for drug delivery to the 




Figure 1.8: Examples of PEG containing block polymers for drug delivery. 
 
As it has been known, cholesterol is a lipid found in the cell membranes and 
transported in the blood plasma of all animals. Its chemical structure is shown by 
Figure 1.9. The molecules of cholesterol are hydrophobic. In the current project, 
non-toxic cholesteryl chloroformate (b-cholesterol) was used to attach the PEG chains 
under suitable conditions by EDC/NHS chemical reaction. After the coating of PEG 
chain to the molecules of b-cholesterol, this amphiphilic polymer micelle can self 
assemble the core shell structure in aqueous solvent. 
 
 
Figure 1.9: Structure of Cholesterol 
 
5.2 TAT: a cell penetrating peptide 
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    In addition to provide spatial stabilization, the presence of PEG on the surface of 
the micelles also allows the preparation of bioactive polymeric micelles. The 
bioactive ligands can be attached on the surface of micelles for drug delivery to the 
targeted brain. Two reasons for the design of ligands coating for drug carriers: 1, 
Ligands (antibody, protein, peptide, sugar moieties, folate or carbohydrate) attached 
to the carrier surface may increase the rate of its elimination in the blood and uptake 
in the liver and spleen; 2, Longevity of the specific ligand-bearing nanocarrier may 
allow for its successful accumulation in targets. 
Covalent linkage of biological ligands to the nanoparticles is typically made by a 
simple coupling reaction between amine-functionalized nanoparticles and 
succinimidyl ester derivatives.  
The successful strategy of delivering substances that are unable to cross the BBB 
is the use of transport vectors, which activate natural transport routes. The 
endogenous CMT for nutrients and AMT /RMT for peptides are portals of entry to the 
brain for circulating drugs.  
The BBB expresses several transport systems for nutrients (Tsuji and Tamai, 
1999), but the utilization of these transport systems for targeting the drugs into the 
brain is mainly limited to peptide drugs, which must have a molecular structure 
mimicking the endogenous nutrients. The prototypical example is levodopa, a 
lipid-insoluble precursor of dopamine that has been used for the treatment of 
Parkinson’s disease because it contains the carboxyl and -amino groups that allow it 
to compete for transport across the BBB by the large neutral amino acid carrier (Wade 
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and Katzman, 1975). In addition, since nutrient carriers stay in the membrane of the 
cells, the size of the drugs must be close to that of the endogenous ligand if they will 
be taken up and transferred into the brain 
     In the past decade, a number of cell-penetrating peptides (CPPs) have emerged, 
facilitating the intracellular delivery of polar biomolecules in vitro and in vivo. While 
these individual peptides differ in length and sequence, they share a few common 
features, which include theoretical hydrophobicity and helical moment, the ability to 
interact with lipidic membranes, and to adopt a distinct secondary structure upon 
association with lipids (Deshayes et al., 2005). These CPPs theoretically would be 
expected to be less able to affect the physicochemical properties of the active 
molecule. In any case, the ability of these short peptides to cross plasma membranes 
even when associated with hydrophilic cargoes, makes them a worthwhile technology 
for further study and development. 
Table 1 summarizes the majority of cell penetrating peptides with their principal 
features. Primary attention is dedicated to TAT peptide.  
Table 1: Principal features of the cell penetrating peptides 
 
Name Sequence Charge Cell lytic activity 
MAP KLALKLALKALKAALKLA +5 YES 
pAntp43-68 RQIKIWFQNRRMKWKK +8 NO 
Transportan GWTLNSAGYLLGKINLKALAALAKKIL +4 YES 
SBP MGLGLHLLVLAAALQGAWSQPKKKRKV +6 _ 
FBP GALFLGWLGAAGSTMGAWSQPKKKRKV +6 _ 
TAT48-60 GRKKRRQRRRPPQ +8 NO 
SynB1 RGGRLSYSRRRFSTSTGR +6 NO 
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SynB3 RRLSYSRRRF +6 NO 
 
TAT protein is a HIV-transcription activating factor with a full length of 101 
amino acids. Figure 1.10 shows the chemical structure of TAT (47-57) peptide, a 
NH2-terminal 11 amino acid cell penetrating peptide used in this study. TAT protein 
consists of five domains; the probably best-studied region of TAT is located in 
domain 4, which contains a highly basic region (with two lysines and six arginines in 
nine residues) involved in nuclear and nucleolar localization (Brigati et al., 2003). 
While all CCPs listed above have been used for small cargoes such as peptide and 
oligonucleotides, TAT has been used more often for delivery of larger molecules such 
as proteins, one example is -galactosidase (MW=540 kDa) (Loftus et al., 2006). 
 
Figure 1.10: Structure of TAT (47-57) peptide 
 
Schwarze firstly synthesized the full-length fusion proteins that contained a 
NH2-terminal 11-amino acid protein transduction domain from HIV transactivator of 
transcription (TAT) protein (Schwarze et al., 1999). Transduction of the proteins 
evaluated was non-cell-specific, and was seen to occur even across the BBB. Further 
proof of this mode of peptide delivery was attained by Cao who fused the 
antiapoptotic protein Bcl-xL to TAT and injected the construct intraperitoneally into 
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mice that were affected by stroke (Cao et al., 2002). The Bcl-xL protein is expressed 
in adult neurons of the CNS and is believed to have an important role in the 
prevention of neuronal apoptosis that normally would occur during brain development, 
or results from varying stimuli leading to pathology, including cerebral ischemia. 
Protein transduction with this entity occurred in a rapid, concentration-dependent 
fashion, with entry into cells thought to occur via the lipid bilayer component of the 
cellular membrane. A study by Kilic using the same model showed that brain tissue 
was progressively transduced with TAT proteins within 3–4 hours after intravenous 
delivery (Kilic et al., 2002). TAT-Bcl-xL treatment reduced infarct volume and 
neurological deficits after long ischemic insults lasting 90 minutes, when applied both 
before and after ischemia. Dietz demonstrated that the same TAT-Bcl-xL construct, 
when injected into the eye, prevented 24% of mouse retinal ganglion cells from 
undergoing retrograde neuronal apoptosis caused by optic nerve lesion (Dietz et al., 
2002). Thus, at least for neurological disorders, application of TAT fusion proteins 
may greatly facilitate protective therapy strategies. 
Studies have also shown that even relatively large particles could be delivered 
into various cells by the TAT vector. A biocompatible 45 nm particle with an iron 
core, a dextrane coating, and covalently linked TAT peptides are efficiently taken up 
by human hematopoietic CD34+ cells (Zhao et al., 2002). Even liposomes having a 
diameter of 200 nm have been reported of cytoplasmatic uptake (Fretz et al., 2005; 
Torchilin et al., 2001).                                                                
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Taking the TAT-mediated nanoparticles delivery approach a leap further, one of 
the most exciting demonstrations of the effectiveness of TAT-shuttled nanocarriers 
across the BBB was accomplished by TAT-conjugated CdS:Mn/ZnS quantum dots 
(Santra et al., 2005). Histological data clearly showed that TAT-QDs penetrated 
endothelial cells and reached the brain parenchyma. TAT-mediated intracellular 
delivery of large molecules and nanoparticles was proved to proceed via the 
energy-dependent macropinocytosis with subsequent enhanced escape from 
endosome into the cell cytoplasm (Wadia et al., 2004). TAT promises a powerful 
delivery of giant cargo, and is the focus of the current project. 
 
6. Pathological model for testing designed nanoparticle drug 
delivery system 
The designed drug delivery system will be evaluated in vitro and in vivo. For the 
in vitro evaluation, the cytotoxicity and cellular intake of designed nanoparticles will 
be studied in different brain cell types. Regarding the in vivo study, in addition to the 
investigation in normal brain, a pathological brain model which mimics the brain 
under pathological condition will be adopted for the testing. 
6.1. Major cell types in the brain 
6.1.1 Neurons 
Neurons are responsive cells in the CNS that process and transmit information by 
electrochemical signaling. They are the core components of the brain, the vertebrate 
spinal cord, the invertebrate ventral nerve cord, and the peripheral nerves. A number 
of different types of neurons exist: sensory neurons respond to touch, sound, light and 
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numerous other stimuli affecting cells of the sensory organs that then send signals to 
the spinal cord and brain. Motor neurons receive signals from the brain and spinal 
cord and cause muscle contractions and affect glands. Inter-neurons connect neurons 
to other neurons within the brain and spinal cord. Neurons respond to stimuli, and 
communicate the presence of stimuli to the central nervous system, which processes 
that information and sends responses to other parts of the body for action (Wikipedia, 
2008).
6.1.2 Main non-neuronal cells 
 
Figure 1.11: Major cell types in the brain. A. oligodendrocytes; B. astrocytes; C. 
Microglia; D. NG2 cells. 
  
Although non-neuronal cells (or neuroglia, which occupy about 90% of total 
brain cells) are believed to possess important roles in the nervous system, these glial 
cells are less studied. Non-neuronal cells in the adult can be divided into two groups 
depending on their distribution: distributed throughout brain parenchyma, or restricted 
to a specific region. Four types of glial cells were conventionally thought to support 
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the brain, namely astrocytes, oligodendrocytes, microglia, and ependymal cells. 
Among them, astrocytes, oligodendrocytes, and microglia are ubiquitously spread 
over the brain parenchyma. Ependyma is a thin epithelial membrane lining containing 
ependymocytes. Ependymocytes, the main cells in the brain ventricular system, 
produce and circulate of cerebrospinal fluid (CSF). 
 Some other special non-neuronal cell types can be found only in specific brain 
regions or during development, for instance, tanycytes on the floor of the third 
ventricle, Müller cells in the retina, pituicytes in the posterior pituitary, and Bergmann 
glia or radial glial cells in the developing CNS. 
Astrocytes:
 Not only are astrocytes distributed evenly in the brain parenchyma, they are also 
important cells in the glial-limiting membrane of ventricular and pial surfaces and the 
BBB. Several functions include providing nutrition to neurons and other non-neuronal 
cells, maintaining extracellular ion balance during neuronal activity, recycling 
neurotransmitter substances, and healing upon CNS injury to form dense glial scar 
tissue. 
Oligodendrocytes:
 Oligodendrocytes ensheath neuronal processes to form either myelinated or 
unmyelinated axons in the white matter, satellite cells for ion exchange with neurons 
in gray matter. Myelination enables the saltatory conduction via nodes of Ranvier and 




 Microglia is the most important immune cells in the CNS because most other 
inflammatory cells are largely excluded from normal CNS. Microglia resembles tissue 
macrophages of the CNS and exhibit many features of monocytes: signaling cascades 
involving chemokines and cytokines and their receptor systems, similar to those in the 
immune system. Under normal physiological conditions, microglial cells are 
quiescent. Upon activation, they begin to proliferate, migrate toward the impaired 
region, and change morphology from ramified resting status into hypertrophic and 
finally amoeboid phagocytic forms. Microglial cells are believed to play a critical role 
in host defense against microorganisms and malignant cells and in the processes of 
neurodegeneration. 
 
6.1.3 NG2 positive cells  
NG2, a chondroitin sulphate proteoglycan (CSPG), is expressed by a special type 
of mature glial cell in the adult CNS. These were identified at first as ‘protoplasmic’ 
astrocytes on the basis of their morphology in adult CNS in 1987 by Levine and Card 
(Levine and Card, 1987). The NG2 positive cells have ultrastructural features in 
common with oligodendrocytes (Dawson et al., 2000). In 1987, Stallcup and 
colleagues (Levine and Stallcup, 1987; Stallcup and Beasley, 1987) demonstrated that 
in glial cultures derived fromdeveloping CNS, antibodies to NG2 label 
oligodendrocyte-type-2 astrocyte (O-2A) cells, which give rise to oligodendrocytes 
and type-2 astrocytes in vitro (Raff et al., 1983). Therefore, NG2 expressing glia are 
considered to be either O-2A cells, or oligodendrocyte precursor cell (OPC) that 
generate oligodendrocytes in the developing brain and then persist in the mature CNS 
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as adult OPC, to regenerate oligodendrocytes throughout life (Levine et al., 1993; 
Nishiyama et al., 1996; Reynolds and Hardy, 1997).  
In the developing CNS: belong to oligodendrocyte lineage 
It has been reported that the NG2 cells can be found by E16 throughout the 
hindbrain and within the basal forebrain (Nishiyama et al., 1996). During the final 
days of embryonic development, there is a dramatic increase in the number of NG2 
cells, so that by birth they are distributed widely throughout the whole CNS. NG2 
cells will reach a maximum density in the spinal cord before birth, in the cerebral 
cortex at postnatal day 3 (P3), and in the cerebellum at P10 (Nishiyama et al., 1996). 
It has been found that the distribution and number of NG2 positive cells is remarkably 
similar to those platelet-derived growth factor  receptor (PDGFR) mRNA- 
expressing cells (Pringle et al., 1992) which is an accepted marker for 
oligodendroglial progenitors (Hall et al., 1996). Therefore, the co-expression of NG2 
positive cells and PDGFR in the developing CNS suggests that NG2 cells are a kind 
of oligodendrocyte progenitors. 
The O4 expression occurs at the late progenitor and prooligodendrocyte stage, at 
which point the cells are still mitotically active (Gard and Pfeiffer, 1990). In the 
developing CNS, O4 expression was also found in the NG2 positive cells. Thus, the 
appearance of O4 expression provides additional evidence that the NG2 positive cells 
in developing CNS are indeed oligodendrocyte progenitors and are capable of 
differentiation into mature oligodendrocytes in vivo. 
In the adult CNS: part of oligodendrocyte lineage  
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The persistence of NG2 positive cells throughout the mature CNS has been 
demonstrated in lots of studies (Levine and Card, 1987; Levine et al., 1993; 
Nishiyama et al., 1996; Reynolds and Hardy, 1997). It has been the subjects of much 
debate for the origins of these cells and their functions in the mature CNS. Up to now, 
it is already clear that, during development of the CNS, not all NG2 cells differentiate 
into oligodendrocytes. It is possible that features of the microenvironment regulate the 
proliferation and differentiation of oligodendrocyte progenitors (Gallo et al., 1996). 
NG2 cells in the adult rat CNS have a highly complex morphology which can not 
easily classify these cells into oligodendrocyte progenitors. They are very unlike the 
progenitors that populate the CNS (Reynolds and Hardy, 1997). Also, in the 
developing animal, NG2 expression in adult CNS does not overlap with any 
expression of markers known to be specific for other glial cell types. Although NG2 
cells are frequently observed in close apposition to microglial cells and astrocytes, 
double labeling with OX-42 (Levine et al., 1993) or GFAP (Reynolds and Hardy, 
1997) has not been demonstrated. 
All this evidence taken together strongly suggests that NG2 positive cells in the 
adult CNS are phenotypically different from oligodendrocyte progenitors. 
6.2 Pathological changes of brain cells in brain focal injury model  
In neuropathological condition, cellular reactions or responses in brain could be 
observed. The cell types to which the current designed nanodrug delivery system may 
target is of importance to study. 
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6.2.1 Microglia  
In mature rat brains, resting microglia exists in a characteristic ramified 
morphology and is responsible for immune surveillance. Microglia become activated 
in response to inflammatory diseases (Kreutzberg, 1996; Liu and Hong, 2003) and 
undergoes dramatic morphologic alterations upon activation, changing from resting 
ramified microglia into activated amoeboid microglia (Kreutzberg, 1996). Further, 
surface molecules are also upregulated when microglia are activated (Graeber et al., 
1988). In addition, activated microglia are capable of releasing a variety of soluble 
factors, which are pro-inflammatory in nature and potentially cytotoxic In addition to 
producing cytotoxic factors such as superoxide (Colton and Gilbert, 1987), nitric 
oxide (Liu et al., 2002; Moss and Bates, 2001), and tumor necrosis factor alpha 
(TNF-) (Lee et al., 1993) in response to immunological stimuli, microglia are also 
reported to increase neuronal survival through the release of trophic and 
anti-inflammatory factors (Liao et al., 2005; Morgan et al., 2004). 
 
6.2.2 Astrocytes 
In normal brain, astrocytes play important roles in providing glia-neuron contact, 
maintaining ionic homeostasis, buffering excess neurotransmitters, secreting 
neurotrophic factors, and serving as a critical component of the BBB (Aloisi, 1999; 
Hansson and Ronnback, 1995). Contrast to microglia, the pro- inflammatory function 
of astrocyte is not prominent as well (Lindsay, 1994; Streit et al., 1999), but they also 
can become activated in response to immunologic challenges or brain injuries and 
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inflammatory dieseases (Aloisi, 1999; Tacconi, 1998). Astrocytes also produce a host 
of trophic factors (Friedman et al., 1990; Lindsay, 1994), which are crucial for the 
survival of neurons. However, activated astroglia exhibit increased production of glial 




As adult Oligodendrocytes ensheath neuronal processes to form either 
myelinated or unmyelinated axons in the white matter, their responses are related to 
the demyelination in the traumatic neural injured brain (Vick et al., 1992). Both 
oligodendrocytes as well as precursor-type oligodendrocytes that previously formed a 
myelin sheath are able to remyelinate in the CNS. Adult oligodendrocytes can gain 
access to relevant mitogens either in the axonal plasma membrane or in a soluble form 
and undergo a wave of proliferation; there is good potential for remyelination after 
neural injury (Levine et al., 2001; Vick et al., 1992). 
 
6.2.4 Neurons 
Brain focal injury may directly induce neuronal damage in the CNS, which 
results in the primary or secondary cell death (Kermer et al., 1999). Injured CNS 
neurons can release glutamate in great amounts owing to depolarization after cell 
damage or energy failure. In addition, nitric oxide synthesis was activated and free 
radical was formed. It is clear that the damage and loss of neurons in the CNS will 
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lead to some neurodegenerative diseases such as Parkinson’s disease or Alzheimer's 
disease (Reichmann, 2008; Ribe et al., 2008). 
 
6.2.5 NG2 positive cells responses to brain injury 
In developing brain, Rhodes found that the oligodendrocyte precursor cells 
(OPCs) can differentiate into myelinating oligodendrocytes in mature, uninjured rat 
CNS (Rhodes et al., 2006). Also, the OPCs have synaptic regulatory functions 
because of the expression of GluR4 glutamate receptor during various developmental 
stages (Ong and Garey, 1996; Ong and Levine, 1999). 
However, when the brains become developed, NG2 cells in the adult CNS 
represent a population of reactive glial cells. Their reactions to damage or injury 
include dramatic changes in cell morphology, increases in NG2 immuno-reactivity, 
and cell proliferation in some cases. In some instances they may be the first cells to 
react to damage, but, unlike microglia, these reactive changes are spatially restricted 
to the immediate damage area (Di Bello et al., 1999; Levine, 1994; Levine and 
Reynolds, 1999). As their responses have been observed in stab wounds (Levine, 
1994), viral infection (Levine et al., 1998; Redwine and Armstrong, 1998) and kainate 
excitotoxicity (Ong and Levine, 1999). The functional significance of this rapid 
response to brain focal injury is not well understood. 
 
7. Hypothesis  
Antibiotics may be a good choice for the treatment of brain infectious diseases 
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caused by bacterial. However, their applications were limited by the difficulty in 
penetrating the BBB. The BBB penetration rate may have a significant impact on their 
final therapeutic efficacy. Using physiologically-based strategy to develop a kind of 
nanoparticle drug carrier to deliver these antibiotics from the blood to the brain is a 
feasible solution. Taking into account of all the advantages of self-assembled core 
shell structured micelles and TAT cell-penetrating peptide, a novel nanoparticle drug 
delivery system will be designed. The nanoparticle of PEG-b-Chol is a kind of 
PEGylated amphiphilic micelles. It has hydrophobic part (b-Cholesterol) and 
hydrophilic part (PEG chain). Therefore, in aqueous solvent of DI water (H2O); their 
molecules of PEG-b-Chol can automatically form the core shell structure by self 
assembly. The hydrophilic PEG forms the coronal outside and the hydrophobic 
b-Cholesterol forms the core inside. The structure of core shell formed by 
PEG-b-Chol was shown by Figure 1.12. TAT peptide can be conjugated to the surface 
of this nanoparticle by EDC/NHS chemistry. The particle of TAT-PEG-b- Chol also 
can form this core shell structure. This nanoparticle system can be a good drug carrier 
to deliver the selected antibiotics to cross the BBB and reach brain parenchyma. 
 
Figure 1.12: The core shell structure formed by PEG-b-Chol. The hydrophilic 




In this research, hydrophobic molecules such as ciprofloxacin lactate (selected as 
drug molecules), FITC and QDs (selected as fluorescent markers) will be 
encapsulated into the core during the process when this structure is formed. 
Just as Figure 1.13 shown, when the biologically active micelles which contain  
drug molecules inside their core meet the cells with appropriate surface receptors, 
they can be bound by those receptors and enter the cell by AMT or RMT induced. 
The drug molecules just use this method to cross the BBB. 
 
Figure 1.13: Designed drug-nanoparticle system (TAT-PEG-b-Chol)  
 
It is expected that this nanoparticle has good BBB penetration ability but not any 
cytotoxicity to brain cell. They can be well taken by brain cells after they enter the 
brain parenchyma. Also, the nanoparticle system can release the drug molecules at 
pathological site and the release of drug should be well controlled. 
Hydrophobic antibiotics such as ciprofloxacin lactate are expected to be well 
encapsulated into the core of nanopaticles formed and delivered to the target site. 
However, the encapsulation of hydrophilic antibiotic such as Penicillin G is not so 
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good. Therefore, another method of delivering hydrophilic antibiotics should be 
explored. It is hoped that the direct connection of Penicillin G and TAT molecules 
may be effective. As TAT conjugated CdS:Mn/ZnS quantum dots (Santra et al., 2005) 
can cross the BBB, it is also of great possibility that TAT-Penicillin G can also 
penetrate the BBB. Penicillin G has –COOH group and TAT peptide contains –NH2 
group, it is possible to connect them together just like TAT and PEG-b-Chol through 
EDC/NHS chemistry. Also, the TAT conjugated new compounds are also expected 
having no cytotoxicity to brain cells. 
 
Figure 1.14: Scheme of the Penicillin G-TAT synthesis 
 
For the nanoparticle drug delivery system testing, both in vitro and in vivo 
model will be investigated. The higher intake of nanoparticles with TAT group in 
cultured brain cells will be expected. In addition, those nanoparticles will not show 
any cytotoxicity to brain cells. For in vivo testing, a LPS triggered pathological brain 
model will be established. After that, the responses of NG2 positive cells in this 
pathological model will be investigated. Then the nanoparticles carriers will be 
observed in this study. The most important thing is that these nanoparticles will be 
supposed to gather at the pathological area and release the drug molecules there. It 
suggests that this nanoparticle may be an ideal carrier for drug delivery cross the BBB. 
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The expected sustained drug release from those nanoparticle micelles in pathological 
area demonstrates their promising applications in future clinical trails. 
     
8. Scope of research 
8.1 To synthesize and characterize the core-shell structured micelles 
of PEG-b-cholesterol and TAT-PEG-b-cholesterol:
First of all, the amphiphilic copolymer of PEG-b-cholesterol (PEG-b-Chol) will 
be synthesized by EDC/NHS chemistry in DCM. In aqueous solution, core shell 
structured micelles can be fabricated by self assembly method. During the process of 
fabrication, molecules of an antibiotic (ciprofloxacin lactate) or fluorescent markers 
(FITC or Quantum dots) will be encapsulated into the central core of PEG-b-Chol. 
When the amphiphilic copolymer of PEG-b-Chol is ready, TAT peptide can be 
conjugated to PEG to form TAT-PEG-b-Chol.. Based on the same methods, the core 
shell structured TAT-PEG-b-Chol also can be formed in aqueous solution, meanwhile 
the encapsulation of ciprofloxacin lactate or fluorescent marker can be achieved. 
The particles size of nanoparticles will be measured and the in vitro release of 
ciprofloxacin lactate from micelles in PBS solution will be studied. 
 
8.2 To study the BBB penetration of PEG-b-Chol and TAT-PEG- 
b-Chol
In SD rats, the BBB penetration of FITC and/or QDs encapsulated PEG-b-Chol 
and TAT-PEG-b-Chol micelles will be investigated. After the administration of 
INTRODUCTION
 59
micelles solution through the femoral vein, their biodistribution in liver, kidney, 
spleen and brain will be studied. Using cultured endothelial cells and astrocytes, the in
vitro cellular uptake of those two types of nanoparticle micelles will also be studied. 
After the nanoparticles enter the brain parenchyma from blood stream, the 
nanoparticle positive cell types will be identified by immunohistochemical staining 
techniques. 
8.3 To study the primary pharmacokinetics of selected antibiotics 
and FITC encapsulated TAT-PEG-b-Chol in vivo 
In SD rats, the primary pharmacokinetics of Penicillin G, Ciprofloxacin and 
Doxycyline in blood plasma will be investigated by High Performance Liquid 
Chromatography (HPLC). After these antibiotics were injected into the blood stream, 
at different time points, rat plasma samples will be collected, extracted and analyzed 
by HPLC. As for FITC encapsulated TAT-PEG-b-Chol, after they enter the rat body, 
rat brain sample also will be collected at different time intervals. Then, brain sections 
will be processed using histological techniques and observed by a confocal 
microscope. 
 
8.4 To synthesize and characterize TAT-Penicillin G 
Penicillin G is a hydrophilic antibiotic which cannot be encapsulated into the 
core of TAT-PEG-b-Chol. Here, it will be conjugated to TAT directly using 
EDC/NHS chemistry. After successful conjugation, the cytotoxicity of TAT-Penicillin 
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G to cultured endothelial cells, microglia, astrocytes, and neuronal cells will be 
investigated. Also, their penetration to the BCEC and astrocytes will be studied in 
vitro. It will be proved that many more TAT-Penicillin G particles may penetrate or 
attach to BCEC and astrocytes with the aid of TAT peptide, suggesting that the 
connection of TAT to Penicillin G is a feasible way to deliver Penicillin G across the 
BBB. 
 
8.5 To evaluate PEG-b-Chol and TAT-PEG-b-Chol in vitro and in
vivo
The cellular uptake and cytotoxicity test of PEG-b-Chol and TAT-PEG-b-Chol 
micelles will be studied in this part. In addition, a LPS triggered in vivo brain 
pathological model will be established by LPS focal injection. In this model, the 
delivery of drug molecules by TAT-PEG-b-Chol will be investigated. Meanwhile, the 
responses of NG2 cells in this pathological brain, including the alteration of 
expression and morphological changes will be investigated. In addition, through the 
inhibition of microglia complement receptor 3, the possible relationship between NG2 
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1. Fabrication and characterization 
1.1 Materials 
. ĉ Chemicals 
- Cholesteryl chloroformate (b-Cholesteryl) (Sigma-Aldrich, USA) 
  - TAT peptide (GL Biochem Ltd, China) 
  - Fluorescein5-isothiocyanate (FITC) (Sigma-Aldrich, USA) 
  - Dichloromethane (DCM) (Sigma-Aldrich, USA) 
  - Dimethylformamide (DMF) (Sigma-Aldrich, USA) 
  - Dimethyl sulfoxide (DMSO) (Fluka, USA) 
  - Triethylamine (TEA) (Fluka, USA) 
  - N-hydroxy-sulfosuccinimide (NHSS) (Sigma-Aldrich, USA) 
- Ciprofloxacin Lactate (Sigma-Aldrich, USA) 
  - Penicillin G Potassium (Sigma-Aldrich, USA) 
  - Doxycycline (Sigma-Aldrich, USA) 
  - BupH MES buffered saline (Pierce, USA) 
  - Heterobifunctional H2N-PEG-COOH (PEG: Mn 5000) (Nektar, USA) 
  -1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC) 
(Pierce, USA) 
 
Ċ. BupH MES Buffered Saline Buffer (pH 4.7) 
  - BupH MES Buffered Saline Packs                         1 pack 
      Each pack yields 500 ml of 0.1 M 2-[morpholino]ethanesulfonic acid, 
0.9% NaCl (Pierce, USA) 
  - Deionized water                                       500 ml 
 
. ċ 1M NaOH solution 
  - NaOH (Sigma-Aldrich, USA)                             4g 
  - Deionized water                                       100ml 
1.2 Synthesis procedures  
   1.2.1 PEG-b-Chol
     For the synthesis of PEG-b-Chol, Cholesteryl chloroformate (0.352g, 0.78mmol) 
in 20ml of DCM was slowly added to a solution of TEA (100l) and NH2-PEG 
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-COOH (1g, 0.2mmol) dissolved in 20 ml of DCM at room temperature (RT) with 
vigorously stirring. The mixtures were left to react for 2 days. The crude product was 
purified by dialysis against DCM for 6 days using membrane with a molecular weight 
cut-off of 2,000 Da. DCM was then removed by vacuum drying to yield a final 
product. 
Figure 2.1: Scheme of the PEG-b-Chol synthesis
1.2.2 TAT-PEG-b-Chol
TAT peptide with a sequence of NH2-YGRKKRRQRRR was conjugated to PEG 
through its carboxylic acid group. Briefly, EDC and NHSS were dissolved in 0.1 M 
MES buffer to get 100 and 40mM stock solutions respectively. TAT peptide stock 
solution was prepared in phosphate-buffered saline (PBS, pH 7.4) at a concentration 
of 1 mg/ml. PEG-b-Chol (5mg) was dissolved in 400 ml of 0.1 M MES buffer, and 
incubated with 40 ml of EDC and NHSS solutions for 1 hour (h) at 4C. TAT peptide 
solution (250 ml) was then added to the activated PEG solution, and incubated for 3h 
at RT. The reaction mixture was dialyzed against de-ionized (DI) water to remove 
byproducts and unreacted TAT peptide molecules by using the membrane with a 
molecular weight cut-off of 3500 Da. The final product was freeze-dried for 2 days 
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prior to use. 
 
Figure 2.2: Scheme of the TAT-PEG-b-Chol synthesis
 
1.2.3 Encapsulation of FITC or QDs into PEG-b-Chol and TAT-PEG-b-Chol
FITC and QDs were respectively encapsulated into PEG-b-Chol or TAT-PEG- 
b-Chol micelles by a membrane dialysis method. Briefly, the polymers (5mg) were 
dissolved in 3ml of DMSO. A certain amount of FITC or QDs (2mg to 5mg) was then 
added. The solution was dialyzed against DI water at 10C for 48 hours using a 
dialysis membrane with a molecular weight cut-off of 2,000 (Spectra/Por 7, Spectrum 
Laboratories Inc.). The water was replaced overnight. After dialysis, the solution in 
the dialysis bag was collected and freeze-dried for two days. 
The antibiotic (ciprofloxacin lactate) was encapsulated into PEG-b-Chol or 
TAT-PEG-b-Chol using the same method. 
1.2.4 TAT-Penicillin G 
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TAT was conjugated to Penicillin G potassium via EDC/NHS chemistry. 
Penicillin G potassium (14.8mg) dissolved in 1ml MES buffer (pH=6.0) was slowly 
added to a solution of EDC (46mg) in 1ml MES buffer (pH=6.0) at RT with vigorous 
stirring. After 5 minutes reaction at room temperature, 1ml NHSS solution (130mg) 
was added into the mixed solution and the mixtures were left to react for 30 minutes 
at RT. After that, the pH value of mixture was adjusted to 7.0 by 1mol/l NaOH 
solution. TAT peptide was prepared in phosphate-buffered (PBS) saline at 1 mg/ml, 
then, this TAT solution (25l) was added to the activated Penicillin G potassium 
solution and incubated for 3 hours at room temperature. Unreacted Penicillin G 
potassium and other reagents were removed by dialysis against de-ionized (DI) water 
using the membrane with molecular weight cut-off of 1000 Da for 24 hours. The final 
product was harvested by freeze-drying. 
1.3 Characterization procedures  
1.3.1 Morphology of blank or drug-loaded nanoparticles 
The morphologies of blank as well as drug-loaded (FITC, QDs and 
ciprofloxacin lactate) PEG-b-Chol or TAT-PEG-b-Chol nanoparticles were observed 
by a field emission scanning electron microscope (SEM) (JEOL JSM-7400F) operated 
at 5.0 kV accelerating voltage. To prepare SEM samples, 20ml of the nanoparticles 
solution were placed on a silicon wafer chip, and air-dried at room temperature. The 
silicon chip was then coated with Pd film and mounted on SEM stud for visualization. 
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1.3.2 1H NMR spectra of nanoparticles  
The 1H NMR spectra were studied using a BrukerAvance 400 spectrometer (400 
MHz). For scanning of PEG and PEG-b-Chol, chloroform-d (CDCl3) was used as 
solvent. Briefly, 5mg of sample was dissolved in 0.6ml CDCl3 and scanned for 1000 
times. As for TAT, TAT-PEG-b-Chol, Penicillin G and TAT-Penicillin G, D2O was 
chosen as solvent. 
1.3.3 MALDI-TOF/MS characterization of Penicillin G and TAT-Penicillin G 
To validate the successful conjugation of TAT to Penicillin G molecules, 
Penicillin G and TAT-Penicillin G were characterized by matrix-assisted laser 
desorption ionization of time-of-flight mass spectrometry (MALDI-TOF/MS) 
(Autoflex II, Bruker Daltronics) respectively. The analysis was performed by the 
dried-droplet method with 2, 5-dihydroxybenzoic acid as matrix. All Penicillin G and 
TAT- Penicillin G samples were run in reflection positive ionization model 
   
 1.3.4 Particle size and zeta potential analysis 
    The particle size and zeta potential of blank, drug-, FITC- and QDs-loaded 
PEG-b-Chol or TAT-PEG-b-Chol nanoparticles in DI water were measured by 
ZetaPALS/BI-MAS (Brookhaven Instruments Corporation) equipped with a HeeNe 
laser beam at 658nm (scattering angle: 90°). The concentration of nanoparticles in DI 
water was about 0.6mg/ml. The intensity of scattered light (in kilo counts per second) 
was also recorded as a function of polymer concentration ranging from 0.0 to 500.0 
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mg/l. A stock polymer solution was prepared with a concentration of 500.0mg/l, and 
diluted using DI water to various concentrations. Each measurement was repeated 5 
times, and an average value was obtained and used. The size measurements were 
performed by multimodel analysis. The zeta potential measurement was repeated for 5 
runs per sample and an average value was reported.  
1.3.5 In vitro drug release of ciprofloxacin-loaded nanoparticles  
Ciprofloxacin lactate-loaded nanoparticles solution (20mg in 5ml of PBS, pH 7.4) 
was poured onto the dialysis membrane with a molecular weight cut-off of 2000 Da. 
The membrane was then immersed in a beaker containing 50ml of PBS (pH 7.4) with 
shaking at 80rev/min at 37C. At specific time intervals, the PBS solution was taken 
out for analysis of drug concentration by the UV/VIS/NIR spectrophotometer and put 
back after the measurement. The standard curve was constructed by dissolving 
ciprofloxacin in PBS in the concentration range from 2.5 to 20.0ppm and r2 value was 
0.999906. The detection wavelength was set at 270nm, and 310nm was used as base 
line. 
 
2. Cell culture 
For the investigation of cellular uptake of nanoparticle micelles, cultured human 
endothelial cells and brain astrocytes which are the main components of BBB were 
used. In addition, the technique of cell culture was also applied for the toxicity test of 
nanoparticle micelles.. 




.ĉ Culture medium and chemicals
-Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma)           450ml 
10% Fetal Bovine Serum (Gibco, Invitrogen Life Technologies, USA) 50ml       
1% Antibiotic-Antimycotic (Invitrogen corporation, USA)           1ml 
   -1×Trypsin-EDTA (0.25% Trypsin-0.53mM EDTA, Sigma, USA) 
   -Dimethyl sulfoxide (DMSO, Sigma, USA) 
   -PEG-b-Chol 
   -TAT-PEG-b-Chol 
   -Penicillin G potassium (MW: 372.48, Sigma, USA) 




   -Human brain astroglia, SV40 transformed (CRL-8621, ATCC, USA) 
   -Human cortical neuron (CRL-10442, ATCC, USA) 
   -Human endothelial cells (Cell system Ltd, USA) 
   -Bacillus subtilius (23857, ATCC, USA)  
-Escherichia coli (25922, ATCC, USA) 
2.2 General operating procedures 
2.2.1 Handing procedure frozen cells 
To insure the highest level of viability, thaw the vial and initiate the culture as 
soon as possible upon receipt. It should be stored in liquid nitrogen vapor phase and 
not at -70C. At the beginning, thaw the vial by gentle agitation in a 37C water bath. 
To reduce the possibility of contamination, keep the O-ring and cap out of the water. 
Thawing should be rapid (approximately 2 minutes). Next, the vial was removed from 
the water bath as soon as the contents were thawed, and decontaminated by dipping in 
or spaying with 70% ethanol. Last, the vial contents was transferred to a T75 flask 
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quickly with at least 10ml of fresh medium and incubated the culture at 37C in a 
suitable incubator. A 5% CO2 in air atmosphere was supplied.  
   
 2.2.2 Subculture procedure 
When cultures reach about 80-90% confluence, subcultures were carried out. 
First, culture medium was removed and discarded and briefly the cell layer was rinse 
with 0.25% Trypsin-0.53mM EDTA (1×) solution to remove all traces of serum 
which contains trypsin inhibitor. Then, 2.0 to 3.0ml of Trypsin-EDTA solution was 
added to flask and observes cells under an inverted microscope until cell layer was 
dispersed (usually with 5 to 15 minutes). When cell layer was fully dispersed, 6.0 to 
8.0ml of complete growth medium added and the cells were aspirated by gently 
pipetting. Next, the Trypsin-EDTA solution was removed and cell suspension 
transfered to centrifuge tube and spined at 2000 rpm for 5 minutes. Last, supernatant 
was discarded and cells resuspended in fresh growth medium, then culture vessels 
were place in incubator at 37C with 5%CO2. 
   
 2.2.3 Cell preservation procedure 
The cell suspension after Trypsin-EDTA administration was spined at 2000rpm 
for 5 minutes. Then the supernatant was discarded and the cells were resuspended 
with fresh preservation medium (10% complete growth medium+10% FBS+10 
DMSO) in preserving vial. After that, the vial was put in the -80C freezer overnight 
and transferred into liquid nitrogen in the next morning. 
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2.3 Procedures of toxicity test  
The nanoparticle drug delivery system should not have cytotoxicity to brain cells. 
Therefore, their cytotoxicity to cultured endothelial cells, astrocytes, microglia and 
neuronal cells were necessarily checked.  
For TAT-Penicillin G, firstly, human brain astrocytes, cortical neuron, brain 
capillary endothelial cells and microglia were cultured in DMEM media with 10% 
fetal bovine serum (FBS) and 1% antibiotics. Among them, endothelial cells and 
astrocytes are the main components of the BBB.  These cells were seeded in 6-well 
plate and incubated at 37C, 5% CO2. 24 hours later, Penicillin G potassium-TAT 
(495g/mL) and controlled pure Penicillin G potassium (496g/mL) were added. And 
another 4 hour incubation of cells and drugs, the medium containing the drug carriers 
was removed and the cells were washed with 1×PBS solution for 2 times, each time 
takes 5 minutes. Then, 1ml of 1×Trypsin-EDTA solution was added in each plate for 
5 minute reaction at 37C, 5%CO2 to disperse the cell layer. Last, 1ml fresh growth 
medium was added to each plate in order to neutralize the reaction of Trypsin-EDTA. 
At last, the number and viability of these cells were checked by VCELL viability 
analyzer instrument (VCELL, USA). Based on the alteration of cell number and 
viability, the cytotoxicity of TAT-Penicillin G potassium could be determined. 
For PEG-b-Chol and TAT-PEG-b-Chol, 10l TAT-PEG-b-Chol-QDs (0.0375 
mg/ml), PEG-b-Chol-QDs (0.0375mg/ml) and pure QDs solution (0.0375mg/ml) 
were added into cultured BVEC and astrocytes (2.2×105 cells/well) respectively. After 
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incubated at 37°C at 5ˁCO2 for 4 hours, their cell number and viabilities were 
measured with the same method described before. 
2.4 Procedures of cellular intake test 
To investigate cellular uptake of PEG-b-Chol and TAT-PEG-b-Chol micelles, 
human brain endothelial cells and astrocytes were seeded into flask respectively in 
DMEM with 10% FBS and 1% antibiotics supply. After becoming 80-90% confluent, 
they were subcultured into 6-well plates with a density of 2x104 cells/well. A piece of 
the coverslips was placed at the bottom of each well. 100l nanoparticle solutions 
(0.1mg/ml) with FITC or QDs fluorescent markers were added and incubated for 1 
hour at 37°C with 5% CO2. Then, cells were fixed with 4% paraformaldehyde 
solution for 10 minutes. After 2 times’ washing with 1×PBS, the coverslips with 
fluorescence labeled cells were mounted with nonfluorescent mounting medium 
(DAKO, USA) and observed with Laser Scanning Confocal Microscopy (Olympus 
FluoView™ FV1000, Japan) in 488nm (FITC) and 560nm (QDs) respectively. 
2.5 Procedures of antibiotic screening 
In order to investigate the antibacterial efficacy of TAT-Penicillin G, experiment 
of antibiotic screening was done. Bacillus subtilius (ATCC23857) and Escherichia 
coli (ATCC25922) were grown in tryptic soy broth (TSB) at 37°C. All 
microorganisms were cultured with 200 rpm shaking to facilitate the growth. Fresh 
overnight cultures (10l) of bacteria and yeast were inoculated into 10ml of respective 
MATERIALS AND METHODS 
 72
broth and cultured till reaching the mid-logarithmic-phase for antimicrobial 
susceptibility testing. The minimum inhibition concentration (MIC) was determined 
using the method of broth microdilution. Briefly, 50l of Penicillin G potassium-TAT 
solution with various concentrations (1.4 and 2.7ppm) and 50 l controlled Penicillin 
G potassium solutions with same concentration respectively were placed into each 
well of 96-well plates respectively. Diluted organism suspensions (50l) were then 
added to each well of the microplate. At different time intervals, the optical density 
readings of ~ 0.1-0.2 at 600 nm were measured. Broth containing cells alone was also 
used as control to validate the assays The MIC was defined as the lowest 
concentration of antibiotic that completely inhibited the growth of the organisms. The 
tests were repeated on three different days. 
 
 
2.6 Cellular uptake study of Penicillin G and TAT-Penicillin G  
The human endothelial cells and astrocytes were seeded into the 6-well palate 
with a cell density of 1.0×105/well and a culture medium volume of 3ml/well. After 8 
hours’ incubation at 37C, 5% CO2, TAT-Penicillin G (1.4ppm and 2.7ppm) and 
controlled pure Penicillin G solution with same concentration were added into the 
culture medium respectively. At different time points (20, 40, 60, 80, 100, 240 and 
720 minutes), 100l medium samples were collected and directly injected into HPLC 
system for analysis. 
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3. Histochemistry and immunohistochemistry studies 
The main purpose of histochemistry and immunohistochemistry studies is to 
investigate the nanoparticles BBB penetration in the animal model. In the study, such 
as the biodistribution of nanoparticles after they enter the body, the cellular uptake of 
nanoparticles in brain parenchyma and the testing of nanoparticle carriers in 
pathological brain could be achieved with histological techniques 
 
3.1 Animal and anesthesia procedures 
Adult male Sprague-Dawley rats (250~350g, 6~8 weeks) were employed in 
experiments. All animal work was carried out in accordance with the Singapore 
Animal Care and Use Committee and performed according to the guidelines set forth 
in the National Institutes of Health Guide for the Care and Use of Laboratory Animals 
(NIH Publications NO. 85-23, revised 1996). The minimum number of animals was 
used for the experiments, and suffering was minimized by the use of analgesia. 
Prior to surgery, perfusion or harvesting of tissue samples or cells, all animals 
were deeply anaesthetized by an intraperitonal injection of ketamine & xylazine 
solution (1ml/kg body weight). After 10-15 minutes, a foot pad of the animal was 
pinched with a pair of toothed forceps to ensure the animal was under full anesthesia. 
All procedures involving animals were approved by Institutional Animal Care & Use 
Committee, DSO National Laboratories, Singapore. 
Anesthesia knockout solution preparation: 7.5ml Ketamine (100mg/ml), 5.0ml 
Xylazine (20mg/ml) and 7.5ml MilliQ water were mixed together to form the total 
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amount of 20ml. For the top-up solution during the surgery, 7.5ml Ketamine 
(100mg/ml) and 12.5ml MilliQ water together to total amount of 20ml. The dosage 
for top-up was half of the knockout dosage. 
 
3.2 Perfusion, tissue sampling and sectioning procedures 
3.2.1 Fixatives 
.4% paraformaldehyde (PF) ĉ  
-Pareformaldehyde                                         40g 
-Phos. Buffer                                          1000ml 
.Phos. Buffer Ċ   
-0.1M Solution ‘B’                                                            
(178 g Na2HPO4.2 H2O in 10 litres Deionised H2O)       750 ml 
-0.1 M Solution ‘A’  
(69 g NaH2PO4. H2O in 5 litres Deionised H2O)              ±250 ml 
(Add approx 1 volume of ‘A’ to 3 volume of ‘B’ till PH 7.4) 
3.2.2 Preparation of gelatinized slides 
.5% gelatin solution:ĉ  
-Gelatin                                                1.5mg    
-Chrome Alum                                          0.15g                
-Distilled water                                          100ml   
Slides were first dipped in the acid solution (400 ml of 98% sulfuric acid mixed 
with 1 tea spoon of potassium dichromate) for 2 minutes, and then washed by running 
tap water for 10 minutes. The slides were rinsed with distilled water and then baked in 
an oven at 80ºC overnight for drying. The following day, dried slides were dipped in 
the gelatin solution and then were hung to dry with the clips. Gelatinized slides were 
kept in an oven at 37ºC for histological or immunohistochemical study. 
3.2.3 Perfusion                                                                  
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Two reservoirs were used, one containing Ringer’s solution and the other 
appropriate fixative. Each reservoir was connected to a long polythene tube with an 
air trap interposed between them. A 19G winged needle (Terum Co., Japan), serving 
as cannula, was connected to the tube. Before introducing the perfusion fluid to the 
heart, all air bubbles in the tubes connected the two reservoirs were removed. 
Perfusion was done under gravity with the two reservoirs fixed at a height of 100cm 
above the perfusion table. 
A midline incision of the skin from the level of the suprasternal notch to the level 
above the symphysis pubis was made. The incision, made through the skin and 
muscles of the anterior abdominal wall, was extended bilaterally along the subcostal 
margins to expose the sternum and diaphragm. The latter was then cut along the 
subcostal margin to fully expose the heart. Care was taken during this process not to 
damage the lungs. The pericardium was then slit with a pair of fine scissors to fully 
expose the heart. Perfusion was initiated whereby a cannula with some Ringer’s 
solution dripping slowly from its tip was inserted into the left ventricle and was 
immediately followed by slitting a portion of the right atrium to let out the blood, and 
subsequently the perfusate. Once the cannula was secured in place, the flow of the 
Ringer’s solution was turned to full pressure by means of a three-way tap. A total of 
100ml of Ringer’s solution at room temperature was allowed to flush the vascular 
system until the lungs and liver were cleared of blood. A total of about 400ml of the 
fixative (4% PF) at 4°C was administered. 
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3.2.4 Tissue sampling and sectioning 
After perfusion, the brain was dissected, along with this, the liver; spleen and 
kidney were also removed for examination the distribution of nanoparticles. All the 
tissues were then postfixed with the same fixative for additional 4 hours. The tissues 
were subsequently transferred to 0.1M phosphate buffer (pH7.4) containing 15-30% 
sucrose and kept overnight at 4°C. The tissue samples were mounted on a metal chuck 
using Lipshaw M-1 embedding matrix (Pittsburgh, USA) and rapidly frozen by 
quenching in liquid nitrogen. Transverse sections of 30m thickness of brainstems 
were cut using a cryostat (Leica CM 3050). The sections were subsequently mounted 
on gelatinized slides and allowed to dry at room temperature for 1 hour. 
 
3.3 Procedures of immunofluorescent staining 
3.3.1 Buffers and solutions 
ĉ. 0.1 M PBS 
-Disodium hydrogen phosphate heptahydrate                   13.3g               
-Sodium chloride                                          8.5g               
-Distilled water                                          900 ml               
(Adjusted to PH 7.4 with 2N HCL and topped up to 1,000 ml with distilled 
water) 
Ċ. PBS containing 0.1% Triton-X 100 (PBS-TX) 
-PBS                                                1000 ml                
-Triton-X 100                                            1 ml   
ċ.  5% Normal goat serum 
-Normal goat serum                                      0.5ml 
-Distilled water                                          9.5ml 
. Č  BrdU injection solution 
-BrdU (5-Bromo-2’-deoxyuridine) (Upstate, USA)             25mg 
-0.9%w/v NaCl solution                                  1ml 
.  Avidinč -Biotinylated horseradish peroxidase Complex (ABC) 
-1 drop of A +1 drop of B                           50l +50l 
       -PBS-TX                                             5ml 
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.  0.1M TBS (pH7.6)Ď  
       - Tris                                                 6g 
       - Sodium chloride                                       8g 
- Distilled water                                     1000ml 
(Adjust with 2N or 4N HCl to pH 7.6) 
ď. 1xDAB Solution 
-10xDAB                                            10ml 
-0.1M TBS                                           90ml 
-30% H2O2                                         0.067ml 
 
3.3.2 Antibodies  
   -Mouse anti-rat CD11b monoclonal antibody (marker for microglia, 1:1000,    
Chemicon, USA)  
-Mouse anti-Glial Fibrillary Acidic Protein (GFAP) monoclonal antibody 
(astrocytes, 1:1000, Chemicon, USA) 
-Mouse anti-CNPase 2’,3-cyclic nucleotide 3’-phosphodiesterase monoclonal 
antibody (oligdendrycytes 1:500, Chemicon, USA) 
-Mouse anti-Neuronal nuclei (NeuN) monoclonal antibody (neuron, 1:500,   
Chemicon, USA) 
-Mouse anti-bromodeoxyuridine (BrdU) monoclonal antibody (1:500, Chemicon, 
USA)    
-Monoclonal anti-Tumor Necrosis Factor- (TNF-), clone 45418.111 (1:500, 
Sigma, USA) 
-Mouse monoclonal [DB-1] to Interferon gamma (ab22543) (IFN-) (1:500, 
Abcam,UK) 
-Rabbit PDGF Receptor- antibody (1:100, Cell Signaling Technology USA) 
-Mouse anti-Transforming Growth Factor- (TGF-) monoclonal antibody 
(1:1000, Chemicon, USA) 
-Mouse monoclonal antibody to HIV TAT (ab24778) (1:100, abcam,USA) 
-Mouse monoclonal anti-rat IL-1 antibody (MAB500 1:500, R&D systems, 
USA) 
-Rabbit anti-NG2 chondroitin sulfate proteoglycan polyclonal antibody (NG2 
1:500, Chemicon USA) 
-Goat anti rabbit IgG (H+L) F(ab’)2 fragments ,Cy3 conjugated affinity purified 
secondary antibody (1:500, Chemicon, USA) 
-Goat anti mouse IgG (H+L) F(ab’)2 fragments ,Cy3 conjugated affinity      
Purified secondary antibody (1:500, Chemicon, USA) 
-Goat anti mouse IgG (H+L) F(ab’)2 fragments, FITC conjugated affinity purified 
secondary antibody (1:500, Chemicon, USA) 
 
3.3.3 Staining procedure 
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For immunofluorescent staining, the prepared slides first were washed with 
PBS-TX for 3 times, each time takes 10 minutes. Then the sections were blocked with 
5% normal goat serum for 1 hour and incubated in only one primary antibodies at RT 
overnight. Next day, after washing the slides with PBS for 3 times, the FITC (for QDs 
encapsulated particles) or Cy3 (for FITC encapsulated particles) conjugated 
secondary antibody was added and incubated at room temperature for 2 hours. At last 
the slides were incubated with DAPI solution (1:5000) for 1-2 minutes. After washing 
these slides with PBS for 2 times, they were mounted with nonfluorescent mounting 
medium (DAKO, USA), then viewed and photographed with Laser-Scanning 
Confocal Microscopy (Olympus FluoView™ FV1000, Japan) in 488nm (FITC) and 
560nm (QDs) respectively. 
Immunofluorescent double labeling technique is the best way to determine the 
co-localization of two different antigens in one cell or tissue preparation. The 
respective positive staining may merge together in one cell. It suggests that these two 
antigens are co-localized. For immunofluorescent double labeling process, two 
primary antibody from different host (such as 1:500 mouse antibody against rat GFAP 
and 1:500 rabbit antibody against rat NG2) were used together to incubate brain 
sections in room temperature overnight. After the same washing procedure as before, 
fluorescent dye conjugated secondary antibodies respectively against their primary 
were added to the section (1:500 goat anti mouse IgG, FITC conjugated and 1:500 
goat anti rabbit IgG, Cy3 conjugated). 2 hours incubation later, the processing and 
observation procedures are as same as before. 
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3.3.4 Procedures of DAB staining  
The cryo-cut sections were first rehydrated in 1xPBS pH7.4 for 30 seconds, then, 
quenched with 3% H2O2 for 5 minutes, washed in 1xPBS solution, and blocked with 
5% normal goat serum in PBS with 0.1% TritonX-100 for 1 hour at RT. The primary 
antibody (rabbit anti-NG2 1:500) was applied for overnight at RT. Next day, the 
slides were rinsed in PBS for 10 minutes, 3 times and incubated with secondary 
antibody (anti-rabbit IgG 1:200) for 1 hour at RT. After rinsed in 1xPBS, the fresh 
prepared ABC (A and B should be mixed at least 30mins before application) was 
added into the section and incubated for 1 hour. One hour later, the sections were 
rinsed in 1xPBS for 2 times and immerged into TBS for half an hour. Last, sections 
were stained with 1xDAB solution and rinsed with TBS for 10 minutes, 3 times for 
methyl green staining. 
The stained slides firstly were immerged into 0.1M acetate buffer (pH 4.8) for 2-5 
minutes. Then, they were put into methyl green solution in 2-4 minutes. It is followed 
with dehydration process from 75% ethanol, 95% ethanol to100% ethanol. Each step 
took 5 minutes around. After immerged into 100% histoclear for 5 minutes, the slides 
were dried in a fume hood for 20-30 minutes and mounted with Permount slides 
mounting medium. These slides were observed and photographed with a light 
microscope (Olympus BX51, Japan). 
 
3.4 Procedures of injection of nanoparticle solution 
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Adult male Sprague-Dawley rats (250~350g, 6~8 weeks) were anesthetized with 
ketamine & xylazine solution (1 ml/kg body weight), and their hair near the thigh 
were shaved. An incision was made on the right side of the thigh to expose the 
femoral vein. Carefully separating the vein and the artery with small scrip, the lower 
femoral vein close to the toes was tied. A very small incision was made on the vein 
and a polyethylene cannula was put inside the blood vessel through this incision. The 
nanoparticles solution (PEG-b-Chol or TAT-PEG-b-Chol at 0.054 mg/ml, dissolved 
in 1×PBS) containing the FITC or QDs were injected into the vein through this 
polyethylene cannula (the injection volumn: 1.5ml/rat). Then the animals were 
monitored in a heated recovery box until fully conscious. Two hours after the 
injection of nanoparticles, the animals were sacrificed for sampling and observation. 
  
3.5 Pathological brain model setup procedures 
3.5.1 Materials 
. ĉ  LPS Solution (1g/l) 
-Lipopolysaccharide (E. coli serotype 0127:B8; Sigma, USA)   1mg 
-1x PBS                                              1ml 
LPS is a bacterial endotoxin released from the surface of replicating and 
dying gram-negative bacteria into the circulation (Rietschel et al., 1996; Rubenstein et 
al., 1962). It is known to have a variety of effects on the brain and cerebral circulation. 
At the molecular level, these changes include activation of transcription factors, 
changes in gene expression, formation of proinflammatory and anti-inflammatory 
cytokines, expression of adhesion molecules, and infiltration of leukocytes. Many of 
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these changes, including the infiltration of leukocytes, are generally thought to 
contribute to neuronal dysfunction and cell death (Barone and Feuerstein, 1999). 
3.5.2 Procedures of LPS and anti-CD11b antibody cortical injection 
    Male SD rats (10 weeks, 310–400g) were anesthetized with xylazine and 
ketamine (1ml/kg body weight). After the animals were placed in a stereotaxic frame, 
their scalp and temporal muscles were reflected and a hollow female Luer-Loc fitting 
(4.5mm) was fixed rigidly with dental cement to the animal’s skull through a 
craniotomy centered over the left parietal cortex, 2mm lateral to the sagittal suture and 
3mm posterior to the coronal suture. This would position the hole parasagittally over 
the cerebral cortex. The dura was left intact. 
As for LPS triggered parhological brain model, LPS was administrated to trigger 
the neuron-inflammation in the cerebral cortex region. After exposing the skull, a 
small hole (2mm lateral to the sagittal suture and 3 mm posterior to the bregma) was 
drilled and LPS solution (1g/l, 1g/rat) was injected into the cortex by 
micro-syringe through this hole. Then, the rat was put back to the cage and 24 hours 
later used in the experiment. Saline served as the control for the LPS. 
As for anti-CD11b antibody blocked and LPS triggered pathological brain model, 
before the administration of LPS, anti-CD11b antibody solution (1g/l, 1g/rat) was 
injected into cerebral cortex region. And 24 hours later, LPS solution was injected to 
the same site. 
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3.6 BrdU assay procedures 
 3.6.1 BrdU solution preparation  
Warm saline solution (0.9%w/v NaCl in sterile H2O) to 40–50C, slowly 
dissolve BrdU in saline solution by gently vortexing, allowing BrdU injection 
solution to cool to room temperature (22–25C) and use them immediately. 
3.6.2 BrdU solution intraperitoneal injection  
The ideal BrdU injected dosage varies from 50mg/kg to 300mg/kg depending on 
experiments and animals in use. Here, the dosage of 50mg/kg was used. For an 
intraperitoneal injection, the lower abdominal cavity must be isolated. A 23-gauge 
needle and a 5-ml syringe were used. The maximum tolerable intraperitoneal injection 
volume in the rat was 10ml. 
3.6.3 Perfusion and sectioning 
After experimental animals were anesthetized, their hearts were exposed by 
sharp dissecting tools. Then, insert the needle connected to the pump into the left 
ventricle and made an incision in the right atrium to allow blood to flow out of the 
animal’s body. The animal was perfused with 0.1M PBS at pH7.4. When the draining 
blood became clear, they were then perfused with 4% paraformaldehyde in 0.1M PBS. 
The brain sample was sectioned into 30m slices by cryostat (Leica CM 3050). 
3.6.4 DNA denaturation 
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Denaturation of DNA allows the access for anti-BrdU antibody, so incomplete 
denaturation may cause problems. There are various denaturation procedures (such as 
ethanol treatment and enzyme treatment), which may have different effects on the 
retention of morphology. The acid treatment with an increased temperature generally 
results in more effective exposure of the halogenated-nucleotide antigen. However, 
harsh HCl treatment (>2M HCl), in conjunction with high temperature (>65C) 
incubation, is detrimental to other antigens, particularly surface antigens and receptors. 
Moreover, some BrdU antibodies can recognize methylated thymidine under harsh 
denaturation conditions. This non-specific staining is evident when all or most of the 
nuclei are stained. Thus, careful adjustments of the denaturation conditions are 
necessary. 
   First, sections were rinsed three times, 5 minutes each with 0.1M PBS (at pH 7.4) 
on a shaker. Then, DNA was denatured by incubating sections in 1M HCl for 30 min 
at 45C (or 2M HCl for 15 min at 37C). 
 
4. HPLC analysis 
4.1 Materials 
.ĉ Instruments  
  -Chromatographic HPLC system (Alliance 2695XE separation Module. Water Ltd, 
USA) 
  - UV-Vis 2996 photodiode array detector (Water Ltd, USA) 
  -Atlantis dC18 column (150×2.1mm I.D.; particle size, 3m. Water Ltd, USA) 
  -SymmetryShieldTM Cartridge Column RP18 (250×4.6mm I.D.; particle size, 5m. 
Water Ltd, USA) 
Ċ.Chemicals 
  -0.01M sodium phosphate (pH4.8) 
     Sodium phosphate monobasic (MW: 119.98, Sigma, USA)        1.20g 
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     Millipore water                                         1000ml 
  -5% acetic acid 
     Acetic acid (MW: 60.05, USA, 1.05 g/ml)                    4.76ml 
     Millipore water                                           95ml  
  -15mM triethylamine  
     Triethylamine (MW: 101.19, Sigma, USA)                   1.52g 
     Millipore water                                        1000ml 
  -Methanol (HPLC) (MW: 32.04, VWR Prolabo, USA) 
  -Acetonitrile (HPLC) (MW: 41.05, VWR, BDH, USA) 
  -Ciprofloxacin (MW: 331.34, Sigma, USA) 
  -Penicillin G potassium (MW: 372.48, Sigma, USA) 
  -Penicillin G-TAT 
 
4.2 Procedures of injection and sample preparation 
   Ciprofloxacin and Penicillin G were injected into the animal body through the 
femoral vein or oral pathway respectively. The dosage of injection is 80 mg/kg body 
weight. After administration, the rat plasma samples were collected at the time points 
of 20,40,60,80,100 and 120 minutes respectively. 
4.2.1 Sample collection 
At different time intervals, 0.5ml rat blood was collected through femoral vein 
respectively. Then, collected blood samples were centrifuged at speed of 5000 rpm for 
5 minutes. The upper clear compartment was extracted for sample preparation. 
4.2.2 Sample preparation 
   Ciprofloxacin: Rat plasma (100l) samples were spiked with concentration 
ranging between 0.5 and 10l/ml of ciprofloxacin and denatured by 200l of 
acetonitrile, vortex for 1 minute and centrifuged at 4500rpm for 10 minutes. The 
supernatant was extracted into a test-tube and dried under nitrogen gas. The resultant 
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residue was reconstituted in (5% acetic acid+15 mM triethylamine) and injected into 
the HPLC system for analysis. 
   Penicillin G: Rat plasma (200l) samples were spiked with concentration ranging 
between 1.0 and 50l/ml of ciprofloxacin and denatured by 200l of acetonitrile, 
vortexed for 1 minute and centrifuged at 14,000 rpm for 15 minutes. The supernatant 
was extracted into a test-tube and dried under nitrogen gas. The resultant residue was 
reconstituted in (75%0.01M sodium phosphate (pH4.8):25% acetonitrile) and injected 
into the HPLC system for analysis. 
4.3 HPLC analysis method 
   10l samples was injected into the HPLC system and analyzed with different 
column and mobile phase. The Ciprofloxacin was separated on Atlantis dC18 column 
(150×2.1mm I.D.; particle size, 3m) at a flow rate of 0.5 ml/min, with mobile phase 
of 90% (5% acetic acid+15mM triethylamine),10%(Methanol : Acetonitrile) in 
isocratic program for 13 minutes. The detector was operated at a wavelength of 
280nm. As for Penicillin G, the column was also SymmetryShieldTM Cartridge 
Column RP18, and the mobile phase was 75% 0.01M sodium phosphate (pH4.8), 
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      All the experiments were repeated at least in triplicate for statistical purpose, 
and where appropriate, the data were presented as mean and standard deviation. All 
quantitative data were statistically evaluated using the Student’s t-test. The level of 






































1. Fabrication and characterization of nanoparticle micelles 
1.1 Synthesis of PEG-b-Chol and TAT-PEG-b-Chol 
As shown in the 1HNMR spectrum of PEG-b-Chol (Figure.3.1), PEG-b-Chol 
was successfully synthesized. The multiple peaks at 3.5-3.7 could be attributed to the 
protons of -CH2- groups in PEG and the weak and multiple peaks at 0.68-1.02 could 
be attributed to b-cholesterol. Figure.3.2 shows the spectra of TAT conjugated 
PEG-b-Chol (TAT-PEG-b-Chol), TAT and PEG-b-Chol in D2O. The weak and broad 
peaks at 4.0-4.2 (signal a) could be attributed to the protons of –NH-CH-(CH2)-CO- 
in TAT. The peaks at 2.52-2.58 (signal b) might be derived from the protons of 
-CH2-NH-NH-NH2 in arginine. The peaks at 6.60-6.66 (signal c) and at 6.95-7.0 
(signal d) could be attributed to the protons from the benzene ring in tyrosine. Based 
on the peak area ratio of signal c (derived from TAT) to signal e (derived from PEG) 
and the number of their representative protons, the molar ratio of TAT to PEG in the 
polymer was estimated to be about 0.9-1.0. After b-cholesterol and TAT conjugation, 
the increase in average molecular weight from 4.96 to 6.72 kDa further proved that 
synthesis of TAT-PEG-b-Chol was successful. The melting points of PEG-b-Chol and 






Figure 3.1: 1H NMR spectrum of PEG-b-Chol in CDCl3. The PEG-b-Chol 




Figure 3.2: 1H NMR spectrum of PEG-b-Chol, TAT-PEG-b-Chol and TAT in 
D2O. From this spectrum, the synthesis of TAT-PEG-b-Chol was also successful. 
 
1.2 Morphology of nanoparticles micelles  
The particle size is an important parameter for nanoparticles synthesized to be 
drug carrier through the BBB. Generally, it is difficult for cells to endocytose particles 
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with an effective diameter higher than 300nm (Kreuter, 2001). Under the fabrication 
conditions, the effective diameter of the blank, drug-loaded, QDs-loaded and 
FITC-loaded nanoparticles was 180,190, 150 and 199nm, respectively. The blank and 
drug-loaded nanoparticles were spherical in nature, and the size of the nanoparticles 
increased slightly after drug loading. 
    The amphiphilic polymers consisting of hydrophilic and hydrophobic segments 
can self-assemble to form core shell structure in aqueous solutions. The morphology 
of blank and ciprofloxacin encapsulated nanoparticles formed with PEG-b-Chol or 
TAT-PEG-b-Chol was examined with scanning electrical microscope (SEM). Figure 
3.3 shows typical SEM images of bland (C) and drug-loaded TAT-PEG-b-Chol 
nanoparticles (A, B and C). In C, the nanoparticles which red arrows pointed had 
successfully encapsulated drug molecules into their core shell. However, the white 
small cycles were blank nanoparticles. A and B show the morphology of drug loaded 
TAT-PEG-b-Chol nanoparticles under SEM. The size of the nanoparticles showed in 
the SEM images was slightly smaller than the results obtained from light scattering 
possibly because of the shrinking of the shell of the nanoparticles during the process 






Figure 3.3: A typical SEM images of drug-loaded and blank TAT-PEG- 
b-Chol nanoparticles. A (lower magnification) and B(higher magnification) show 
the morphology of drug loaded TAT-PEG-b-Chol nanoparticles. C shows the 
nanoparticles which have successfully encapsulated the drug into their core shell 
(red arrow). Others are blank TAT-PEG-b-Chol. (Scale bar: 1m for A,C and 100 
nm for B). 
 
1.3 Drug loading into nanoparticle micelles 
Ciprofloxacin was loaded into the nanoparticles at different initial drug loadings 
(i.e. 3, 5 and 8mg) at RT. Increasing initial drug loading led to an increased actual 
drug loading level, i.e. 2.3%, 2.7% and 3.2%, respectively. However, the particle size 
increased as well as the increase of initial drug loading reaching up to the highest of 
297nm at the initial loading of 8mg. This size might be too high to yield a prolonged 
blood circulation of the nanoparticles. The ciprofloxacin-loaded nanoparticles were 
also fabricated at 10C with an initial drug loading of 3mg, and an increased drug 
loading level was achieved (3.7% vs. 2.3%). This may be due to the fact that the 
solvent removal rate was lower at 10C so that the drug molecules had more time to 
assemble into the nanoparticles. 
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In addition, the particle size of the drug-loaded nanoparticles fabricated at 10C 
was smaller (190nm) than those fabricated in room temperature (208nm). Therefore, 
loading of FITC or QDs into nanoparticles was conducted at 10C and low initial 
loading (i.e. 0.75mg) to yield small size particles. Figure 3.4 shows the effect of initial 
drug (ciprofloxacin) loading on loading capacity of the nanoparticles. When the initial 
drug loading amount increased from 1 mg to 3 mg, the actual drug loading rate also 
increased from 12.2% to 13.8%. However, when the initial drug loading amount 
continued increasing, the actual drug loading rate nearly has no change. 
 
Figure 3.4: Effect of initial drug loading (Ciprofloxacin) on loading capacity 
of the nanoparticles. When the initial drug loading amount is 3 mg, the actual drug 
loading rate reaches the highest point. 
 
1.4 In vitro drug release in PBS 
To get in vitro drug release of ciprofloxacin loaded nanoparticle in PBS solution, 
at specific time intervals, the PBS solution with 20mg drug loaded nanoparticle 
micelles was taken out for analysis of drug concentration by the UV/VIS/NIR 
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PBS in the concentration range from 2.5 to 20.0ppm and r2 value was 0.999906. 
Figure 3.5 shows drug release profile from the nanoparticles in PBS (pH 7.4) at 37C. 
The release of the drug was sustained over a period of 5 hours. The results indicated 
that the release of the drug was well sustained. It suggested that after the nanoparticles 
get into the brain, a sustained release of ciprofloxacin lactate could be achieved. On 
the other hand, the in vitro drug release results also indicated that the drug molecules 
were well encapsulated into the nanoparticles. 
 
Figure 3.5: In vitro ciprofloxacin lactate release from the nanoparticle,, 
which shows the release of drug molecules was well sustained over a period of 5 
hours. It indicates that the drug molecules were well encapsulated into the 
nanoparticles and a sustained drug release would be achieved. 
 
2. Investigation of BBB integrity  
2.1 BBB in developing rat 
Qtracker 565 non targeted Quantum Dots are intended for use in vivo imaging or 
the imaging of micro-injected cells. These materials can exhibit long in vivo 
circulation times, non-specific binding and low immune response. In order to 
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investigate the integrity of developmental rat’s BBB, Qtracker 565 was injected into 
the bodies of rats (Postnatal 1 day, Postnatal 7 days and Postnatal 14 days respectively) 
as fluorescent marker. Figure 3.6 shows the labeling results in the brain of 
developmental rat. There were many positive cells (green dots the arrow pointed) in A 
and B. Although we did not study the type of these positive cells, the results suggest 
that Qtracker 565 can penetrate the BBB in P1 and P7 rats. It may because in these 
stages, the BBB function of rats is not completely developed and can let substance 
enter the brain. However, in C, there was not any cell labeled with Qtracker 565. It 
indicates that in P14, the BBB was fully developed and excluded foreign molecules 
entering the brain. 
 
Figure 3.6: Investigation of BBB integrity in developmental rat with Qtracker 
565 non-targeted Quantum Dots. The arrows point the positive cells which labeled 
with Qtracker in brain. (A: Postnatal 1 day; B: Postnatal 7 days; C: Postnatal 14 
days. Scale bar: 100m) 
 
2.2 The BBB penetration of Rhodamine B  
As rats’ BBB become complete from P14 onwards, therefore, fluorescent dyes 
such as fluorescein or Rhodamine can easily penetrate the BBB before P14. Figure 
3.7 shows the images that come from Rhodamine B stained brain of baby rat 
(postnatal 5). Here, 50l 1% Rhodamine B solutions (A and B) and 0.25% 
Rhodamine B (C and D) solutions were injected into the rat respectively. 4 hours later, 
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the brain tissues were collected. In A and B, many brain cells in cerebral cortex were 
labeled with Rhodamine B (red cells which arrows pointed). In C and D, also many 
Rhodamine B labeled cells could be found. However, contrast to A and B, the number 
of Rhodamine B labeled cells in C and D was much lower because of concentration 
difference in injected Rhodamine B. These results indicate that Rhodamine B really 
can cross the BBB without any aid in the baby rat. Therefore, some brain drugs such 
as antibiotics are supposed to enter the brain parenchyma in the developing brain 
freely. 
 
Figure 3.7: The penetration of Rhodamine B through the BBB in P5 rat. A and B: 
50l 1% Rhodamine B solutions; C and D: 50l 0.25% Rhodamine B solutions. 
(Observation area: cerebral cortex. Scale bar: 100m) 
 
3. In vivo BBB permeability of nanoparticle micelles 
3.1 BBB penetration of FITC Encapsulated nanoparticles 
The penetration ability of PEG-b-Chol and TAT-PEG-b-Chol nanoparticles 
through the BBB and their distribution in major rat organs has been observed. Firstly, 
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FITC as a fluorescent trace marker was successfully encapsulated into the core of 
PEG-b-Chol. Then, FITC-PEG-b-Chol solution was injected into the body through the 
femoral vein. Figure 3.8 shows that after entering the blood stream, 
FITC-PEG-b-Chol were distributed in most organs of the body except brain because 
of the existence of BBB. In the rat brain (A), it is obvious that very few nanoaprticle 
positive cells were found after the administration of FITC-PEG-b-Chol. However, 
many of green fluorescent positive cells could be observed in the liver (E), kidney (C) 
and spleen (G). It suggests that FITC-PEG-b-Chol can be taken by liver, kidney and 
spleen by not brain. 
The TAT peptide has been successfully conjugated with FITC-PEG-b-Chol to 
form the nanoparticle of FITC-TAT-PEG-b-Chol. When rats were treated with 
FITC-TAT-PEG-b-Chol through intravenous administration, many cells in liver (F), 
kidney (D), and spleen (H) could also be labeled by TAT conjugated FITC-PEG-b- 
Chol nanoparticle micelles. In addition, some micelles positive cells with long 
processes (B) were found in the brain. It suggests that although PEG-b-Chol can be 
excluded entering the brain by BBB, with the aid of TAT group, TAT-PEG-b-Chol 
can penetrate BBB and reach the brain parenchyma. Therefore, the nanoparticle 
system of TAT-PEG-b-Chol may serve as a carrier to deliver drug molecules cross the 






Figure 3.8: Distribution of nanoparticles in rat organs after administration by 
FITC-PEG-b-Chol (A, C, E, and G) or FITC-TAT-PEG-b-Chol (B, D, F, and H). 
Many cells in kidney(C, D), liver (E, F) and spleen (G, H) are labelled with FITC in 
both groups, but only in TAT-FITC-PEG-b-Chol injected rats, some fluorescent 
positive cells with long extending processes(arrows in B) were detected in the brain 
hippocampus (A, B) . (Scale bar: 50m) 
 
3.2 BBB penetration of QDs Encapsulated TAT-PEG-b-Chol  
QDs encapsulated TAT-PEG-b-Chol was also used to determine whether this 
kind of nanoparticles could cross the BBB. Here, QDs loaded PEG-b-Chol solution 
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with the same concentration was used as negative control. 4 hours after femoral vein 
injection, rat the brain sections were sampled and the distribution of fluorescent 
positive cells were observed under fluorescent microscope. Obviously, only a few 
traces of QD fluorescence were detected in the section (Figure 3.9 A) treated by QDs- 
PEG-b-Chol. However, the fluorescent intensity increased showed an obvious 
increase in the brain sections administrated with QDs-TAT-PEG-b-Chol nanoparticles 
(Figure 3.9 B, C and D). The positive staining could be observed to surround the 
nuclei in many brain cells (Figure 3.9 C, D, white arrows). In addition, the sections of 
the liver, kidney, heart and lung were also positive for QDs loaded micelles 
distribution (data not shown) at 4 hours after injection. It suggests that QDs 
encapsulated TAT-PEG-b-Chol could also penetrate the BBB and reach the brain 
similar like the nanoparticles of FITC loaded TAT-PEG-b-Chol. 
Figure 3.9 also shows that after QD-loaded TAT-PEG-b-Chol nanoparticles 
crossed the BBB, they mainly surrounded the nuclei of neuronal cells (Figure 3.9 D, 
white arrows). This finding is in agreement with the results reported in the literature 
(Santra et al., 2005b), in which TAT-conjugated QDs were detected in the rat brain 
after QDs injection. The QD-loaded nanoparticles did not enter the cell nucleus of 






Figure 3.9: Transduction of QDs-PEG-b-Chol (A) and QDs-loaded TAT-PEG-b 
-Chol nanoparticles (B-D) across the BBB. A few traces of QD fluorescence were 
shown in the hippocampus sections of the brain in QDs-PEG-b-Chol administrated 
rat brain (A). Positive fluorescent labeled cells increased significantly when the QDs 
delivered by TAT-PEG-b-Chol particles (B-D).The white arrows (C and D) show the 
cells in hippocampus of the brain were marked by the QDs loaded micelles and the 
perinucleus fluorescence indicates the micelles were mainly distributed in the 
cytoplasm of neuronal cells. (Blue-stained nuclei; Red dots-QDs. Scale bar: 20m.)   
 
3.3 Particle size of micelles for its BBB penetration 
The ideal size of drug-loaded nanoparticle system for delivery through the BBB 
should be lower than 300 nm. Otherwise, it may be difficult to be endocytosed by a 
cell (Olivier, 2005). In the process of FITC-TAT-PEG-b-Chol fabrication, extending 
the dialysis time and lowering the reaction temperature are providing a better 
condition to produce nanoparticles with evenly distributed sizes. The FITC 
encapsulated nanoparticles with diameters lower than 200 nm can be achieved. In 
order to investigate the relationship between BBB permeability and nanoparticle size, 
FITC encapsulated nanoparticles with different sizes were prepared and used. Figure 
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3.10 shows FITC encapsulated nanoparticles in the brain cortex. It is obvious that, in 
A (particle size 151.7nm), many more nanoparticle positive cells were found in 
cerebral cortex contrast to the same area of B (particle size 354.6nm). Also, these 
nanoparticle positive cells in the A emitted a stronger fluorescence than those cells in 
the B. It indicates that FITC-TAT-PEG-b-Chol with smaller diameters (151.7nm, A) 
could pass the BBB easily than those with larger diameters (354.6 nm, B).  
Generally, nanoparticles with small particle size have stronger nanoparticle 
bioadhesion to human vascular endothelial cells (Lohbach et al., 2006), they showed 
highest binding percentage than those particles with higher diameters. Therefore, with 
the aid of TAT peptide group, small-sized nanoparticles can more easily be taken up 
by endothelial cells and penetrate the BBB. For brain drug delivery, most successful 
nanoaprticle carriers have the size under 200nm (Liu et al., 2008a; Rao et al., 2008; 
Reimold et al., 2008). 
It was clear that TAT can help nanoparticle of PEG-b-Chol cross the BBB (Liu 
et al., 2008a). The differences in in vivo brain uptake between FITC-TAT-PEG- 
b-Chol (A and B) and FITC-PEG-b-Chol (C) are also shown in Figure 3.10. Although 
there were still some sporadic positive cells were labeled by FITC-PEG-b-Chol (C) 
contrast to saline injected brain (D), many more FITC-TAT-PEG-b-Chol micelles 
could enter the brain parenchyma and label brain cells with the aid of TAT peptide 




Figure 3.10: Particle size and BBB penetration. A: FITC-TAT-PEG-b-Chol, 
particle size: 151.7nm, concentration of FITC: 0.45mg/ml. B: FITC-TAT-PEG- 
b-Chol, particle size: 354.6nm, concentration of FITC: 0.45mg/ml. C: FITC-PEG-b- 
Chol, particle size: 187.9nm, concentration of FITC: 0.45mg/ml. D: Control: 0.9% 
Saline injection. There were more FITC-positive cells in the rats admistrated with 
nanopartiles with lower diameter (<200nm, A) than those with high diameter 
(>300nm, B). Also, TAT peptide group (A and B) can help more particles enter the 
brain contrast to those without this group (C). (Scale bar: 200m) 
 
4. Further in vivo investigation of TAT-PEG-b-Chol  
4.1 Identification of cell types of nanoparticle positive cells in Brain 
parenchyma  
The current results have shown that FITC and/or QDs encapsulated TAT-PEG-b- 
Chol nanoparticles could penetrate the BBB and intake by brain tissue. Here, the 
micelles positive cell types were further identified. The anti-CD11b for microglia 
(Figure 3.11 A, B and C), anti-NG2 for NG2 cells (D, E and F) and anti-GFAP for 
astrocytes (G, H and I) were applied to the brain sections from FITC-TAT-PEG-b- 
Chol administrated rats respectively. Very few co-localization between nanoparticle 
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positive cells (green) and stained brain cells (red) was observed, suggesting that cells 
take up the nanoparticles of FITC-TAT-PEG-b-Chol (white arrows pointing in A, D 
and G) were not microglia (white arrows pointing in B), NG2 cells (E) and astrocytes 
(H). The results of Figure 3.11 indicated that these three kinds of brain cells seldom 
uptake FITC-TAT-PEG-b-Chol when these nanoparticles reach the brain parenchyma. 
 
Figure 3.11: Cell type identification. Double labeling of FITC-TAT-PEG-b- 
Chol nanoparticles (A, D and G, green) and anti-CD11b (for microglia, B and C, 
red), anti-NG2 (for NG2 cells, E and F, red), anti-GFAP (astrocytes, H and I, red) in 
the brain section of the rat. Hardly any CD11b, GFAP or NG2 positive cells (arrows 
pointing cells in B, E, and H) are co-labeled with FITC (arrows pointing cells in A, D, 
and G) in respective immunohistochemstrical staining. It suggests that microglia, 
NG2 cells and astrocytes seldom absorbed the FITC-TAT-PEG-b- Chol when these 
nanoparticles reached the brain parenchyma. (Blue: stained nuclei with DAPI, Scale 
bar: 50m) 
 
Figure 3.12 shows the dual labeling results of anti-MAP2 antibody (marker for 
neurons) and FITC-TAT-PEG-b-Chol positive cells. In the brain cortex area (A, B 
and C) and hippocampus area (E, F and G), the nanoparticle positive cells (A and E, 
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green) were co-localized with the neuronal cells (B, C and F, G, red). It suggests that 
FITC-TAT-PEG-b-Chol were mainly taken up by neurons. 
As TAT transduction domain came from HIV transactivator of transcription 
protein and was non-cell-specific (Schwarze et al., 1999), theoretically, the TAT 
conjugated nanoparticles can be taken up by all types of cells in the brain. However, 
the current results showed that most nanoparticles showed that most nanopartilces in 
the brain parenchyma were distributed in neuronal cells. The reason for this selective 
distribution is still unknown. It may be because the intake of micelles is competitive 
and neurons possess the most suitable membrane receptor which can well recognize 
TAT peptide and induce the AMT/RMT. 
 
Figure 3.12: Double labeling of FITC-TAT-PEG-b-Chol nanoparticles (A and E, 
green) and MAP2 positive neuronal cells (B, C and F, G, red) in the cortex (A-C) and 
hippocampus (E-G) of brain sections from 10 weeks old SD rat. Some cells with the 
FITC fluorescent positive (arrows in A and E) are double labeled with the MAP2 
(arrows in B and F), suggesting that intravenous injected TAT-PEG-b-Chol were 
mainly taken up by neurons. (Blue: stained nuclei with DAPI, Scale bar: 50m) 
 
4.2 The cellular uptake of TAT-PEG-b-Chol by neurons  
As mentioned before, TAT-PEG-b-Chol nanoparticles could be taken up by 
neuronal cells concentrated in the area of cerebral cortex and hippocampus. Figure 
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3.13 shows the detailed distribution of FITC-TAT-PEG-b-Chol in these two areas. 
The positive green cells in A, B and E were located in hippocampus area and those in 
C and D were located in cerebral cortex area (white arrows pointing cells). In 
hippocampus (A, B and E), neurons that uptake FITC-TAT-PEG-b-Chol have longer 
processes than those in cerebral cortex. These cells might be internal neurons located 
in the hippocampus area. However, in cerebral cortex area, these cells may be cortical 
neurons. Figure 3.13 also demonstrated that these FTIC encapsulated nanoparticles 
only distributed in cytoplasm of neurons but not nuclei. This result is also in 
agreement with results in the Figure 3.10.  
 
Figure 3.13: The uptake of FITC-TAT-PEG-b-Chol in hippocampus area (A, B 
and E) and cerebral cortex area (C and D). Those neurons which absorbed the 
FITC-TAT-PEG-b-Chol in brain hippocampus have longer processes than those 
neurons in cerebral cortex, suggesting they are different type of neurons. (Scale bar: 
A, B and C 100m; D 1 m; E 50m. Blue: stained nuclei). 
 
Similar results were acquired when QDs-TAT-PEG-b-Chol penetrated the BBB 
and reached the brain parenchyma. Figure 3.14 shows the QDs-TAT-PEG-b-Chol 
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nanoparticle positive neurons in the same two areas. These nanoparticles also 
distributed mainly in hippocampus area (A, B) and cerebral cortex (C, D). Both 
neurons with long process (A and B in hippocampus) and those without processes (C 
and D in cortex) could absorb these nanoparticles. In addition, in the area between the 
hippocampus and cerebral cortex (Figure 3.14, E), both these two kinds of neurons 
were found. 
 
Figure 3.14: The distribution of QDs-TAT-PEG-b-Chol positive neurons in 
hippocampus (A and B) and cerebral cortex areas (C and D). In the area between 
hippocampus and cerebral cortex (E), two types of neuron that could absorb 
nanopaticles were found. (Scale bar: A 50m; B, D and E 20m; C 10m. Blue: 
stained nuclei). 
 
4.3 Primary in vivo kinetics of the BBB penetration of nanoparticles  
In the study of BBB penetration of nanoparticles, the, brain samples were 
generally collected 4 hours after intravenous injection. Because the previous in vitro 
staining experiments (data not shown) showed that the absorbance of fluorescent 
RESULTS 
 106
particles reaches the highest point after 4 hour incubation. However, Schwarze 
believed that particles with TAT group can rapidly enter the brain shortly within 30 
minutes (Schwarze et al., 1999). In order to clarify the dynamic BBB penetration of 
TAT-PEG-b-Chol, the rat brain samples were respectively collected at different time 
points (5, 15, and 30 minutes) after intravenous injection of these FITC encapsulated 
nanoparticles. Figure 3.15 shows the results of penetration of these three time points. 
5 minutes after injection, the nanoparticles had already entered the blood stream, but 
they only existed in the blood and perhaps were absorbed by the endothelial cells of 
the blood vessels (Figure 3.15, A, B). It suggests that the FITC-TAT-PEG-b-Chol had 
not yet penetrated the BBB 5 minutes after they enter the body. 
However, from 15 minutes, the positive cells with green dots were already found 
both inside (write arrow points) and outside the blood vessel (yellow arrow points) 
(green in Figure 3.15, C and D). It indicated that the BBB penetration of FITC-TAT- 
PEG-b-Chol began between 5 and 15 minutes after they were injected into the blood 
stream. 30 minutes later since injection (Figure 3.15 E and F), the nanoparticles also 
existed both inside the blood vessel and in the brain parenchyma. It might because the 





Figure 3.15: Primary in vivo kinetics of nanoparticle penetration through the 
BBB. The white arrows pointing cells are endothelial cells which taken the 
nanoparticles of FITC-TAT-PEG-b-Chol in the blood vessels. The yellow arrows 
pointing cells are neuronal cells in brain parenchyma which absorb the nanoparticles. 
The results indicated that BBB penetration of FITC-TAT-PEG-b-Chol began between 
5 and 15 minutes after they entered the blood stream. (Scale bar: 50m) 
 
As Figure 3.16 shown, the QDs encapsulated TAT-PEG-b-Chol also was firstly 
found outside the blood vessel around 10-15 minutes after they entered the rat body. 
Just as FITC-TAT-PEG-b-Chol, QDs-TAT-PEG-b-Chol also began to penetrate the 
BBB at the time point of 10-15 minutes. Here, FITC conjugated Lectin protein 
staining results clearly displayed that QDs-TAT-PEG-b-Chol dots (red) were 
completely constrained inside the blood vessels at 5-minute time point (Figure A and 
B). However, 15 minutes and 30 minutes later, many nanoparticles could be seen both 
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inside and outside the blood vessels. They may be respectively taken by endothelial 
cells inside the blood vessel (Figure C, D, E and F, white arrows pointing cells) and 
cortical neurons in the brain parenchyma (Figure 3.16 C, D, E and F, yellow arrows 
pointing cells). These results also proved that the designed nanoparticles 




Figure 3.16: The BBB penetration of QDs-TAT-PEG-b-Chol in 5 minutes (A, B), 
15 minutes (C, D) and 30 minutes (E, F) after intravenous injection. The QDs 
encapsulated nanoparticles (red in A, C, and E) were only seen inside the blood 
vessel (green in B and D) in 5 minutes. However, they could be seen both in the blood 
vessel and brain parenchyma 15 minutes later. (Scale bar: A and B: 100m, C, D, E 




5. In vitro characterization of nanoparticle micelles  
5.1 Uptake of nanoparticles in cultured cells 
The brain capillary endothelial cells and astrocytes are main components of the 
BBB. Therefore, they are widely used in some in vitro studies related to the BBB. 
Here, cultured endothelial cells and astrocytes were used to investigate in vitro 
cellular intake of TAT-PEG-b-Chol and PEG-b-Chol. As shown in Figure 3.17, in 
cultured endothelial cells (Figure 3.17 A and C) and astrocytes (B and D), both 
nanoparticles with (C and D) and without TAT peptide (A and B) could enter the cells 
after 1 hour incubation. However, the uptake of the nanoparticles with TAT peptide 
was higher as the fluorescent intensity of the cells incubated with FITC-TAT-PEG 
-b-Chol (C and D) was much stronger compared to that of the cells incubated with 
FITC-PEG-b-Chol (A and B). It suggests that many more nanoparticles with TAT 
group could attach to the surface of cells or enter the cells. It might because the 
presence of TAT cell penetrating peptide on the surfaces of the nanoparticles 
promoted their cellular uptake by endothelial cells and astrocytes. This finding is also 
in accordant with those results in vivo, suggesting TAT peptide could facilitate 





Figure 3.17: Uptake of FITC-TAT-PEG-b-Chol and FITC-PEG-b-Chol by 
cultured endothelial cells (A, C) and astrocytes (B, D). Although both nanoparticles 
without (A, B) and with (C, D) TAT peptide group could enter cultured cells, those 
cells administrated with TAT group emitted a relatively stronger fluorescence (C, D). 
It suggests that many more nanoparticles with TAT group (FITC-TAT-PEG-b-Chol) 
could attach to the surface of cells or enter the cells than FITC-PEG-b-Chol. (Scale 
bar: A, B, D 20m, C 50m) 
 
 
5.2 The cytotoxicity of nanoparticle micelles  
An ideal nanoparticle drug carrier should hardly have toxicity to body and cells. 
In current in vivo study, no rat died during the experiment, suggesting that 
TAT-PEG-b-Chol was not fetal to those animals. In Figure 3.18 A and B, in vitro 
cytotoxicity of QDs loaded TAT-PEG-b-Chol was investigated with cultured 
endothelial cells and astrocytes. Pure QDs solution administration was selected as 
control group. Here, QDs-TAT-PEG-b-Chol (0.0375mg/ml) and pure QDs (0.0375 
mg/ml) were added into cultured endothelial cells and astrocytes (2.2×105 cells/well) 
respectively. 12 hours later, the cell number and viability of endothelial cells (A) 
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hardly changed, suggesting that QDs-TAT-PEG-b-Chol was not toxic to endothelial 
cells. However, significant decreases in cell number and viability have been observed 
in astrocytes (B). But the decrease of cell number and viability might be due to 
cytotoxicity came from pure fluorescent QDs (Hoshino et al., 2007). Its toxicity may 
be caused by released cadmium and selenium, two of the most wildly used constituent 
metal in the QDs core crystal (Lovric et al., 2005). Indeed, when the administration of 
FITC-TAT-PEG-b-Chol particles was applied, no change of cell number and viability 
was detected for both endothelial cells and astrocytes (Figure 10 C, D). This result 
suggested that, at the same time fame, TAT-PEG-b-Chol nanoparticle was not toxic in 
vitro. 
 
Figure 3.18: The cytotoxicity investigation of QDs-TAT-PEG-b-Chol (A,B) and 
FITC-TAT-PEG-b-Chol (C,D) in cultured endothelial cells (A,C) and astrocytes (B,D). 
The cell number and cell viabilities hardly changed after the treatment of these 
nanoparticles. It means that the nanoparticle of TAT-PEG- b-Chol has no cytotoxicity 




6. Synthesis and characterization of TAT-Penicillin G  
Hydrophilic antibiotics, Penicillin G potassium can not be encapsulated into the 
core of PEG-b-Chol. As Penicillin G has –COOH group and TAT peptide has –NH2 
group, therefore, using EDC/NHS chemistry, it is feasible to directly connect 
Penicillin G molecules to TAT peptide to form TAT-Penicillin G. With the aid of 
TAT cell penetrating peptide, this complex was supposed to cross the BBB and reach 
the brain parenchyma. 
6.1 1HNMR spectrum of TAT-Penicillin G potassium 
Figure 3.19 showed the 1H-NMR spectra of TAT peptide, Penicillin G potassium 
and TAT-Penicillin G potassium. In the 1H-NMR spectra displayed, TAT-Penicillin G 
molecules presented characteristic peaks from both TAT and Penicillin G. In the 
spectra of TAT-Penicillin G, signal a, b, c and d came from TAT peptide. The weak 
and broad peak at 4.0-4.2 (signal c) can be attributed to the protons of 
–NH-CH(CH2)-CO- in TAT. The peaks at 2.52-2.58 (signal d) might be derived 
from the protons of -CH2-NH-NH-NH2 in arginine. The peaks at 6.60-6.66 (signal b) 
and at 6.95-7.0 (signal a) could be attributed to the protons from the benzene ring in 
tyrosine. However, the peaks at 5.30-5.41 (signal e) came from Penicillin G; it might 
be derived from –CO-NH- in Penicillin G potassium. The result suggests that the 




Figure 3.19: 1HNMR spectra of TAT peptide, Penicillin G potassium and 
TAT-Penicillin G potassium. TAT-Penicillin G molecules presented characteristic 
peaks from both TAT and Penicillin G. It proved that the synthesis was successful. 
 
6.2 Determination of molecular weight of TAT-Penicillin G  
The molecular weight of TAT-Penicillin G potassium was determined using 
MALDI-TOF mass spectrometry. The MALDI-TOF mass spectrum of TAT peptide 
was used as a control to estimate the results obtained for TAT-Penicillin G potassium 
conjugate. The molecular weight of TAT peptide is 1560, after conjugation of 
Penicillin G, the molecular weight of TAT-Penicillin G potassium should be around 
1875. Figure 3.20 shows the MALDI-TOF spectrum of TAT-Penicillin G (Figure 3.20 
A) and TAT (B). A narrow distribution from 1850 to 1888m/z was found in the mass 
spectrum of TAT-Penicillin G, The existence of those peaks not only suggested the 
conjugation of TAT to Penicillin G was successful but also verified the ratio of TAT 





Figure 3.20: The MALDI-TOF spectrum of TAT-Penicillin G (A) and TAT (B). 
The peaks around 1560 (A and B) represent the TAT molecules, particularly in B. It 
may be attributed to some un-reacted TAT molecules. Peaks around 1875 represent 
TAT-Penicillin G. 
 
6.3 The cytotoxicity of TAT-Penicillin G potassium 
Figure 3.21 shows the results of cytotoxicity investigation of TAT-Penicillin G 
potassium to 4 types of brain cell lines: neuron (A, NSC-34); microglia (B, BV2); 
astrocytes (C) and endothelial cells (D). It was obvious that after microglia, astrocytes 
and endothelial cells were treated by TAT-Penicillin G, their numbers and cell 
viabilities had hardly changed (B, C, and D) It suggested that TAT-Penicillin G was 
not toxic to those cell types. However, the number of neuronal cells (A) decreased to 
some extent contrast to that of control group after the administration of 
TAT-Penicillin G, although their cell viability remained as high as those controlled 
cells. Because when neurons were treated by pure Penicillin G, their number nearly 
remained unchanged. Therefore, it was not Penicillin G that resulted in the cell 
number decrease. As it was reported that the HIV-1 TAT protein is neurotoxic to the 
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cultured rat midbrain fetal neurons (Aksenova et al., 2006), it was believed that it was 
free TAT peptide that lead to the decrement. The free TAT may come from the tiny 
amount of unreact TAT peptide that were not removed by the method of membrane 
dialysis. Here, no direct evidence proved whether TAT-Penicillin G was toxic to 
cultured neurons. Further investigation is required to clarify this issue or TAT 
fragment might be modified to reduce its toxicity. 
 
Figure 3.21: Cytotoxicity investigation of TAT-Penicillin G potassium in neuron 
(A, NSC 34); microglia (B, BV2); astrocytes (C) and endothelial cells (D). The 
concentration of Penicillin G and TAT-Penicillin G (counted with Penicillin G) used 
are 500g/l. (*P<0.05) 
 
7. Application of TAT-Penicillin G 
7.1 Antibacterial efficacy test of TAT-Penicillin G 
B. subtilius and C. albicans were used in the antibacterial efficacy test of 
TAT-Penicillin G. The concentration of microorganism was determined using the 
method of broth microdilution. Here, the OD value at 600 nm was measured at 
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different time points after the treatment of TAT-Penicillin G. Those values which 
come from the treatment of pure Penicillin G were set as the control.  
    Figure 3.22 respectively shows the anti-B. subtilius (A) and anti-C. albicans (B) 
efficacy test of TAT-Penicillin G at 0, 2, 4, 6 and 13 hours after the administration. In 
this experiment, B. subtilius or C. albicans treated with 1.4ppm and 2.7ppm 
TAT-Penicillin G were used as experimental groups and those microorganisms 
without any treatment were used as control. In A, at the beginning, OD values of all 
groups were 0.1. Two hours later, the OD value of all three groups began to increase, 
but the control group increased faster than other two groups, suggesting that 2.7ppm 
TAT-Penicillin G could prevent the growth of B. subtilius more effectively than other 
two groups. At the time points of 4, 6 and 13 hours, the OD values of 1.4ppm 
TAT-Penicillin G group, 2.7ppm TAT-Penicillin G group and non-treatment group 
continued increasing, however, those of non-treatment group increased fastest, next 
the 1.4 ppm TAT-Penicillin G group and the last 2.7ppm TAT-Penicillin G group. It 
is obvious that the sequence of anti-B subtilius efficacy was 2.7ppm TAT-Penicillin G 
> 1.4ppm TAT-Penicillin G> non-treatment control group. It suggests that just as pure 
antibiotics, TAT conjugated Penicillin G as well has the ability to inhibit the growth 
of some infectious microorganisms.  
When C. albicans was administrated with TAT-Penicillin G, till 13 hours after 
the treatment, the OD value of three groups increased sharply. Similar as before, the 
values of two TAT-Penicillin G treated group were smaller than non-treatment control 
group. However, nearly no difference was observed in anti-C. albicans efficacy of 
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2.7ppm and 1.4ppm TAT-Penicillin G group. It is because that the minimum 
inhibition concentration (MIC) of TAT-Penicillin G to C albicans was much smaller 
than 1.4ppm. These two groups can obtain almost same inhibition efficiency to C 
albicans. Overall, as well as pure Penicillin G, the TAT-Penicillin G also has the 
ability to inhibit the growth of some infectious microorganisms.  
 
Figure 3.23: The anti-B subtilius (A) and anti-C albicans (B) efficacy test of 
TAT-Penicillin G. 2.7ppm of TAT-Penicillin G has higher inhibition efficiency to B 
subtilius that 1.4 ppm of TAT-Penicillin G and non-treatment control group. But for C 
albicans, although those two groups of TAT-Penicillin G both obtained good anti-C 
albicans efficacy than non-treatment control group, they two had no difference. 
(*P<0.05, **P<0.01) 
 
7.2 In vitro uptake of TAT-Penicillin G  
Figure 3.24 shows the cellular uptake of TAT-Penicillin G and pure Penicillin G 
in cultured brain capillary endothelial cells. In this study, TAT-Penicillin G and pure 
Penicillin G solution with same concentrations were added into BCEC seeded 6-well 
plates (2.2×105 cell/well). The initial concentrations of drugs in the culture medium 
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were set as 100%. At different time intervals (0, 20, 40, 60, 80, 100, 240 and 720 
minutes), 100l medium was collected respectively and analyzed by HPLC. The 
percentage of absorption by endothelial cells was indirectly calculated from the 
difference between drugs concentrations remained in collected medium samples and 
the initial concentration added. 
     For 1.40ppm (Figure 3.24 A red line) and 2.7ppm (Figure 3.24 B blue line) pure 
Penicillin G groups, the concentrations of Penicillin G has little change within the first 
4 hours when they were added. It may be because that Penicillin G was nearly not 
taken up by endothelial cells in this period. Until 12 hours after the administration, 
only about 4% (1.4ppm) and/or 6% (2.7ppm) were endocytosed into the cell or 
attached to the cell membrane. 
However, when these cells were administrated with TAT-Penicillin G (black 
lines in A and B), the drug concentration in the culture medium began to decrease 
early in 1 hour after the add-in. 12 hours later, there was only around 85% of 
TAT-Penicillin G remained in the medium. It suggests that already about 13% (1.4 
ppm group) and/or 17% (2.7ppm group) of added drugs may be endocytosed into the 
cell or attached to the cell membrane. Using cultured astrocytes, similar results were 
obtained. It was obvious that many more TAT-Penicillin G molecules were taken up 
by endothelial cells or astrocytes than pure Penicillin G. It may because TAT peptide 
helps TAT-Penicillin G to enter the cell body easily or be attached to the cell 
membrane. The result suggests that the conjugation of TAT may enhance the ability 




Figure 3.24: In vitro uptake of TAT-Penicillin G and pure Penicillin G. 12 hours 
after the treatment with TAT-Penicillin G or pure Penicillin G respectively, much 
more TAT-Penicillin G was taken than pure Penicillin G. It suggests that this TAT 
compound can facilitate Penicillin G to penetrate brain cells which are main 
components of the BBB. 
 
8. Pharmacokinetics investigation of selected antibiotics  
8.1 HPLC spectra of Penicillin G, Ciprofloxacin and Doxycyline  
Figure 3.25 are the HPLC spectrums of two selected antibiotics: Penicillin G (A) 
and Ciprofloxacin (B). When scanning Penicillin G with UV from 210nm to 400nm, 
its highest UV absorbance was at 229nm. Therefore, the detective wavelength of 
Penicillin G was set as 229nm. When analyzed by SymmetryShieldTM Cartridge 
Column RP18 column, the peak of Penicillin G came out in 8.5 minutes (retention 
time). As Figure 3.26 shown, the retention time of Ciprofloxacin was around 11.1 




Figure 3.25: HPLC spectra of Penicillin G (A) and Ciprofloxacin (B). Their 
retention time and detective wavelength were 8.5 minutes (at 229nm) and 11.1 
minutes (at 280nm) respectively. 
 
8.2 Within and between day assay validation (n=5)  
Table 2 shows the results of within- and between-day assay validation of selected 
antibiotics. The object of this validation is to validate the feasibility of antibiotics 
analytical methods. Coefficients of variation (CV) and Accuracy are two important 
parameters to evaluate the feasibility. Here, CV (%) was defined as the ratio between 
SD and Mean value (CV=SD/Meanh). For a good analytical method, the value 
of CV must be lower that 10%. The accuracy was defined as the ratio between mean 
of the drug concentration measured and initial standard drug concentration added 
(Accuracy=Mean/Standardh). The value of accuracy must fall into the zone 
between 95% and 105% for a proper analytical method.  
As the validation results shown, the values of CV and accuracy of the four added 
concentration almost met the requirements. It suggests that the established analytical 
methods for Penicillin G and Ciprofloxacin are feasible and can be used for the 
pharmacokinetics research of these antibiotics. 
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Table 2: Validation of the selected antibiotics 
Measured concentration (g/ml) 
Within-day          Between-day 
Added 
concentration 






1.0 ± 0.08 
5.0 ± 0.07 
10.1 ± 0.17 





1.1 ± 0.09 
















0.54 ± 0.05 
1.10 ± 0.07 
4.80 ± 0.10 

















Note: Within and between day assay validation (n=5) of Penicillin G and 
Ciprofloxacin. The values of CV and Accuracy suggest the analytical methods are 
feasible.  
 
8.3 Inter-Assay precision for the analysis of Penicillin G in rat plasma 
Before in vivo investigation of pharmacokinetics of Penicillin G, the methods of 
Penicillin G extraction from rat plasma and analysis by HPLC should be established. 
Also, the inter-Assay Precision for the analysis of Penicillin G in rat plasma should be 
done. Here, different amounts of pure Penicillin G were added into the fresh rat 
plasma to form standard solutions. Using extraction method described before, the 
extracted samples were injected into the HPLC system and analyzed. 
Figure 3.26 shows the standard curve of Penicillin G in rat plasma extracted and 
analyzed by HPLC. It was obvious that this curve displayed a perfect linear relation 




Figure 3.26: Standard curve of Penicillin G analysis in rat plasma. The curve 
shows a perfect linear relation between the concentration and the peak area. 
 
The table 3 shows the results of inter-Assay Precision for the analysis of 
Penicillin G in rat plasma. When the concentration of Penicillin G was low in the rat 
plasma (1.0-5.0g/ml), the value of CV was higher than 10%. As well, their values of 
accuracy were not in the zone between 95% and 105%. However, with the increase of 
Penicillin G concentration in the rat plasma, ideal CV and accuracy values could be 
acquired. It suggests that when the concentration of sample lies between 10g/ml and 
250g/ml, the concentration measurement results by HPLC with the current 
established method are creditable. 
Table 3: Inter-Assay Precision for the analysis of Penicillin G in rat plasma 
Measured concentration in Rat Plasma(n=3, g/ml) 




(g/ml) Mean ± SD CV Accuracy Mean ± SD CV Accuracy 
1.0 0.899f0.21 23.1% 89.9% 1.041f0.17 16.3% 104.1% 
5.0 5.292f0.56 10.6% 105.8% 3.869f0.37 9.6% 77.4% 
10.0 10.06f0.44 4.3% 100.6% 8.776f0.27 3.1% 87.8% 
50.0 52.07f1.83 3.5% 104.1% 49.38f0.89 1.8% 98.8% 
250.0 251.25f4.11 1.6% 100.5% 248.35f5.23 2.1% 99.3% 
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Note: Inter-Assay Precision for the analysis of Penicillin G in rat plasma. The 
results suggest that when the concentration of sample lies between 10g/ml and 
250g/ml, the HPLC measured concentration results with our established method are 
creditable. 
 
8.4 Pharmacokinetics of selected antibiotics after intravenous 
injection 
Figure 3.27 shows the pharmacokinetics results of Penicillin G (A) and 
Ciprofloxacin (B) when they were intravenous injected into the rat body through the 
femoral vein. The dosage of injection was 80 mg/kg body weight. At different time 
points, the rat plasma samples were collected and analyzed by HPLC. As the figure 
shown, the concentration of these three antibiotics in the plasma greatly decreased in 
the first 40 minutes since administration. It may be because that the antibiotics were 
taken by the some organs such as liver and digested by the cells inside. After 60 
minutes, the trend of decrease became smooth, suggesting that the plasma 
concentration of antibiotics was getting balanced with the concentration in other 
organs.  
 
Figure 3.27: Plasma concentration–time curves for Penicillin G (A) and 





9. Establishment of brain pathological model 
Microglia is a brain cell type in the CNS with the capacity of full 
immunocompetence. Resting microglia has a unique ramified morphology. However, 
microglia can react to various CNS injury rapidly accompanied with the changing of 
morphology from ramified to amoeboid microglia. Therefore, the morphology 
change of microglia may be an obvious symbol to show the status of CNS: normal 
or pathological. As LPS is a highly proinflammatory molecule that elicits a wide 
array of responses, including the upregulation of cytokines, adhesion molecules, and 
tissue factor (Bannerman and Goldblum, 2003), the administration of LPS to the 
animal brain may certainly result in the brain injury. Also, the administration of LPS 
can damage the BBB through the action of gelatinase B (Mun-Bryce et al., 2002). 
Therefore, the intracerebral injection of LPS can be used to establish the brain 
pathological model and the activation of microglia can serve as a sign of successful 
establishment. In Figure 3.28, after the focal injection of LPS to the rat brain, it was 
obvious that the shapes of ramified microglia in non-LPS-administration side (A) 
had greatly transformed to round amoeboid microglia (B). It suggests that microglia 
had been activated after the LPS administration. This result demonstrated that the 




Figure 3.28: Alteration in microglial cells morphology in LPS focal injected 
pathological brain model. A: Normal side; B: LPS administration side. The shapes of 
ramified microglial cells in A had greatly changed into round amoeboid microglia in 
B, suggesting that microglia was activated and the model establishment was 
successful. (Scale bar: 50.0m) 
 
10. NG2 cell responses in LPS treated pathological brain 
10.1 NG2 cell responses 
The real function of NG2 cells in the CNS is still unclear now. Some scientists 
considered the NG2 cells as progenitor cells for oligodendrocytes while others 
thought that these cells were a specific type of glial cells (Dawson et al., 2000; Polito 
and Reynolds, 2005). Therefore, it is of great interest to investigate the NG2 cell 
responses in pathological brain to learn their possible responses and functions. In 
addition, this investigation may be useful to future drug delivery through BBB to 
targeted cell type in the brain. Figure 3.29 has shown that in the surrounding region 
near LPS injection site (B and D), the body size of NG2 cells become enlarged and 
the upregulation in expression of NG2 molecules was observed, compared with those 
in normal side (A) as well as saline administration side (C). Meanwhile, the number 
of the cells seemed increased in contrast to that in normal side and saline injected side. 
It suggests that, the NG2 expressing cells were responding to the stimulus in the brain 
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as well as microglial cells. Their morphology greatly changed and their expressions 
were upregulated. However, the reason is unknown and needs to be elucidated in the 
future. 
 
Figure 3.29: The NG2-positive cells, after LPS challenge, increased their sizes of 
cell body. NG2 positive staining became more intense (B, D) in comparison with 
those in the normal side (A) and saline injected side (C). The cell number also 
increased in LPS administration side as obvious increase in the intensity of the NG2 
positive cell population. (Scale bar: 50.0 m Blue: Stained nuclei) 
 
In the further investigation of NG2 cells response to brain injury, the average 
NG2 cells’ numbers in LPS injected area, saline injected area and controlled 
non-injected area were counted respectively. In Figure 3.30, contrast to the normal 
side, the cell number in LPS or saline administrated sides both increased around 50%. 
It means that the injury of injection also resulted in the upregulation of NG2 cells 
expression. However, after administration of LPS, the number of NG2 cells 
significantly increased in LPS injected area. LPS administration to the rat brain could 
promote the increment of NG2 cells number both in LPS injected side and non- 
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injected side. Overall, this result suggested that in the pathological brain, the focal 
injection of LPS can activate NG2 positive cells and increase the number of NG2 cells 
in the surrounding region near LPS injection site 
 
            
Figure 3.30: Cell number counting of NG2 positive cells in LPS and saline 
administrated rat brain. As the injury caused by the injection also resulted in an 
increase in the number of NG2 cells, after administration of LPS, the number of NG2 
cells significantly increased in LPS injected area. (Average counting area: 0.357 mm2, 
* *P<0.01) 
 
10.2 The activated NG2 cells do not produce some cytokines 
Brain cells, such as microglia or astrocytes can secret cytokines when they are 
activated under pathological condition in response to brain injury (Lee et al., 1993; 
Lindsay, 1994). An overwhelming number of animal studies indicated that there were 
chronic elevation of certain inflammatory cytokines, including IFN-, IL-1, TGF-, 
and TNF- by activated microglial cells in the inflammatory area (Lee et al., 1993). 
As the previous study shows, NG2 cells can be activated in pathological brain. Can 
these cells also produce some cytokines just as microglial cells? In the current study, 
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the NG2 cells were double stained with IFN- (Figure 3.31 A), IL-1 (B), TGF- (C), 
and TNF- (D) respectively by immunohistological techniques. As Figure 3.31 shows, 
there was no any co-localization observed in either LPS administrated side, saline 
administrated side or non-LPS injected side (not shown) in the brain. However, a 
significant upregulation in these cytokine expressions could be recorded. The result 
suggests that, unlike microglia or astrocytes, the activated NG2 cells do not produce 
the detected cytokines in this LPS focal injected brain. 
 
Figure 3.31: Double labeling of NG2 cells and selective cytokines. No 
colocalization of NG2 positive cells (red) with IFN- (green dots in A), IL-1 (green 
dots in B), TGF- (green dots in C) and TNF- (green dots in D) were detected after 
LPS administration, suggesting activated NG2 cells did not expression the detected 
cytokines. (Scale bar: 50.0 m) 
 
10.3 Expression of BrdU in NG2 cells after LPS administration 
The increment of the number of NG2 cells may be attributed to the cell 
proliferation in pathological areas both in brain cortex and hippocampus. Here, in 
order to certify this hypothesis, BrdU solution was injected into the rats body at the 
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same time when LPS was administrated to the brain. Figure 3.32 show the results of 
double staining of NG2 cell (red) and BrdU (green) in brain sections. A and B are 
sections from LPS injected brain cerebral cortex. C and D came from hippocampus 
area just near LPS injection site.  As Figure 3.32 shows, the green BrdU positive 
cells were seldom co-localized with red NG2 cells in both cortex and hippocampus, 
indicating that BrdU was not mainly expressed by NG2 cells. It suggests that the LPS 
induced increment of NG2 cells number was not due to proliferation. 
 
Figure 3.32: Expression of BrdU in brain after LPS administration. A and B: 
Cerebral cortex; C and D: Hippocampus area. Obviously, the BrdU positive staining 
was seldom co-localized with NG2 cells in these two affected areas. It suggests that 
the upegulation of NG2 cells after LPS administration can not be attributed to their 
proliferation. (Scale bar: 50.0m). 
 
11. NG2 cell responses after blockage of microglial 
complement receptor type 3 in LPS treated brain  
11.1 The change of NG2 positive cells’ expression 
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It has been reported that microglia has reactive responses in various brain 
pathologies including neuron-inflammation (Kreutzberg, 1996; Liu and Hong, 2003). 
Microglial activation has been observed in the current study in the brain pathological 
model triggered focal injection of LPS. As well as microglia, NG2 cells also can be 
activated in response to brain injury in LPS focal injected pathological brain. 
Anti-CD11b antibody, as a specific marker of microglia, can recognize and bind the 
complement receptor type 3 of microglial cells. In order to investigate the possible 
relationship between microglia and NG2 cells, microglia were blocked by the focal 
injection of anti-CD11b antibody to the cortex 24 hours before the LPS administration 
at the same site. The reactions of NG2 cells were studied. 
As previous result shows, the expression of NG2 positive cells was upregulated 
contrast to the expression in non-LPS administration side. Figure 3.33 also confirm 
this conclusion. However, after the administration of anti-CD11b antibody and LPS, 
the increase in the number of NG2 cells was significant inhibited contrast to LPS 
administration only. Just as Figure 3.33 shows, the total number of NG2 cells 
decreased significantly. As the detailed mechanism was still unknown, this result 
suggested that microglia may participate in the activation of NG2 cells in the 
pathological brain. It plays a role in the NG2 cells’ responses to brain injury. Their 




Figure 3.33: NG2 positive cell number counting when the rat was treated with 
anti-CD11b antibody only; LPS only and anti-CD11b antibody+LPS. After the 
administration of anti-CD11b antibody and LPS, the increase in the number of NG2 
cells was significant inhibited contrast to LPS administration only, suggesting that 
microglia may participate in the activation of NG2 cells in the pathological brain. 
( **P<0.01) 
 
11.2 Morphology of NG2 cells after anti-CD11b antibody+LPS 
treatment  
As Figure 3.34 A and C show, the difference in the morphology of NG2 cells 
were also observed after anti-CD11b antibody+LPS administration compared to those 
only treated by LPS. NG2 positive cells in LPS-administrative areas increased their 
cell body sizes (A and C) in contrast to the NG2 cells in non-administrative area (B 
and D). Also, the processes of cells in A and C also became short in contrast to the 
long processes of those cells in normal side (B and D). The area presented in the 
Figure 3.34 C was the surrounding region near the needle track. There were some 
round amoeboid microglia (green) found in this area, suggesting they were activated 
by LPS there. However, at the same place in the normal side (D), the shape of 
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ramified microglia (green) was remained. The results of morphological alteration of 
NG2 cells after anti-CD11b antibody+LPS treatment were consistent to those of LPS 
administration only. It suggested that microglia blockage by anti-CD11b antibodies 




Figure 3.34: The morphological alteration in NG2 cells after anti-OX42 
antibody+LPS treatment. After treated by LPS only, NG2 cells became hypertrophic 
and the processes also shortened. It suggests that the anti-OX42 antibody blockage 
may have little effect to the morphology transformation of NG2 cells under the 
existence of LPS. (Scare bar: 50m) 
 
11.3 The cells near the needle track  
In the area near the anti-CD11b antibody and LPS focal injection site (the area 
inside the frame in Figure 3.35 D and E), things became different contrast to 
surrounding region (A, B and C). After the treatment of anti-CD11b antibody+LPS in 
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the brain cortex, the microglia near the injection site changed their morphology from 
resting ramified to amoeboid microglia as well (A, arrow pointing). Also, the NG2 
positive cells increased their body sizes (B) and their numbers increased as well. 
However, in the center of needle track, there was no any microglia (D) found. Only 
few of amoeboid microglia (D, arrow pointing) were seen near the center. It might be 
because of inhibition of anti-CD11b antibody injected in this site. However, it was 
surprised that there was not any NG2 cell labeled in the same site (E), as well as 
microglia, only a few of NG2 positive cells can be found near the center (E, arrow 
pointing). The real reason is still unknown. Perhaps the expression of NG2 in the 
needle track area was suppressed by the blockage of complement receptor type 3. This 
finding may be useful to future function investigation of NG2 cells in pathological 
brain. 
 
Figure 3.35: The cells in the injection site. After the administration of 
anti-CD11b antibody and LPS, in this area, neither microglia (green) nor NG2 cells 
(red) were observed. This finding may be useful to future function investigation of 




12. Distribution of TAT-PEG-b-Chol nanoparticles in LPS 
triggered pathological brain 
12.1 The permeability of TAT-PEG-b-Chol 
It was known that brain damage or diseases can increase the permeability of 
foreign substance such as protein or big organic molecules because of compromise of 
the BBB in pathological condition (Hawkins and Davis, 2005; Persidsky et al., 2006). 
Here, in order to investigate the permeability of designed nanoparticle drug carrier in 
pathological brain, TAT-PEG-b-Chol was injected into the rat body via femoral vein. 
These rat brains had already been treated with LPS focal injection to the cerebral 
cortex 24 hours before. Rat brain sample was collected just 5 minutes after injection. 
The staining results in Figure 3.36 showed that the nanoparticles positive cells had 
already been found both inside the blood vessel (A, left) and in the brain parenchyma 
(A, right). Previous data had proved that in normal rats brain whose BBB are intact, 
the TAT-PEG-b-Chol positive cell can only be seen till 10-15 minutes after the 
injection. It suggested that, in the LPS triggered pathological brain, the nanoparticle 
of TAT-PEG-b-Chol can penetrate the BBB much quickly than in normal rats. This 
result will be of great importance for future clinical use of TAT-PEG-b-Chol in drug 




Figure 3.36: The permeability of TAT-PEG-b-Chol in pathological brain in 5 
minutes. A: Staining results of TAT-PEG-b-Chol using Mouse anti-TAT antibody, Cy3 
conjugated second antibody was also used. B: Staining of blood vessel (white arrow 
pointing) and microglia (yellow arrow pointing, there were round amoeboid 
microglia, suggesting they were activated) by FITC conjugated Lection protein. It 
suggests that, in our established brain pathological model, TAT-PEG-b-Chol could 
penetrate the BBB much quickly than in normal rats whose BBB were intact. 
 
12.2 The distribution of TAT-PEG-b-Chol  
An ideal nanoparticle carrier and delivered drug system should target the 
pathological area specifically and release the drug molecules there. Therefore, it may 
be of importance to study the distribution of TAT-PEG-b-Chol micelles with drug 
molecules after they penetrate the BBB in pathological brain. Figure 3.37 shows their 
distribution in different areas within LPS triggered brain pathological model when 
they reached the brain parenchyma. Figure A and B are images from the cerebral 
cortex and C and D from hippocampus. The distribution of TAT-PEG-b-Chol in this 
pathological brain is different contrast to their distribution in normal brain. Although 
it is not easy to determine the cell types here which uptake these particles, it is 
obvious that many more nanoparticles were found in the pathological areas (B and D, 
the red dots which arrows pointed). However, only few red dots were sporadically 
distributed in non-LPS administration areas (A and C, arrows pointing). The result 
RESULTS 
 136
suggested that in this pathological brain, the nanoparticles of TAT-PEG-b-Chol can 
assemble in the pathological area and may release drugs there to take the therapeutic 
effect. Although the reason of this distribution is not clear, this result indicates that 
TAT-PEG-b-Chol micelles can be an ideal targeting drug carrier which can deliver 
drug molecules through the BBB and release them in special targeted pathological 
zone. 
 
Figure 3.37: The distribution of TAT-PEG-b-Chol in pathological brain. The 
anti-TAT antibody staining results showed that there many more nanoparticle of 
TAT-PEG-b-Chol congregated in pathological areas (B and D) either in cortex (A 
and B) or hippocampus (C and D). It suggests that TAT-PEG-b-Chol can be an ideal 
targeting drug carrier which can deliver drug molecules through the BBB and release 









1. PEG-b-Chol and TAT-PEG-b-Chol system 
1.1. Critical micelle concentration value of nanoparticle micelles 
Critical micelle concentration (CMC) value is an important parameter, above 
which an amphiphilic copolymer forms core shell structured micelles. The 
amphiphilic polymers consisting of hydrophilic and hydrophobic segments can be 
self-assembled core shell structure in aqueous solutions. In this study, although the 
NMR spectrums of polymers had proved that the synthesis was successful, other 
evidences are required to show that the formation of core shell nanoparticles with 
PEG-b-Chol and TAT-PEG-b-Chol was achieved. Therefore, CMC values of these 
formations were detected by a fluorescence technique, where pyrene was chosen as a 
fluorescent probe. 
 
Figure 4.1: Plot of I339/I334 ratio as a function of logarithm of polymer PEG-b 
-Chol (a)and TAT-PEG-b-Chol (b) concentration (Log C) in DI water. 
 
The peak intensity increased markedly when the polymer concentration was 
above 6.2mg/l (Log C0.8) for PEG-b-Chol or 7.8mg/l (Log C0.9) for TAT-PEG- 
b-Chol. At low concentrations, the intensity ratio of I339/I334 changed slightly. 
However, as polymer concentration increased, the intensity ratio increased sharply, 
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indicating the partitioning of pyrene into the hydrophobic core of the nanoparticles. 
As shown in Figure 4.1, the CMC values of PEG-b-Chol and TAT-PEG-b-Chol in DI 
water were about 6.6 and 11.2 mg/l, respectively. The low CAC values indicate that 
the core shell nanoparticles can be formed at low concentrations because of the strong 
hydrophobicity of cholesterol, allowing their use in much diluted media, such as body 
fluids. The presence of TAT led to a slight increase in the CMC. This is because more 
cholesterol molecules are probably needed to interact and to form the core of 
nanoparticles due to the strong interactions between TAT and water molecules, and 
the repulsion force between TAT molecules. 
 
1.2. Particle size control in the nanoparticles fabrication 
The size of nanoparticles prepared from self assembly method for targeted drug 
delivery is normally distributed between 100 to 200nm (Liu et al., 2007), even smaller 
than 100nm (Chen et al., 2008). It has been consistently shown that PEGylated 
nanoparticles with smaller particle size are easier to be taken up by cells. Also, these 
nanoparticles with small sizes can reduced plasma protein adsorption on their surface 
and also reduce hepatic filtration, which makes them have a long blood residence time 
to avoid taking by other cells in the body. In addition, the nanoparticles with smaller 
size have a high rate of extravasation into permeable tissues (Alexis et al., 2008). In 
this project, under the fabrication conditions, the effective diameters of the blank, 
drug-loaded, QDs-loaded and FITC-loaded nanoparticles were 180, 190, 150 and 199 
nm, respectively. It demonstrates that the designed nanoparticles can achieve effective 
and targeted drug delivery with a longer circulating time.  
DISCUSSION 
 140
During the process of blank and ciprofloxacin lactate loaded PEG-b-Chol 
micelles fabrication, extending the dialysis time up to 48 hours and changing the DI 
water outside the dialysis bag frequently may be good to achieve ideal micelles with 
smaller and even-distributed particle size. In addition, a lower environmental 
temperature for dialysis (10°C) may also benefit the formation of core shell structured 
nanoparticles. In this project, the formed blank and drug-loaded nanoparticle micelles 
were spherical in nature. Their size of slightly increased after drug and FITC loading. 
In the core shell structure formation of PEG-b-Chol and TAT-PEG-b-Chol, the 
dialysis bags were put into 10°C DI water with stirrer bar in medium speed. However, 
in the conjugation of TAT peptide to Penicillin G, the environmental temperature 
hardly affects on the connection rate of TAT-Penicillin G. For sake of the stability of 
Penicillin G, the dialysis time can not exceed 24 hours. Although the dialysis time 
was half as before, current results showed that TAT-Penicillin G could be well 
endocytosed by cultured brain cells. It suggests that total size of designed 
TAT-Penicillin G system is acceptable. 
 
1.3 The length of PEG chain and TAT-PEG-b-Chol BBB penetration 
Properties of PEGylated nanoparticles such as size, hydrophilicity, surface 
charge, morphology, PEG chain length and homogeneity may affect the relationship 
between nanoparticles and cell membrane (Mosqueira et al., 2001a). For our designed 
TAT-PEG-b-Chol nanoparticles, we have examined the effect of PEG chain length to 
the BBB penetration ability of nanoparticle micelles. 
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In this study, TAT-PEG3290-b-Chol and TAT-PEG5000-b-Chol were successfully 
synthesized and used to investigate the effect of PEG chain length in vivo and in vitro. 
Our previous results had showed that both TAT-PEG3290-b-Chol (Liu et al., 2008b) 
and TAT-PEG5000-b-Chol (Liu et al., 2008a) can penetrate the BBB and reach the 
brain parenchyma. Few differences were found in the cellular uptake of TAT-PEG3290 
-b-Chol and TAT-PEG5000-b-Chol at the time point of 2 hours. However, as the Figure 
2 shows, 15 minutes after venous injection, the number of FITC-positive cells which 
uptake the TAT-PEG3290-b-Chol nanoparticles (FITC encapsulated) was more than 
those uptake the TAT-PEG5000-b-Chol in the same brain area, suggesting that more 
nanoparticles of TAT-PEG3290-b-Chol could penetrated the BBB and uptake by brain 
cells in a shorter time frame. Regarding the nanoparticle micelles designed, shorten 
their PEG chain length may further improve their permeability through the BBB 
which in concert with the results from Mosqueira (Mosqueira et al., 2001b). 
 
Figure 4.2: The number of FITC positive cells 15 minutes after venous injection 
of FITC-TAT-PEG3290-b-Chol (black) and FITC-TAT-PEG5000-b-Chol (white). The 
concentrations of both injected nanoparticles solution were 0.045 mg/ml. There were 
many more FITC positive cells in the brain cortex after intravenous injection of 




Figure 4.3 shows the in vitro results of cellular uptake of TAT-PEG3290-b-Chol- 
FITC (A), TAT-PEG5000-b-Chol-FITC (B), PEG3290-b-Chol-FITC (C) and pure FITC 
(D). They share the same initial concentration and incubation time. It was obvious 
that astrocytes incubated with TAT-PEG3290-b-Chol-FITC (A) presented much 
stronger fluorescence intensity than those astrocytes incubated with TAT-PEG5000-b- 
Chol-FITC (B). It also proved that nanoparticles with shorter PEG chain length could 
be prone to be taken up by cultured cells.  
In addition, in figure 4.3,it was observed that cells incubated with nanoparticles 
linked with TAT peptide (A and B) emitted stronger fluorescence contrast to cells 
incubated with nanoparticles without TAT (C) or pure FITC (D), indicating that TAT 
may play an important role in nanoparticles penetrating the BBB. 
 
Figure 4.3: Cultured astrocytes can uptake many more FITC-TAT-PEG3290 
-b-Chol particles (A) than FITC-TAT-PEG5000-b-Chol (B), FITC-PEG3290-b-Chol (C) 
and pure FITC (D) particles. It suggests that PEGylated nanoparticles with shorter 
PEG chain length may penetrate the cell easily than those longer ones. Nanoparticles 




1.4 Ciprofloxacin and ciprofloxacin lactate 
It has been reported that the leading causes of bacterial meningitis are 
gram-positive Streptococcus pneumoniae (Editorial, 2003), gram-negative Escheri- 
chia coli (Regoes et al., 2004) and Neisseria meningitides (Tzankaki et al., 2006) 
since 1990s. Ciprofloxacin (C17H18FN3O3) may be one of the most effective 
antibiotics and has a wide spectrum of these bactericidal activities. It functions by 
inhibiting bacterial chromosome replication (Torriero et al., 2006a; Torriero et al., 
2006b). For example, an Escherichia coli O18:K1:H17 susceptibility test revealed 
that minimum inhibition concentration (MIC) of ciprofloxacin was 0.03ppm, whereas 
ampicillin and streptomycin were 8 and 32ppm respectively. Therefore, in our study, 
ciprofloxacin was firstly chosen as an antibiotic drug that will be encapsulated into 
the core of TAT-PEG-b-Chol. 
However, ciprofloxacin has poor solubility in DMSO which is the main solvent 
for encapsulation. It will directly result in low loading efficiency of drug molecules 
into the core. It is necessary to find solutions for this problem. Ciprofloxacin lactate is 
another antibiotic within the ciprofloxacin family. As well as ciprofloxacin, 
ciprofloxacin lactate is also a kind of fluoroquinolone antibiotics. Contrast to the 
molecular structure of ciprofloxacin, ciprofloxacin lactate has an added lactate group 
connected in one of carbon atom (marked with * in Figure 4.4 B) with weak physical 
force. The ciprofloxacin lactate can be well dissolved in DMSO and the lactate group 
was in dissociative status when it was in DMSO. Because ciprofloxacin lactate and 
ciprofloxacin both possessed crucial element of fluoroquinolone group which can kill 
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the bacteria through its binding to bacterial DNA topoisomerase, they may almost 
obtain the same antibacterial efficacy. We had investigated the MIC of ciprofloxacin 
lactate to Bacillus subtilius and Escherichia coli. The result shows that ciprofloxacin 
lactate displayed the lowest MIC (0.2ppm) when compared with penicillin G 
potassium (MIC: 156ppm) and doxycycline monohydrate (MIC: 6.25ppm) (Liu et al., 
2008b). Therefore, ciprofloxacin was finally substituted by ciprofloxacin lactate with 
good solubility in DMSO as the antibiotic chosen in the encapsulation into TAT-PEG- 
b-Chol. 
 
Figure 4.4: The chemical structure of ciprofloxacin (A) and ciprofloxacin lactate 
(B). The only difference of structure lies in the existence of lactate group in 
ciprofloxacin lactate. 
 
1.5 Consideration in injecting and sampling methods for application 
of nanoparticles in BBB penetration  
Collective results in the current study have demonstrated that TAT-PEG-b-Chol 
could easily cross the BBB into the brain parenchyma. From these observations, most 
of those nanoparticles that already reached the brain parenchyma were distributed in 
cerebral cortex and hippocampus area. However, in the project, there still many 
nanoparticles were found in other organs such as liver, spleen or kidney. It may be 
due to the intravenous injecting method (through femoral vein) adopted in the 
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research. This intravenous injection would increase amount of nanoparticles within 
the blood stream, resulting the drug distribution in the whole body. As the cells in 
liver, spleen and kidney can also uptake these nanoparticles, the loss of nanoparticles 
into other cells may eventually reduce the amount of drug in the brain and therefore 
affect therapeutical efficacy. 
In the quantitative investigation, shifting way of injection from femoral vein (or 
tail vein) injection to common carotid artery (CCA) infusion may decrease the loss of 
injected nanoparticles (Santra et al., 2005b). However, up to now, the research of 
TAT conjugated nanoparticles mostly focused on qualitative investigation (Santra et 
al., 2005b; Schwarze et al., 1999; Torchilin et al., 2001) because of the difficulties in 
pharmacokinetics research in vivo. So that, more research efforts should be spent on 
studying new way of delivery of the TAT conjugated systems. 
Microdialysis technique is a well developed sampling method in vivo in either 
awake, free moving or anesthetic animals (Fillenz, 2005; Justice, 1993; Mas et al., 
1996; McKenzie et al., 2002; Olson and Justice, 1993; Watson et al., 2006; Zhou et al., 
1995). In this project, this technique was used to sample the drug in the brain. 
However, during the pre-testing process of measuring nanoparticle concentration, 
only around 5% of nanoparticles can be sampled in 90 minutes. Perhaps only 5% can 
cross through the membrane of microdialysis probe. Pure antibiotics (Penicillin G 
potassium or ciprofloxacin lactate) were injected into the animal body (dosage: 80 
mg/kg) and the whole rat brain were collected without any blood flushing. Even 
though, there is only about 0.03% of injected antibiotics was detected (including 
DISCUSSION 
 146
antibiotics both in the blood and brain parenchyma) after 15 to 20 minutes (data not 
shown). That indicates to use microdialysis, only 5% x 0.03% = 0.0015% of injected 
nanoparticles can be sampled and then analyzed by HPLC. As the amount of 
synthesized nanoparticles is far from the dosage requirement of injection, the 
microdialysis technique can not sample enough nanoparticles from brain for the next 
analysis by HPLC.  
Therefore, it is difficult to investigate quantitatively investigate the penetration 
percentage of TAT-PEG-b-Chol through BBB at present. However, the current 
histological staining results revealed that this penetrating ratio may not be so low. In 
future study, other more sensitive methods, like radio labeling technique, should be 
employed to determine this percentage. For future clinical application, in order to 
increase the penetration ratio across the BBB, except for reducing the circulation time 
in blood stream, the blockage of the binding site for nanoparticles in the cells from 
other organs (for instance the liver, spleen or kidney) or finding other specific 
biological ligand to specific surface receptors of brain cells should be considered. 
 
1.6 The cellular uptake of TAT-PEG-b-Chol in brain parenchyma 
TAT-PEG-b-Chol positive cells were mainly distributed in cerebral cortex and 
hippocampus area after this nanoparticle reached the brain parenchyma. In this project, 
obviously mnay FITC or QDs, loaded nanoparticle positive cells were observed in 
these two areas. It is clear that the cells which can uptake TAT-PEG-b-Chol are 
abundant in these two areas than other areas, suggesting the designed 
TAT-PEG-b-Chol carrier system might be region-preferable. Although the relevant 
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mechanism for this phenomenon is still not understood, the designed drug carrier 
system may be a good candidate for the purpose of targeting to specific pathological 
region in the brain after drug administration.  
Histological double staining results had already demonstrated that it was neurons 
that mainly uptake these nanoparticles. However, other brain cells, such as microglia, 
astrocytes, oligodendrocytes and NG2 cells also can uptake some tiny amount of 
TAT-PEG-b-Chol. Our study discovered that those intake generally fulfilled by cells 
near the blood vessel. In Figure 3.13, both cortical neurons in cortex and internal 
neurons can be labeled with FITC encapsulated TAT-PEG-b-Chol. Perhaps neuronal 
cells have specific surface receptors in their cell membrane, which can bind the TAT 
ligand specifically and induce the transcytosis. 
Previous research had discovered that TAT peptide can rapidly translocate 
through the plasma membrane and accumulate in nucleus (Brooks et al., 2005; Santra 
et al., 2005b; Vives et al., 1997). However, in this research (Figure 3.10 D and Figure 
3.13 D), the nanoparticles of TAT-PEG-b-Chol were not seen inside the nuclei, but 
mainly surrounding the nuclei. The uptake of nanoparticles by cultured brain cells 
(astrocytes and endothelial cells) also certified this finding (Figure 3.17). The FITC or 
QDs encapsulated TAT-PEG-b-Chol did not enter the nuclei possibly because of their 
relatively big sizes. The particles might be too big to pass through the nuclear pores. 
1.7 Dynamic transport of TAT-PEG-b-Chol in vivo
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In 1999, Schwarze discovered that particles of FITC-TAT can rapidly enter the 
brain within 30 minutes since injection (Schwarze et al., 1999). In 2005, Santra found 
that the TAT conjugated Quantum dots (CsS:Mn/ZnS) can also rapidly and 
effectively label the brain tissues after 5 minutes pump infusion (Santra et al., 2005b). 
The findings in the current project are in agreement with these previous findings. 
Within 15 minutes after injection, these nanoparticles could be found in brain 
parenchyma. When the nanoparticles of TAT-PEG-b-Chol were injected into the 
blood stream, because of the non-specificity of TAT peptide, they can be taken up by 
cells in other organs before they reach the brain. The nanoparticles with smaller 
particle size have longer blood residence time (Alexis et al., 2008) to avoid taking by 
liver cells or kidney cells. In addition, TAT-PEG-b-Chol particles with relative 
shorter PEG chain length also can shorten the time from blood to brain. Therefore, in 
future clinical application, the drug encapsulated TAT-PEG-b-Chol system with 
smaller particle size and shorter PEG chain length can rapidly deliver the drug to the 
pathological site of the brain. The rapid delivery of the designed nanoparticle carrier 
system through the BBB may be an important feature to benefit treatment effects for 
brain diseases and injuries. 
 
1.8 Drug transport with TAT-PEG-b-Chol in pathological brain 
It has been reported that LPS can disrupt the BBB through the action of 
gelatinase B (Mun-Bryce et al., 2002). The opening of BBB makes the entry of 
substance through the BBB easier, including the entry of drug molecules. The current 
results have demonstrated that the nanoparticles system of TAT-PEG-b-Chol can 
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rapidly penetrate BBB and reach the brain parenchyma within 15 minutes. In the 
current focal injury model plus LPS stimulation, the time for the nanoparticle delivery 
was shortened to only around 5 minutes. It was the damaged BBB that make the entry 
of TAT-PEG-b-Chol so fast. The rapid penetration will minimize the decrement of 
effective drug concentration to achieve better delivery outcome.  
The most interesting finding is the congregation of TAT-PEG-b-Chol 
nanoparticles in LPS administration area. It indicated that TAT-PEG-b-Chol can bring 
most of drug molecules encapsulated cross the BBB and may release drugs in the 
pathological areas. However, in current experiments, only the congregation of 
nanoparticles carrier in the pathological site was confirmed. The release of drug 
molecules from the core shell of TAT-PEG-b-Chol should be further investigated. In
vitro drug release data in PBS had shown that only 10% of drug inside the core shell 
was released after 10 minutes. So it is of great possibility that most nanoparticles 
accumulated in the pathological area still contained the drug molecules. As pH value, 
temperature or other features can affect the drug release from micelles (Blanco et al., 
2008), the use of the pathological model will be ideal for the investigation of drug 
delivery and release in the brain. Although the reason why TAT-PEG-b-Chol and 
drug system accumulated in the brain pathological area is not known yet, it is of great 
significance for their clinical application in future drug targeted delivery. Therefore, 
in pathological brain, the drug molecules loaded TAT-PEG-b-Chol nanoparticles may 
quickly penetrate the BBB to avoid the significant loss before they were delivered to 
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targeted brain area. Their congregation in the pathological areas may achieve better 
therapeutic results. 
 
1.9 HPLC analytical and detective method for nanoparticle system
Current research has successfully established the HPLC analytical methods of 
selected two antibiotics. Because all those antibiotics have benzene-like groups in 
their chemical structures, they can show strong absorption in UV zone at special 
wavelength. Therefore, photodiode array detector can be used to measure their 
respective concentration in samples. This detective method also can be used to 
analyze the concentration of antibiotics loaded TAT-PEG-b-Chol or PEG-b-Chol. But 
for the HPLC analysis of FITC or QDs encapsulated nanoparticles (PEG-b-Chol or 
TAT-PEG-b-Chol), fluorescent detector (Waters, USA) may be used in future study. 
From the inter-assay precision analysis results for these three antibiotics, it can be 
concluded that the established methods are feasible for the antibiotics concentration 
analysis. They can be used in future for quantitative investigation of pharmacokinetics 
of antibiotics encapsulated in TAT-PEG-b-Chol nanoparticles. 
 
1.10 Application of nanoparticle micelles for gene targets delivery 
Successful gene delivery into the targeted cells or organs is the most important 
step in the treatment of diseases caused by genetic disorders, mutation or genetic 
defects such as leukemia and tumors (Yi-Yan et al., 2006). Since 1990, little progress 
had been made because of the difficulties in the development of gene delivery vector. 
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Up to now, the research of gene delivery vectors only constrain inside the laboratory 
and has not proven successful in clinical trails. 
In the research of gene delivery vector development, non-viral have recently 
received increasing attention. Recent years, nanoparticle as a promising non-viral 
gene delivery vector has fully developed. Those vectors, such as polyethylenimine 
(PEI) (Kleemann et al., 2004), cationic polymer micelles (Wang et al., 2007a; Wang 
et al., 2007b), self-assembled oligopeptide nanoparticles (Seow et al., 2009; 
Wiradharma et al., 2009) and peptide-functionalized carbon nanotubes (Pantarotto et 
al., 2004; Singh et al., 2005), have proven to deliver transgenes into targeted cells 
successfully. 
For the successful delivery of gene to targeted cells or organs by nanoparticle 
micelles, there are three things need to be concerned. The first is the fabrication of 
gene into vectors. Nanoscaled complexes of cationic polymer and DNA can be 
fabricated by simply mixing these cationic polymer solutions with DNA (Yi-Yan et 
al., 2006). However, the encapsulation of DNA fragments into the core of 
TAT-PEG-b-Chol was not so simple. As hydrophobic b-Chol form the central core, if 
the gene could be well dissolved in organic solvent and can be successfully 
encapsulated into the central core, these TAT-PEG-b-Chol nanoparticle micelles also 
can be used for gene delivery. The second is the cytotoxicity. As it had proved by 
previous data, TAT-PEG-b-Chol micelles were nontoxic. And the last is the gene 
transfection efficiency. It was reported that conjugation of HIV-1 Tat cell penetrating 
peptide to nanocomplexes could improve cellular uptake of gene vectors and 
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enhanced gene transfection efficiency of neurons (Jabbari, 2009; Suk et al., 2006). We 
have reasons to believe that because of the existence of TAT peptide, 
TAT-PEG-b-Chol micelles also can achieve high gene transfection efficiency when 
they were used as gene delivery vectors. 
 
2. TAT-Penicillin G potassium system 
2.1 Encapsulation of hydrophobic and hydrophilic antibiotics 
The polymer micelles of PEG-b-Chol were synthesized in DCM which is a 
hydrophobic organic solvent. In hydrophobic organic solvent such as DCM, these 
polymers are not in the form of core shell structure. However, when they are in 
aqueous solvent, core shell structure will be automatically formed by self assembly 
method. During the process of formation, hydrophobic b-Cholesterol formed the core 
inside and hydrophilic PEG formed the coronal shell outside. Therefore, only drugs 
that could be dissolved in hydrophobic organic solvent with PEG-b-Chol could be 
encapsulated into the core during this process. In current project, FITC, QDs and 
ciprofloxacin lactate all had good solubility in non-aqueous solvent and therefore 
could be well encapsulated into the core of PEG-b-Chol or TAT-PEG-b-Chol. But 
regarding hydrophilic antibiotics, such as Penicillin G, the encapsulation was not so 
good. 
Because of this fact, the application of TAT-PEG-b-Chol nanoparticles was 
unfortunately limited the delivery of hydrophobic drug molecules. Therefore, other 
kind of nanoparticles or liposomes should be explored for encapsulation and delivery 
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of hydrophilic antibiotics through the BBB in the future. However, as far as Penicillin 
G concerned, a substitutable method of direct conjugation using TAT penetrating 
peptide comes out. 
 
2.2 Conjugation of TAT to Penicillin G potassium 
In this study, the TAT peptide has been successfully conjugated to the surface of 
PEG-b-Chol nanoparticles and antibiotics such as ciprofloxacin lactate were 
successfully encapsulated into the core, and then delivered through the BBB (Liu et 
al., 2008a; Liu et al., 2008b). The connection of TAT to PEG-b-Chol was based on 
the EDC/NHS chemistry. As for the chemical structure of Penicillin G, it processes 
the carboxyl group (-COO) in the terminal of -lactams as well as PEG-b-Chol. 
Therefore, it makes the direct connection of Penicillin G to the amido (-NH2) of TAT 
peptide via EDC/NHS chemistry possible. 
In order to conjugate TAT peptide to Penicillin G successfully, a three-step 
reaction was taken to achieve this goal: activation, conjugation and dialysis. During 
the processes of synthesis, many different factors, such as temperature, pH value, may 
take effect to the final production. Previous data had showed that reaction temperature 
hardly affected the final connection efficiency. Therefore, the synthesis temperature 
was chosen at room temperature. However, the pH value may affect the connection 
efficiency much more than temperature. More TAT peptide molecules could be 
conjugated with Penicillin G in a higher pH value buffer environment, especially in 
the second step. It is because that although the EDC reactions were usually performed 
in MES buffer at pH at 4.7-6.0, the reaction of Sulfo-NHS-activated molecules with 
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primary amines was most efficient at pH 7.0-7.5. To get best results, the first step of 
reaction (EDC reaction) was performed in MES buffer at pH 5-6, then adjusted it to 
7.0-7.5 with 1M NaOH solution immediately in the second step (Sulfo-NHS reaction). 
Therefore, in the first step of activation, the reaction was started with a pH value 6 
MES buffer. After this step completed, the pH value had already been changed to 5.4. 
Before the second step of adding TAT peptide solution, the pH value should be 
adjusted to 7.0 around, but must be lower than 7.5 (Grabarek and Gergely, 1990). 
Under this circumstance, the TAT conjugation rate may reach the highest value in 
theory. 
    In addition, the molar ratio of Penicillin G: TAT peptide: Sulfo-NHS: EDC also 
affect the final connection rate. In current experiments, when this ratio increased 
from 1:0.5:4:1.6 to 1:0.5:15:6, the connection efficiency also greatly improved. This 
indicated that higher concentration of Sulfo-NHS and EDC may result in the 
increment of conjugation of TAT peptide. 
 
2.3 Cytotoxicity of TAT-Penicillin G
Cytotoxicity test of TAT-Penicillin G to astrocytes, endothelial cells, neuron and 
microglia had demonstrated that TAT conjugated Penicillin G was nearly not toxic to 
these brain cells. However, Aksenova found that the HIV-1 TAT protein is neurotoxic 
to the cultured rat midbrain fetal neurons in 2006 (Aksenova et al., 2006). In addition, 
in rat hippocampus cell culture, the expression of D1 dopamine receptor can be very 
low also because of the existence of TAT protein (Silvers et al., 2007). It means that 
TAT protein may be of some toxicity to some specific cell type. 
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Although full-length TAT protein exerts a toxic action on primary rat neuronal 
cultured cells, however, it was completely nontoxic to microglia, astrocytes and 
oligodendrocytes (Strijbos et al., 1995). In addition, TAT peptides which come from 
TAT protein with different amino acid also differ in their toxicity. In 2004, it was 
found that TAT (47–57) which selected in this project turned out to be non-toxic for 
concentrations of up to 100M (Trehin and Merkle, 2004). Therefore, the toxicity 
comes from TAT peptide part may be minimized. 
During synthesis of TAT-Penicillin G, the superfluous Penicillin G and 
unconjugated TAT were removed by means of membrane dialysis. However, for sake 
of the stability of Penicillin G molecules, the dialysis time should be limited within 24 
hours. Therefore, it was very difficult to completely remove free TAT in the final 
product. The spectrum of TAT-Penicillin G (Figure 3.20) also verified this point. 
Perhaps it is the reason why the cell number of neurons (Figure 3.21 A) decreased to 
some extent when treated with TAT-Penicillin G. However, for pure TAT conjugated 
Penicillin G, there was no evidence to prove that it was toxic to cultured neuron. In 
future study, when the concentration of unconjugated TAT is determined, the cultured 
neuronal cells can be treated with the pure TAT solution with the same concentration 
determined. If the number of neuron decreases to the same extent as current results 




Current results had demonstrated that TAT-Penicillin G din not cause significant 
damage to rat brain cells. It may be a feasible way to deliver Penicillin G through the 
BBB.  
2.4 Antibiotics screening of TAT-Penicillin G 
The antibiotics screening is a method to determine value of minimum inhibition 
concentration (MIC) to bacteria or fungi (Fabio et al., 2007; Foroumadi et al., 2003). 
Here, the MIC was defined as the lowest concentration of antibiotic that completely 
inhibited the growth of the organisms (Liu et al., 2008b).  
In this project, for the anti-bacterial efficacy test of TAT-Penicillin G, B.subtilius 
and C.albicans were used as the bacterial organisms. The results demonstrated that 
just as pure antibiotics, TAT conjugated Penicillin G as well has the ability to inhibit 
the growth of some infectious microorganisms. However, it still needs to know 
whether the chemical conjugation of TAT to Penicillin G affect its anti-bacterial 
efficacy to those organisms. Previous discovery has showed that the MIC of pure 
Penicillin G to B.subtilius was 156ppm (Liu et al., 2008b). It was found when B. 
subtilius was incubated with 50ppm pure Penicillin G, no inhibitory effect on the 
growth of B.subtilius was observed. However, after the 2.7ppm of TAT-Penicillin G 
was applied to the same B.subtilius solution, an inhibition on the growth was achieved. 
This result means that the anti-bacterial ability of 2.7ppm TAT-Penicillin G is higher 
than 50ppm pure Penicillin G. As it suggests that the MIC of TAT-Penicillin G B 
subtilius may be much smaller than 156ppm, we do believe that for TAT-Penicillin G 
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and pure Penicillin G with same concentration, the anti-bacterial ability of the former 
will be much higher because of the conjugation of TAT peptide. 
Similar result was obtained when C. albicans co-incubated with TAT- Penicillin 
G (Liu et al., 2008b). Sader found the MIC of Penicillin G to C. albicans was 64ppm 
in 2004 (Sader et al., 2004). In current project, when 2.7ppm or 1.4ppm TAT 
conjugated Penicillin G was applied to C. albicans, obvious inhibition effect on the 
growth of C. albicans was observed. It means that TAT-Penicillin G with much lower 
concentration than MIC of pure Penicillin G still had strong anti-bacterial efficacy. It 
was clear that MIC of TAT-Penicillin G to C. albican was much smaller than that of 
pure Penicillin G. In summary, these results both indicated that TAT-Penicillin G had 
a higher anti-bacterial efficacy than pure Penicillin G because of the TAT peptide 
conjugation. 
The conjugation of TAT peptide could enhance its anti-bacterial efficacy both to 
B.subtilius and C.albicans. Possibly because the conjugation of HIV-1 TAT cell 
penetrating peptide could improve cellular uptake of particle-complex and enhanced 
uptake efficiency of cells (Jabbari, 2009; Suk et al., 2006). The increased cellular 
uptake result in that many more TAT-Penicillin G could attach or enter the cell and 
function there. Perhaps the existence of TAT remaining in the product of 
TAT-Penicillin G may contribute to the inhibition effect to B. subtilius and C.albicans 
due to antibacterial action of TAT (Jung et al., 2008). In fact, this effect in this project 
may be very small and could be neglected. First, the amount of remaining 
unconjugated TAT was very low after 24 hour dialysis. Second, when pure TAT 
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peptide solution with same concentration as TAT-Penicillin G (2.7ppm) was used in 
screening test, very little inhibition to the growth of bacteria was observed (Data now 
shown). Therefore, the remaining amount of free TAT should have no affect on the 
growth of bacteria in the experiments. Therefore, the conjugation of TAT to Penicillin 
G not only might increases its BBB penetration ability, but also might enhance its 
anti-bacterial efficacy.  
 
2.5 In vitro uptake of TAT-Penicillin G 
The cell penetrating peptide TAT can promote efficient intercellular delivery 
when it is on the surface of liposome (Torchilin et al., 2001). Therefore, when 
Penicillin G was coupled with this TAT peptide vector, it may be possible for the new 
compound easily taken up by cells. The current results for in vitro uptake of 
TAT-Penicillin G (astrocytes and endothelial cells) have validated the hypothesis. 
Here, the HPLC was used to detect the remaining drug concentration in culture 
medium at different intervals after incubation. From the amounts of drugs decreased 
from the culture medium, the amount of drug taken up by the cultured cells can be 
quantified indirectly. The uptake of TAT-Penicillin G and pure Penicillin G at five 
different concentrations was measured in the current study. The results demonstrated 
that when the concentration added was higher than 10ppm, perhaps the saturated 
uptake of drug made the relative uptake ratio very small contrast to initial lower drug 
concentrations (data not shown). It may result in the difficulty in discriminating real 
value from measurement error. So Penicillin G with initial drug concentrations lower 
than 10ppm should be used to investigate in vitro uptake. As it is not easy to 
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determine the drug concentration completely inside the cells by HPLC using 
extraction process from cultured cells, the remaining drug concentration in the culture 
medium was used to measure the cell drug intake. Although this concentration 
decreased in medium may be attributed to both those drugs inside the cells and those 
on the cell surfaces, they all displayed TAT peptide’s affection on the enhancement of 
in vitro uptake. 
 
2.6 The in vivo labeling of TAT-Penicillin G 
Some recent studies of TAT drug delivery system focus on the conjugation of 
TAT to fluorescent particles, such as FITC (Schwarze et al., 1999) and CdS: Mn/ZnS 
quantum dots (Santra et al., 2005b). However, no fluorescent marker has been 
conjugated with the TAT-Penicillin G for observation of the drug trace in vivo or in 
vitro. Without such visible marker, it difficult to track the designed TAT-Penicillin G 
after they enter the blood stream and penetrate the BBB. Up to now, there is still no 
direct evidence to show that TAT-Penicillin G is able to penetrate the BBB and reach 
the brain parenchyma for the treatment of inflammation there. The conjugations of 
TAT to FITC or/and CdS: Mn/ZnS quantum dots have already proved that with the 
aid of TAT peptide, these particles can definitely cross the BBB (Santra et al., 2005b; 
Schwarze et al., 1999). The conjugation of TAT to proteins (Fawell et al., 1994; 
Schwarze et al., 1999), oligonucletides (Astriab-Fisher et al., 2002), plasmid DNA 
(Hellgren et al., 2004) or nanoparticles (Liu et al., 2008a; Santra et al., 2004; Santra et 
al., 2005a; Zhao et al., 2002) has also proved this point. Therefore, it is believed that 
the conjugation of TAT to Penicillin G can also promote their penetration through the 
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BBB. In future research, if possible, the radio-labeling technique may be used in 
labeling of TAT-Penicillin G in vivo in the investigation of their BBB penetration and 
pharmacokinetics studies.  
 
3. Application of TAT conjugated drug delivery system 
In current project, TAT peptide conjugated PEG-b-Chol can encapsulate FITC, 
QDs or ciprofloxacin lactate into the core of the micelles. During the process of 
encapsulation, no covalent bond formed between the drug molecules and cholesterol 
molecules that formed the core. This may be beneficial feature for release of 
encapsulated drug after entering the brain. Once the core shell structure of 
nanoparticles was broken in brain parenchyma, the drug molecules would be released 
out. The properties of drug molecules would not be affected. Therefore, other 
hydrophobic antibiotics or chemical drug molecules can also be encapsulated into the 
core if they had suitable particles size. In addition, peptide or protein may also be 
considered for such encapsulation and be carried through BBB using this micelles 
system. In future application, perhaps packed DNA fragments or gene can be 
encapsulated into these nanoparticles and delivered to targeted brain site. 
TAT directly conjugated Penicillin G has been shown in the current study to 
possess the ability to penetrate BBB. So, the method of direct conjugation of TAT 
peptide with drug molecule provides another possible solution for delivery of some 
drugs through the BBB. In general, chemical drugs, peptide drugs or protein drugs all 
could be coupled with TAT, in taking advantage of TAT role in facilitating increase 
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permeability of the BBB. In the future, after understanding of the function of TAT 
transduction domain and the interaction between TAT and their receptors, new protein 
drug compounds infusing with the functional domains of TAT peptide may be 
developed for treatment of brain diseases or injuries. 
 
4. LPS focal injected rat pathological brain model 
4.1 The responses of NG2 expressing cells 
The current results had shown that the responses of NG2 positive cells in LPS 
triggered pathological brain mainly lay in three aspects. 
The first is morphological alterations in the NG2 cell bodies: NG2 cells in LPS 
administration side changed their morphology from slim shape to round ones as well 
as microglial cells shift from resting ramified shape to round activated amoeboid 
ones. 
The second is that their processes shrank in pathological region contrast to their 
previous long processes in normal area. These two morphology changes indicated that 
NG2 cells are activated by LPS focal injection, just as the activations of microglia or 
astrocytes in response to brain injury. The NG2 cells possess the ability in response to 
pathological challenges in the brain. However, the mechanisms of NG2 cell responses 
are not understood. It is worthwhile to study the function of NG2 cells in pathological 
brain. 
The third is the expression upregulation of NG2 positive cells in pathological 
region. As the expression of NG2 chondroitin-sulfate proteoglycan was also increased 
DISCUSSION 
 162
after brain injury (Levine, 1994), indeed more NG2 positive cells could be observed 
in the brain of the saline injected side compared to that in the normal control side. The 
LPS administration could significantly increase the total number of NG2 cells. Two 
possibilities may explain the significant increment in the number of NG2 cells in the 
pathological brain region: proliferation or migration The current results showed that 
no BrdU positive cells were positive to NG2 staining; suggesting that the increase in 
the NG2 cell numbers could not be attributed to NG2 cell proliferation. Therefore, 
NG2 cell migration might account for this cell number increase. It is possible that the 
NG2 cells migration from the area adjacent to the impaired brain region or from blood 
to brain parenchyma. In addition, it is also possible that other cells might be 
transformed into NG2 positive cells in particular brain pathology. However, currently, 
there is no direct evidence to verify these hypotheses. In the future study, more efforts 
can be put in to study the mechanism of NG2 cell reaction, its role in brain pathology, 
and especially the effect of NG2 cell reaction on drug application in treatment of brain 
diseases and injuries. Although the current study showed that NG2 cells are not major 
cells to uptake in the designed nanoparticle carrier system, NG2 cell activation may 
have certain impact, positive or negative, on drug delivery or drug effects. 
 
4.2 The relationship between NG2 positive cells and microglia 
It is still not clear what the relationship between NG2 cells and microglia is 
either in resting or activating status. Obviously, in LPS triggered pathological brain, 
microglia can be activated and release some cytotoxic factors (Colton and Gilbert, 
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1987; Lee et al., 1993; Liu et al., 2002; Moss and Bates, 2001). These factors include 
some cytokines such as TNF-, IL-1, and IL-6 (Ajmone-Cat et al., 2003; Chao et al., 
1992; Nagai et al., 2001). However, the current results showed that NG2 positive cells 
did not produce these cytokines when they were in pathological brain. Therefore, the 
role of NG2 cells was not fulfilled by releasing of these cytokines. 
Interestingly, when the function of microglia complement receptor type 3,was 
partly blocked by their specific antibody, anti-CD11b in cortical injection site, the 
responses of NG2 cells in LPS treated surrounding area was down-regulated. Contrast 
to those increased NG2 cells in the cortex treated without microglial inhibition (LPS 
only); this down-regulation may suggest that microglia play an important role in the 
activation of NG2 positive cells. Microglia may participate in the activation of NG2 
cells. In other words, NG2 cell reaction might be a downstream event of microglial 
activation. What this cascade reaction would be for drug delivery and drug effect in 
treatment of brain diseases and injuries will be further studies in the future. 
One possible method to investigate NG2 cell responses to pathological stimuli or 
their possible relationship with microglia is to study the NG2 expressing cells in vitro. 
However, up to now, no study has been reported in which NG2-expressing cells have 
been directly isolated from the mature CNS and followed in culture (Dawson et al., 
2000). Isolation and the primary culture of the NG2 cells may be another project for 
future research on impact of non-neuronal cells including NG2 cells on drug delivery 
or drug effects. 
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CHAPTER 5 
CONCLUSIONS AND FUTURE STUDIES 
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1. Conclusions 
The present studies have come to these conclusions: 
1.1 PEG and b-cholesterol could be connected together to form PEG-b-Chol 
micelles with a diameter arrange from 150nm to 200nm in hydrophobic solvent. This 
amphiphilic copolymer could self assemble as a core shell-structured nanoparticle in 
aqueous solvent. The PEG chains formed the outer corona and the b-cholesterol 
makeup the inner core. TAT peptide (47-57), a cell penetrating peptide from HIV 
protein, could be conjugated to the surface of PEG-b-Chol to fabricate nanoparticle of 
TAT-PEG-b-Chol. The TAT-PEG-b-Chol particle could also form core shell structure 
under hydrophilic condition. 
1.2 Hydrophobic molecules, such as FITC, QDs or ciprofloxacin lactate could 
be successfully encapsulated into the core of nanoparticles. The encapsulation has had 
an acceptable loading efficiency and could achieve linear drug release in PBS solution. 
The drug (or fluorescent marker)-loaded nanoparticles had a round morphology and 
an even-distributed particle size smaller than 200 nm. 
1.3 The nanoparticles micelles with shorter PEG chains length and smaller 
particle size could be easily taken up by cultured endothelial cells and astrocytes. In 
the drug delivery through the BBB, FITC and QDs encapsulated TAT-PEG-b-Chol
could penetrate the BBB around 15 minutes after they entered the blood stream. After 
these nanoparticles micelles crossed the BBB and reached the brain parenchyma, they 
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were mainly distributed in neuronal cells both in cerebral cortex and hippocampus 
areas. In addition, these particles did not enter the cell nuclei of neurons and were 
mainly in the cytoplasm around the nuclei possibly because of their relatively large 
size to nuclear pore. During the penetration of these nanoparticles through BBB, TAT 
peptide played an important role. Only TAT conjugated PEG-b-Chol nanoaprticles 
could penetrate the BBB and reached the brain parenchyma. 
1.4 Hydrophilic antibiotics such as Penicillin G could be directly connected to 
TAT peptide by EDC/NHS chemistry. This compound had no cytotoxicity to cultured 
brain cell lines. With the aid of TAT group, many more Penicillin G-TAT had entered 
cultured endothelial cells and astrocytes than pure Penicillin G. It suggests that the 
conjugation of TAT to Penicillin G can promote its penetration to cell membrane. In 
addition, TAT-Penicillin G expressed higher anti-bacterial efficacy than pure 
Penicillin G. In the project, feasible HPLC analytical methods for selected two 
antibiotics, namely, Penicillin G, Ciprofloxacin have been successfully established. 
1.5 In LPS triggered pathological brain, NG2 positive cells were activated after 
LPS administration. Their morphological alterations with enlarge of cell bodies and 
shrinkage of processes were observed. Also, the number of NG2 cells in pathological 
region increased contrast to that of normal areas. However, unlike microglia and 
astrocytes, NG2 cells did not produce some cytokines when they were activated. 
Interestingly, a down-regulation of NG2 reaction was detected when function of 
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microglia complement receptor type 3 in pathological area were blocked by 
anti-CD11b antibody, suggesting that NG2 cells reactions may be an event down 
stream to microglial activation.  
1.6 For drug delivery by TAT-PEG-b-Chol in this pathological brain, these 
nanoparticles micelles could quickly penetrate the BBB within 5 minutes and 
automatically assembled in the pathological area. The LPS trigged pathological brain 
model is suitable to the investigation of drug delivery using these nanoparticle carriers. 
In addition, this result suggests that the designed nanoparticle micelles have a 
promising clinical application in future drug delivery for brain disease therapies.  
2. Future studies 
Possible future work to continue this project includes: 
2.1 The present study has revealed that nanoparticles of TAT-PEG-b-Chol could 
penetrate the BBB. However, this was just an explorative research. Further detailed 
research should be carried out in future studies. The following questions should be 
answered: How many TAT-PEG-b-Chol nanoparticles will finally reached brain 
parenchyma? Contrast to the amount of drug which been encapsulated into the core of 
nanoparticles, what is the penetration rate and release rate for drug molecules finally 
at the brain parenchyma? These quantitative researches are of great importance for 
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future clinical trials. As it has been known, the penetration rate of drug loaded 
nanoparticles will directly determines the dosage used in clinical therapy. 
2.2 The current results have shown that TAT-PEG-b-Chol nanoparticles were 
mainly taken up by neurons after they reached brain parenchyma. But the reason is 
still unknown. It will be very interesting to investigate the biological binding between 
TAT peptide and receptors at cell membrane. If the mechanisms of AMT or RMT that 
occurred in the membranes of endothelial cells and neuronal cells are completely 
elucidated, more specific carrier for drug delivery can therefore be designed to 
targeted specific cells in the brain. 
2.3 As the main components of BBB are endothelial cells and astrocytes, in 
future studies, in vivo BBB can be mimicked by coculture system using these two 
cells in vitro. Based on this system, the in vitro pharmacokinetics of drug-loaded 
TAT-PEG-b- Chol and TAT conjugated Penicillin G or other drug-carrier systems can 
be investigated.  
2.4 LPS trigged pathological brain model is suitable to the investigation of drug 
delivery using nanoparticle carriers. In future, the nanoparticle micelles should be 
further studied in this brain pathological model or other models to bring specific drug 
molecules to cross the BBB and release drug molecules in pathological site for 
disease therapy. The cell responses may be compared before and after this treatment. 
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It can confirm the efficacy of therapy to brain inflammation using drug-nanoparticle 
carrier system. In addition, to clarify the functions of NG2 cells in pathological brain 
and their relationship with microglia will help us well understand their roles in the 
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